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AGM Aorta-gonado mesonephros 
AHR Aryl hydrocarbon receptor 
BAC Bacterial Artificial Chromosome 
BM Bone marrow 
BMP Bone morphogeneic protein 
CAR Chimeric antigen receptor 
CAS CRISPR associated nuclease 
CB Cord blood 
CD Cluster of differentiation 
cDNA Complementary deoxyribonucleic acid 
CFU Colony forming unit 
CLP Common lymphoid progenitor 
CMP Common myeloid progenitor 
CRISPR Clustered regularly interspaced short palindromic 
repeats 
crRNA CRISPR RNA 
DN Double negative 
DP Double positive 
DSB Double strand break 
E- Embryonic 
EB Embryoid Body 
eGFP Enhanced green fluorescent protein 
EMP Erythro-myeloid precursors 
EpiSC Epiblast stem cells 
ERG Ets related gene 
ESC Embryonic stem cell 
Etv Ets variant gene 
FL Fetal liver 
Flt Fms-like tyrosine kinase 
Fos v-FOS FBJ murine osteosarcoma viral oncogene 
homolog 
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FRT Flippase recognition target 
Gata GATA zing finger domain-containing protein 
GCM Goblet cell metaplasia 
Gfi Growth factor-independent 
GMP Granulocyte-monocyte precursor 
GVHD Graft-versus-host disease 
hESC Human embryonic stem cell 
hIPSC Human induced pluripotent stem cell 
HLA Human leukocyte antigen 
HOX Homeobox 
HPC Hematopoietic progenitor cell 
HR  Homologous Recombination 
HSC Hematopoietic stem cell 
HSPC Hematopoietic stem or progenitor cell 
IBD Inflammatory bowel disease 
IEL Intra-epithelial lymphocytes 
IFN Interferon 
IL Interleukin 
ILC Innate lymphoid cell 
IL-xR Interleukin x receptor 
indel Insertion of deletion 
IPSC Induced pluripotent stem cell 
ISP Immature single positive 
IT-HSC Intermediate-term repopulating HSC 
KIR Killer cell immunoglobulin-like receptors 
Klf Kruppel-like factor 
LIF Leukemia inhibitory factor 
Lin Lineage 
Lmo Lim domain only 
LMP Lympho-myeloid precursor 
LoxP Locus of X-over P1 
LSK Lin-Sca1+cKit+ 
LT-HSC Long-term repopulating HSC 
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Lti Lymphoid tissue inducer 
LTR Long terminal repeats 
MEF Murine embryonic fibroblast 
Meg Megakaryocyte 
Meis Meis homeobox protein 
MEP Megakaryocyte-erythrocyte precursor 
mESC Murine embryonic stem cell 
MHC Major histcompatibility complex 
miPSC Murine induced pluripotent stem cell 
MLP Myelo-lymphoid progenitor 
MPP Multipotent progenitor population 
MPS Mononuclear phagocyte system 
mRNA Messenger Ribonucleic acid 
Myb v-MYB avian myeloblastosis viral oncogene 
homolog 
Myc v-MYC avian myelocytomatosis viral oncogene 
homolog 
NCR Natural cytotoxity receptors 
NHEJ Non Homologous End Joining 
NK Natural killer 
Oct Octamer-binding proteins 
PAMP Pathogen-associated molecular pattern 
PAS Para-aortic splanchnopleura 
Pbx Pre B-cell leukemia transcription factor 
Prdm PR domain containing protein 
PRR Pattern recognition receptor 
PSC Pluripotent stem cell 
ROR RAR-related orphan receptor 
Run Runt-related transcription factor 
SCF Stem cell factor 
SCID Severe combined immunodeficiency 
SIN Self-inactivating 
SLT Secondary lymphoid tissue 
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Sox SRY (sex determining region Y)-box  
SRC SCID repopulating cell 
SSEA Stage specific embryonic antigen 
ST-HSC Short-term repopulating HSC 
TALEN Transcription activation like effector nuclease 
Tcm Central memory T cell 
TCR T cell receptor 
Tem Effector memory T cell 
TGF Transforming growth factor 
TH T helper 
TNF Tumor necrosis factor 
TRA Tumor rejection antigen 
tracRNA trans-activating CRISPR RNA 
UCB Umbilical cord blood 
UG Uro-genital 
VEGF Vascular endothelial growth factor 
WAS Wiskott-Aldrich syndrome 
WASP Wiskott-Aldrich syndrome protein 
Wnt Wingless-type MMTV integration site family 
YS Yolk sac 
ZFN Zinc finger nuclease 
Zfp Zinc finger protein 
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Part I :  
In vitro generation of hematopoietic cells from pluripotent stem cells 
 
The use of transgenic transgenic MYB-eGFP hESC as a study tool for in vitro 
hematopoiesis 
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1. Summary of part I 
 
For the treatment of severe hematopoietic diseases such as severe combined 
immunodeficiency (SCID) or Wiskott-Aldrich syndrome (WAS), current therapy 
involves allogeneic transplantation with hematopoietic stem cells (HSC) from a 
matched sibling (haploidentical donor). Alternatively gene corrected autologous HSC 
can be used, a method called gene therapy. This gene correction currently involves 
transduction of HSC with viral vectors, which encode a corrected copy of the affected 
gene. Here, the corrected gene is inserted in the genome at random and is 
constitutively expressed. While this therapy has proven successful in the clinic, 
adverse events have been described due to insertion of the viral vector in, or in the 
proximity of, potential oncogenes leading to malignant transformation. Recent 
advances in transgenic methods have provided tools to edit a specific genomic 
sequence, so called “tailored nucleases”. This allows the correction of the mutated 
gene itself, without the need for random integration of a corrected copy of the gene. 
While a proof of principle of this method has been recently reported, genetic 
correction using this method has low efficiency and would only be feasible in cases 
where the corrected gene confers a selective advantage over the mutated copy. In 
addition, as currently no protocols are available to culture hematopoietic stem cells, 
there are thus no means to control for mutations or random insertions induced by this 
method prior to transplantation.  
Pluripotent stem cells (PSC) have the ability to generate every cell type of the human 
body. Almost a decade ago, a protocol was described to confer this property to 
differentiated cells isolated from adult skin cells. This process is called 
“reprograming”. Recently also cells isolated through less invasive methods, such as 
blood cells, have been successfully reprogrammed. The cells generated using this 
method are called induced pluripotent stem cells (iPSC). These cells can be cultured 
indefinitely without losing their pluripotency, and can thus be cultured in a clonal 
manner. As genetic modification using tailored nucleases is readily implemented in 
PSC research and their properties allow thorough screening for off-target effects and 
selection of successfully modified cells, these cells would be the ideal candidate to 
generate gene corrected HSC for gene therapy.  
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The generation of HSC from PSC has been the goal of many stem cell researchers. 
Although several reports have claimed the generation of cells with HSC 
characteristics from human embryonic stem cells (hESC), another type of PSC, no 
reports convincingly show the generation of bona fide HSC.  
During in vivo embryonic development, also other progenitor cells are generated 
besides HSC. These progenitor cells are largely generated early in development in 
the yolk sac (YS) before the generation of a HSC. Together, the progeny of these 
cells contains cells of all blood cell lineages.  
We therefore set out to define whether HSC are generated upon in vitro 
differentiation of hESC. To this end, we inserted a transgenic marker into hESC, 
which allows to track the emergence and presence of HSC. This transgenic marker 
induces expression of a fluorescent protein encoding gene (enhanced green 
fluorescent protein, eGFP) when expression of a key HSC marker is induced. As key 
HSC marker, we chose MYB, as this gene was shown to be highly expressed in 
murine HSC and MYB was found to be essential for establishing a hematopoietic 
system based on HSC in the mouse model.  
Using an in vitro hematopoietic differentiation protocol for hESC, we were able to 
show that during the onset of hematopoiesis, no MYB-eGFP expression could be 
detected in cells that had emerged from hemogenic endothelium. Only later on in 
culture, CD34+ cells expressing MYB-eGFP became apparent. Upon assessment of 
the phenotype and properties of these MYB-eGFP+ cells, we found that while these 
express several progenitor markers, they were also marked by expression of myeloid 
lineage markers. Upon analysis of the lineage potential of MYB-eGFP+ progenitors, 
these cells showed clear myeloid granulocytic lineage restriction. These data thus 
argue against the formation of MYB-eGFP+CD34+ HSC in this in vitro differentiation 
system. In addition, the myeloid cells that are generated from hESC upon 
hematopoietic differentiation resemble myeloid cells generated in the embryo during 
a wave of HSC independent hematopoiesis in the YS. 
In conclusion, based on our study and previous reports, we conclude the in vitro 
hESC hematopoiesis resembles yolk sac hematopoiesis and thus that there is no 
formal proof for the generation of MYB-eGFP+ bona fide HSC in vitro. However, use 
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of a transgenic reporter line, as the one described here, might aid in the optimization 
of protocols with the aim of generating HSC from PSC. 
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2. Samenvatting van deel I 
 
Ernstige bloedziekten zoals severe combined immunodeficiency (SCID) of Wiskott-
Aldrich syndrome (WAS) worden momenteel behandeld door middel van een 
allogene transplantatie met bloedstamcellen (hematopoietische stamcellen, HSC) 
van een compatibel familielid (haploidentisch donor). Een alternatieve behandeling 
bestaat uit transplantatie van autologe HSC waarin het aangetaste gen werd 
gecorrigeerd, de zogenaamde gentherapie. Deze genetische correctie gebeurt door 
het inbrengen van virale vectoren in de HSC. Deze virale vectoren bevatten een 
correcte kopie van het aangetaste gen. Bij deze methode wordt een correcte kopie 
van het gen willekeurig in het genoom ingebracht en ononderbroken tot expressie 
gebracht. Deze therapie wordt momenteel succesvol toegepast in de kliniek, 
ondanks maligne transformatie die beschreven werd bij deze methode. Vaak 
ontstaan deze ongewenste effecten door de integratie van de virale vectoren in, of 
nabij, potentiële oncogenen. Deze inserties kunnen mogelijk leiden tot maligne 
transformatie en de ontwikkeling van leukemie induceren. Door recente 
ontwikkelingen in transgene methoden, is het momenteel mogelijk om een specifieke 
genomische sequentie aan te passen, door gebruik van “tailored nucleases”. Dit laat 
toe het gemuteerde gen zelf te corrigeren, zonder willekeurig inbrengen van een 
gecorrigeerde kopie. Een bewijs voor de toepasbaarheid van dit principe werd recent 
beschreven voor gentherapie in autologe HSC. Echter, de efficiëntie van deze 
methode is laag en zou enkel succesvol kunnen zijn in gevallen waar het 
gecorrigeerde gen een sterk selectief voordeel geeft ten opzichte van het 
gemuteerde gen. Momenteel zijn geen methodes beschikbaar om HSC in kweek te 
houden, dus is het niet mogelijk om na te gaan of deze methode ongewenste 
mutaties of additionale integraties van het gecorrigeerde gen induceerde in de cellen. 
Pluripotente stamcellen (PSC) hebben de mogelijkheid om elk celtype van het 
lichaam te vormen. Bijna 10 jaar geleden, werd een methode beschreven om deze 
eigenschappen over te brengen naar cellen die geïsoleerd werden uit de huid van 
volwassen individuen. Dit proces noemt men “reprogrammering”. Recent werden ook 
methoden beschreven om cellen die geïsoleerd zijn met behulp van minder invasieve 
methoden, zoals bloedcellen, te reprogrammeren. De cellen die via deze methode 
worden gegenereerd noemt men geïnduceerde pluripotente stamcellen (iPSC). Deze 
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cellen kunnen ongelimiteerd worden gekweekt zonder hun pluripotente 
eigenschappen te verliezen, en kunnen dus op een klonale manier worden 
opgegroeid. Genetische modificatie met tailored nucleases word reeds toegepast in 
PSC onderzoek. Deze cellen zouden ideaal zijn voor de generatie van HSC voor 
gentherapie. Gezien hun eigenschappen, laten deze cellen immers toe om na te 
gaan of er ongewenste effecten zijn door de behandeling. Bovendien kunnen correct 
aangepaste cellen geselecteerd worden. 
De generatie van HSC uit PSC is al lang een doel voor stamcelonderzoekers. De 
succesvolle generatie van cellen met HSC eigenschappen uit humane embryonale 
stamcellen (hESC), dewelke een ander soort pluripotente stamcel is, werd reeds 
geopperd. Echter, geen enkele publicatie kon overtuigend de aanwezigheid van 
cellen die aan alle HSC eigenschappen voldoen aantonen. Tijdens embryonale 
ontwikkeling worden ook verschillende progenitorcellen gegenereerd naast HSC, 
dewelke niet aan alle stamcel eigenschappen voldoen. Deze progenitoren worden in 
het embryo vooral gegenereerd in de dooierzak vóór het ontstaan van een HSC. De 
dochtercellen die door deze verschillende progenitoren worden gegenereerd, 
bevatten samen alle types bloedcellen.  
In onze studie hebben we onderzocht of HSC worden gevormd tijdens de in vitro 
differentiatie van hESC. Hiervoor werd een transgene merker ingebouwd in hESC die 
toelaat om de vorming en aanwezigheid van HSC te volgen. Deze transgene merker 
breng een fluorescent eiwit (eGFP) tot expressie, gelijktijdig met de expressie van 
een belangrijke HSC merker. Als HSC merker kozen we MYB, gezien dit gen sterk 
tot expressie komt in muis HSC en het MYB eiwit essentieel is om een 
hematopoietisch systeem op te bouwen op basis van HSC in de muis.  
Door gebruik te maken van een methode voor in vitro hematopoietisch differentiatie 
van hESC, waren we in staat om aan te tonen dat tijdens bloedvorming, geen MYB-
eGFP expressie kon worden gedetecteerd in cellen die ontstaan uit bloedvormend 
endotheel. Pas later tijdens de kweek konden CD34+ cellen worden gedetecteerd die 
positief waren voor MYB-eGFP. Tijdens het bepalen van het fenotype en de 
multipotente eigenschappen van deze cellen, vonden we dat ondanks de expressie 
van verschillende progenitor merkers, deze cellen ook positief waren voor myeloide 
merkers. Bij het bestuderen van het lineage potentieel, werd duidelijk dat deze cellen 
niet multipotent zijn, maar enkel in staat zijn om myeloide granulocytaire cellen te 
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vormen. Deze data ondersteunen de hypothese dat MYB-eGFP+ CD34+ HSC worden 
gevormd bijgevolg niet. Bovendien vertonen de myeloide cellen die worden gevormd 
tijdens in vitro differentiate van hESC sterke gelijkenissen met myeloide cellen die 
worden gevormd in de dooierzak van het embryo onafhankelijk van HSC. 
We concluderen, dat op basis van onze studie en voorgaande publicaties, in vitro 
hESC hematopoiese lijkt op dooierzak hematopoiese en dat er dus geen formeel 
bewijs is voor de vorming van echte HSC in vitro. Het gebruik van transgene 
reporterlijnen, zoals deze hier beschreven, zou kunnen helpen in de verbetering van 
methoden die richten op de vorming van HSC uit PSC. 
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3. Introduction of part I 
 
3.1 Pluripotent stem cells 
 
Pluripotent stem cells (PSC) can give rise to cells of all three germ layers (endoderm, 
mesoderm and ectoderm) and thus possess the ability to generate virtually every cell 
type of the human body.  
After decades of research on teratocarcinoma cells (1, 2) and embryonal carcinoma 
cells (3, 4), murine embryonic stem cells (mESC) were first derived in 1981 (5, 6). 
mESC are derived from the inner cell mass (ICM) of a developing blastocyst, through 
culture on a mitotically inactivated fibroblast feeder layer (Figure 1).The first human 
embryonic stem cell (hESC) lines were derived by the group of James Thomson 17 
years later (7). These hESC are derived by culture of human pre-implantation 
embryos and develop through a post-ICM intermediate (PICMI) (Figure1) (8). Both 
murine and human ESC are cultured on a feeder layer, which consists of murine 
embryonic fibroblasts (MEF). However, feeder-free culture systems for pluripotent 
stem cells (PSC) have been described (9, 10). Both mESC and hESC can be kept in 
culture indefinitely without differentiation, using the aforementioned culture 
techniques. 
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Figure 1: Differences in the origin of murine embryonic stem cells (mESC) and 
human embryonic stem cells (hESC).  
Derivation of hESC proceeds through a post-inner cells mass (PICMI) stage, leading 
to epiblast-like stem cells (EpiSC). In contrast, mESC can be isolated directly from 
the ICM (figure adapted from O’leary et al. (8)).  
 
Both murine and human ESC are pluripotent, however they are markedly different in 
their origin and characteristics. While mESC are ICM derived, hESC show close 
similarity to epiblast-like stem cells (EpiSC)(Figure1) (11, 12). These differences are 
reflected in the different behavior of hESC compared to mESC: they are not 
dependent on LIF signaling, and readily undergo apoptosis upon dissociation (13-
15). The surface marker profile of mESC and hESC was also found to be different 
(table I) (16). mESC are in a naive pluripotent ground state, while EpiSC are in a 
primed state, meaning that their fate is somewhat skewed, rendering them not fully 
pluripotent sensu stricto. PSC with similar characteristics as hESC have been derived 
from mouse post implantation blastocysts (11). These EpiSC do not efficiently 
contribute to blastocyst chimeras, proving their priming (11, 17). During differentiation 
into post-implantation epiblast cells, naive PSC are skewed to become primed PSC, 
with more restricted differentiation capacity, and elicit different sensitivity to 
environmental cues (18). It has been shown that EpiSC can be successfully 
reprogrammed towards naive PSC in the murine system (19); similarly hESC have 
been induced towards a naive pluripotent state by addition of kinase inhibitors (20) 
 
Table I. Surface marker profile of human and murine ESC  (data adapted from Ginis 
et al.(16)). 
Surface marker Human ES (H1) Murine ES (D3) 
SSEA1 - + 
SSEA3 + + 
SSEA4 + - 
TRA1-60 + - 
TRA1-81 + - 
SSEA: stage specific surface antigen; TRA: tumor rejection antigen 
In vitro studies on human hematopoiesis  Stijn Vanhee 
!
28 | 
!
 
A standard assay to assess pluripotency of PSC is the ability to generate teratomas 
upon injection of mESC and hESC in immune deficient mice (6, 7). Teratomas, which 
are formed after injection of ESC, should contain cells derived from all three germ 
layers, which proves the pluripotent properties of ESC. mESC pluripotency is 
evaluated in the tetraploid complementation assay. In this assay, tetraploid 
blastocysts are injected with mESC (21, 22). The ESC derived germ cells should then 
be able to give rise to a healthy adult animal. 
The derivation and use of hESC lines remains a topic of ethical debate and their use 
in the clinic is limited. Almost a decade ago the group of Shinya Yamanaka described 
protocols which allowed the induction of pluripotent stem cell (PSC) properties in fully 
differentiated adult cells. The cells generated through this method are called “induced 
pluripotent stem cells” (iPSC). Both murine iPSC (miPSC) and human iPSC (hiPSC) 
were initially generated by reprogramming of fibroblasts (23, 24). In these reports, 
reprograming was obtained by introducing Oct3/4, Sox2, c-Myc and Klf4 through 
retroviral transduction of the somatic cells. iPS cells show close morphological 
similarity to ESC and have similar properties (23-25). For murine iPSC it was shown 
that these can contribute to the development of a chimeric murine embryo after 
blastocyst injection, formally proving their pluripotency (26, 27).  
Since these initial reports, other protocols have been described to generate hiPSC 
from different sources which are less invasive, such as hematopoietic stem cells 
(HSC) from cord blood (CB) samples or peripheral blood mononuclear cells (PBMC) 
(28-30). Also, advances have been made in reprogramming using non-integrating 
techniques such as transfection of mRNA (31), transfection of protein (32) or 
transduction with non-integrating Sendai viral particles (33). All these methods 
circumvent the use of potentially oncogenic viral integration techniques and bring the 
application hiPSC in the clinic one step closer.  
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3.2 Human embryonic stem cell transgenesis 
 
The generation of transgenic models has become the standard method to study the 
function of genes. In the murine system, the use of knockout models or reporter 
strains has greatly added to the knowledge of gene function during hematopoietic 
development. Similar in vitro models are powerful tools to study human 
hematopoiesis. In addition, reporter cell lines can be used for the optimization of in 
vitro protocols that aim at generating HSC.  
Transgenic mice are frequently generated by bacterial artificial chromosome (BAC) 
transgenesis. BACs are large plasmids containing genomic DNA of the organism of 
interest. For the murine and also for the human genome a library has been generated 
with an average insert size of approximately 200kbp (34, 35). These BACs can be 
modified in bacteria through recombineering (36, 37). This allows for the induction of 
point mutations and introduction of deletions, selection cassettes, genetic code for 
fluorescent markers as well as recombination sites (LoxP, FRT). In addition, BACs 
can be used for the introduction of homology arms in donor constructs for 
homologous recombination (HR) in the endogenous genomic locus (38). Alternatively, 
as promoter regions and regulatory elements are often included within the BAC 
sequence, modified BACs can be used for the generation of reporter cell lines (39, 
40). Insertion of such large genomic sequence can isolate the transgene, so that 
expression is not influenced by neighboring genes (41).  
To date, only a limited set of hESC reporter lines are available, which are useful in 
the analysis of hematopoietic development. The group of Andrew Elefanty has 
generated hESC reporter lines which mark primitive streak mesoderm (MIXL1) (42), 
β-globin expression (43), hemogenic endothelium and emerging HSCs (SOX17) and 
hemogenic endothelium and hematopoietic cells (RUNX1) (meeting proceedings and 
personal communication). 
It has to be noted that although murine transgenic protocols are well established, 
protocols for transgenic modification of hESC have only improved in recent years. 
One of the major limitations has been the induction of apoptosis upon dissociation of  
hESC (15). This hampers transfection of hESC by electroporation and nucleofection 
for which a suspension of single cell hESC is required (44, 45). This problem was 
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partially alleviated by blocking the pathway leading to apoptosis through addition of 
the Rho kinase inhibitor Y-27632 (14).  
An additional problem with hESC transgenesis is the low efficiency of successful HR. 
HR is essential if reporter constructs are to be integrated in their endogenous loci. 
While reports have shown feasibility of this method in hESC using “gene trap” vectors, 
in which the expression of a selectable marker is driven by the gene to be targeted 
(42, 46), HR in hESC remains a relatively rare event (47, 48).  
With the emergence of tailored nucleases the efficiency of targeted transgenesis has 
improved. The use of tailored nucleases has proven to be highly efficient for the 
introduction of locus specific mutations (49-51). These nucleases are all based on a 
similar concept: nuclease proteins are guided to a specific genomic sequence to be 
targeted. This induces a sequence specific double strand break (DSB) in the DNA 
(Figure 2). There are 2 options by which a cell will subsequently repair DSB. Either 
the cell will ligate the two ends of the DSB, in a process called non-homologous end 
joining (NHEJ). This process generally introduces mutations by insertions or 
deletions of one or more nucleotides (indel mutations). NHEJ can be used to 
generate knockout cell lines. Alternatively, the cell may use a homologous DNA 
strand as a template for repair, in the process of homology directed repair (HDR). 
HDR can used to introduce transgene insertions by cotransfection of an excess of 
donor plasmid (52). 
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Figure 2: Options for genome repair upon induction of double strand breaks (DSB) 
by tailored nucleases.  
 
Induced DSB are corrected by one of two mechanisms. Either the cellular repair 
machinery ligates both ends of the break together through the process of non-
homologous end-joining (NHEJ), or the break is repaired through homology directed 
repair (HDR). The latter method can be used to introduce transgenes (Figure 
adapted from Naldini et al. (52)).   
 
Different tailored nucleases have been described: zinc finger nucleases (ZFN), 
transcription activator- like effector nucleases (TALEN) and Clustered Regulatory 
Interspaced Short Palindromic Repeats and associated nucleases (CRISPR/Cas9) 
(Figure 3). ZFNs consist of a pair of heterodimeric FokI nuclease domains, which are 
linked to a tandem of zinc finger domains. Each domain recognizes a nucleotide 
triplet in the genomic sequence. These zinc finger domains confer sequence 
specificity to the nuclease activity. ZFN generally consist of 6-8 zinc finger domains, 
that recognize 18-24 base pairs, which should in theory be sufficient to generate a 
site specific DSB. TALEN are based on a similar principle as ZFN, but have the 
advantage that single base recognition can be used in their design, in contrast to the 
triplet design of ZFN. The CRISPR/Cas9 system uses an alternative method for DNA 
recognition. Here a sequence specific crispr RNA (crRNA) anneals to a trans-
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activating crispr RNA (tracRNA), this complex is then bound by the Cas9 nuclease 
and guided to the targeted DNA sequence (reviewed by Gaj et al. (53)). The 
specificity of the CRISPR/Cas9 system can be further improved by the use of 
modified Cas9 proteins (nickases) or modified guiding RNA (50). The use of these 
tailored nucleases greatly increases the amount of potential HR events.  
 
 
Figure 3: Different options for genetic engineering using tailored nucleases.  
 
Several methods for the introduction of DNA breaks have been described, either a 
CRISPR/Cas9 complex can be used, in which a tracRNA can be introduced to induce 
sequence specific DNA breaks(a) or a chimera of the 3’ crRNA end and the 5’ 
tracrRNA end can be used (b). Alternatively, heterodimeric FokI nuclease domains 
can be coupled to either (c) transcription activator- like effectors (TALE) or (d) zinc 
finger (ZF) motifs (d), which confer sequence specificity to these nucleases (Figure 
adapted from Barrangou et al. (54)). 
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3.3 Hematopoiesis 
 
During murine hematopoiesis, hematopoietic cells with different characteristics are 
generated during the development of the embryo, at different locations and different 
time points (Figure 4)(reviewed by Dzierzak and Speck (55)). Hematopoiesis occurs 
both inside the embryo and in extra-embryonic tissues and consists of different 
waves. The first wave of hematopoiesis is termed the “primitive” wave and is initiated 
outside the embryo proper, within the yolk sac (YS). The second wave of 
hematopoiesis is termed the “definitive” wave and occurs both outside the embryo 
proper and inside the embryo. Definitive hematopoiesis is initiated in the YS and 
shifts towards hematopoietic sites inside the embryo. Here, HSC are generated in the 
aorta-gonado-mesonephros (AGM)/splanchnopleura region, which will subsequently 
migrate to the fetal liver (FL). In the FL, these HSC mature and expand, after which 
they colonize the bone marrow to sustain lifelong hematopoiesis. 
 
Figure 4: Overview of the ontogeny of the hematopoietic system in mice. 
Sites of active hematopoiesis are shown at the respective time points during 
embryonic development. E: embryonic day, AGM: aorta-gonado-mesonephros 
(Figure adapted from Dzierzak et al. (55)) 
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3.4 Primitive hematopoiesis 
 
During the primitive hematopoietic wave, the first hematopoietic cells are formed in 
the extra-embryonic tissues around E7.5. These cells are formed within the blood 
islands of the YS (56). Here, hematopoietic cells are found in close proximity of the 
endothelial cells lining these blood islands. The first blood cells generated within the 
blood islands are nucleated red blood cells and primitive macrophages. They are 
marked by their large size and the expression of both embryonic and fetal 
hemoglobin chains (57). During primitive hematopoiesis no HSC are formed, as at 
E7.5-E8.25 no transplantable HSC can be derived from the YS. At this timepoint, no 
evidence for the presence of multipotent progenitors can be found (58). 
 
3.5 Early definitive hematopoiesis 
 
The primitive wave of hematopoiesis is followed by a definitive wave, spatially 
overlapping both YS and AGM/splanchnopleura regions. During early definitive 
hematopoiesis, the YS gives rise to multiple types of hematopoietic (progenitor) cells. 
At E7.5-E8.5 monocytes are generated, which are part of the mononuclear 
phagocyte system (MPS) in the YS. These monocytes are generated independent of 
a HSC and sustain lifelong. The cells generated at this timepoint include tissue 
macrophages such as Kupffer cells, skin Langerhans cells and microglia. The YS has 
also been shown to form a lympho-myeloid restricted precursor (LMP) already before 
the initiation of AGM hematopoiesis. It has been reported recently, that lymphoid 
potential can be found through ex vivo culture of the YS and para-aortic-splanchno 
pleura (PAS) endothelium derived at E9.5 (59). At this timepoint HSC have not yet 
been formed. Proof for this concept in vivo has also been provided recently (60).  
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3.6 Late definitive hematopoiesis 
 
After the initial wave of definitive hematopoiesis in the YS, bona fide HSC are formed 
in the aorta-gonado-mesonephros (AGM)/splanchnopleura region. Proof for the 
generation of HSC in the AGM region at E10 was provided almost two decades ago 
(58). Using explant cultures of YS, AGM and FL regions, it was shown that HSC 
formation is initiated in the E10 AGM region, and that the YS lacks any transplantable 
activity at this time point. Immature HSC are formed in the ventral region of the E10 
AGM directly from the endothelial lining, a concept also found in other model 
organisms, such as the zebrafish (61, 62). However, HSC generated in the AGM do 
not immediately hold their full potential, but first require functional maturation and 
expansion in the FL (63). These mature definitive HSC will then seed the spleen and 
bone marrow to sustain lifelong HSC-dependent hematopoiesis. The embryo 
becomes dependent on HSC hematopoiesis around E15.  
Human hematopoiesis has been described to follow similar pathway (Figure 
5)(reviewed by Peters et al. (64)). 
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Figure 5: Overview of human hematopoietic development. 
During human hematopoiesis, the embryo will generate a primitive hemangioblast 
from the extraembryonic mesoderm and generate primitive hematopoietic progenitors 
(15-18 days of gestation). In the AGM region, the hemogenic endothelium will give 
rise to HSC (21-26 days of gestation)(Figure adapted from Peters et al.(64)) 
 
During the onset of hematopoiesis hematopoiesis, several transcription factors are 
important at different time points. Some of these transcription factors are already 
essential during the onset of primitive hematopoiesis, while others are not essential 
until the hematopoietic system becomes dependent on HSC. Among these factors 
are SCL, LMO2, GATA2, RUNX1 and MYB. 
 
During early  hematopoiesis SCL is an important factor, as mice lacking this 
transcription factor die around day 9.5 of gestation (E9.5). In the yolk sac of these 
SCL-/- animals, no hematopoietic activity can be detected (65). Similarly LMO2-/- mice 
fail to engage primitive and definitive hematopoiesis, this genotype is embryonically 
lethal around E9.75 (66). Other factors are not essential for the onset of primitive 
hematopoiesis, both are necessary for HSC generation and expansion. One of these 
factors is GATA2. As primitive and early definitive hematopoiesis is initiated, these 
mice survive until the point where the embryo generates and expands HSC. These 
GATA2-/- mice die around E10.5 (67). RUNX1-/- mice, die at E12.5. While 
erythrocytes have been described to be abnormal, suggesting a role already in 
primitive hematopoiesis, these mice do generate primitive erythrocytes (68). Using 
conditional deletion models, Chen et al. were able to show that RUNX1 plays an 
essential role during endothelial to hematopoietic cell transition, but not once the 
HSC are formed in the AGM (69). During definitive hematopoiesis, the transcription 
factor MYB has been shown to play an essential role in regulating HSC. in the murine 
system, a MYB-/- transgene is lethal E15 (61). This is due to a failure of the embryo to 
switch to HSC based hematopoiesis. More recently, conditional MYB knockout 
models were described, where the important role of MYB in HSC biology has been 
emphasized. Not only is MYB highly expressed in long-term repopulating HSC (LT-
HSC), it plays an essential role in the maintenance of self-renewal properties (62, 63).  
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There seems to be a differential role of MYB during early and late definitive 
hematopoiesis. The first is HSC independent while the latter depends on HSC. Here 
recent reports show that tissue macrophages develop from MYB- YS precursors (64). 
This data suggests that MYB is a preferred marker for HSC, as it can distinguish 
HSC based hematopoiesis from primitive and early definitive hematopoiesis. 
 
3.7 Hematopoietic stem cells 
 
A HSC has three essential characteristics: 1) it is capable of generating every type of 
blood cell (multipotent); 2) is able to reconstitute the blood system of animals upon 
transplantation (engraftable); and 3) is able to divide, with one of the daughter cells 
maintaining these properties (self-renewing). A cell that lacks any one of these three 
properties is not a bona fide HSC, but rather a type of hematopoietic precursor.     
The characterization of bona fide HSC using surface markers is of great interest for 
both the clinic and fundamental research. As a number of distinct multipotent stages 
are generated from the LT-HSC, the differential surface expression of membrane 
markers should be able to discriminate between these stages of HSC development 
(Figure 6). The HSC population can be functionally subdivided into LT-HSC, 
intermediate-term repopulating HSC (IT-HSC) and short-term repopulating HSC (ST-
HSC). Eventually, the ST-HSC will differentiate into a population of multipotent 
progenitors (MPP). All of these cells are multipotent and provide (limited) engraftment, 
however only the LT-HSC can sustain lifelong hematopoiesis. The MPP will undergo 
lineage commitment during further differentiation. In the human system, the MPP 
develops either into a myelo-lymphoid progenitor (MLP) or a common myeloid 
progenitor (CMP). The MLP can give rise to B, T, NK, dendritic and monocytic cells, 
while the CMP can develop into a granulocyte-monocyte precursor (GMP) or a 
megakaryocyte-erythrocyte precursor (MEP) that will differentiate into granulocytes 
and monocytes and megakaryocytes and erythrocytes, respectively (reviewed by 
Doulatov et al. (70)). 
The surface phenotype of both murine and human LT-HSC has been partly 
characterized (Figure 6). All murine HSC reside within the lineage negative (Lin-) 
Sca1+cKit+ (LSK) population. Here, the MPP can be excluded, by their expression of 
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CD34 and their absence of CD150 expression. The LT-HSC containing population 
can be defined as being Lin-CD34-CD150+CD48-CD41-Flt3-CD49blo. This extended 
phenotype defines the LT-HSC population, as about 33-50% of cells are LT-HSC. For 
human HSC, use of the Lin−CD34+CD38−CD45RA−Thy1+RholoCD49f+ phenotype 
described by Notta et al. defines a population in which about 14-28% of the cells are 
LT-HSC (71).  
 
 
Figure 6: Developmental model for hematopoietic stem cell differentiation in mouse 
and human. 
HSC: hematopoietic stem cell, LT: long-term, IT: intermediate-term, ST: short-term; 
MPP: multipotent progenitor population; LMPP: lympho-myeloid progenitor 
population; CLP: common lymphoid progenitor; CMP: common myeloid progenitor; 
ETP: early thymic progenitor; GMP: granulocyte-monocyte precursor; MEP: 
megakaryocyte-erythrocyte progenitor; MLP: myelo-lymphoid progenitor (Figure 
adapted from Doulatov et al. (70)) 
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However, the surface phenotype of HSC, especially of cells generated or 
manipulated in vitro does not always correlate with their functional capacities. It is 
therefore required to validate the phenotype by in vitro or in vivo functional assays for 
stem cell function.  
Multipotency can be tested in vitro using colony forming unit (CFU) assays. For this 
assay, cells are cultured in semisolid medium containing a mixture of hematopoietic 
cytokines. As the medium is semisolid and migration of cells is limited, the progeny of 
one single cell can be assessed. The progeny is usually scored for red blood cells, 
megakaryocytes and myelomonocytic cells. However it has to be noted that lymphoid 
potential is not addressed using this CFU assay. Alternatively, presumptive HSC can 
be tested in a differentiation assay where a single cell of the population of interest is 
deposited per well. By addition of instructing cytokines and feeder cells, cells can be 
differentiated towards erythroid, megakaryocytic, myeloid and lymphoid cells. The 
phenotype of this progeny can then be assessed using flow cytometry.  
The capacity to engraft and to self-renew can only be addressed using an in vivo 
assay: the SCID repopulating cell assay (SRC) (72). Here, sublethally irradiated 
immune deficient mice are injected with a human hematopoietic progenitor cell 
suspension. After 6-8 weeks, engraftment is scored by assessing human/mouse 
chimerism in the blood. Self-renewal is assessed by secondary or tertiary 
transplantation of bone marrow from the engrafted animals (73).  
 
3.8 Hematopoietic differentiation of human pluripotent stem cells 
 
Since the initial derivation of hESC several protocols have been described to induce 
their hematopoietic differentiation (74-80). Differentiation towards several 
hematopoietic lineages has been described from PSC. NK cells (81), T cells (82), 
megakaryocytes (83), erythrocytes (84), monocytes and granulocytes (85) have all 
been generated through in vitro differentiation of hESC and hIPSC . 
 
In vitro studies on human hematopoiesis  Stijn Vanhee 
!
40 | 
!
 
Figure 7: In vitro hematopoietic differentiation of human embryonic stem cells. 
Pluripotent stem cell colonies are dissociated and are re-aggregated to form 
embryoid bodies. After 7-10 days, clear “hematopoietic zones” are visible. Here 
endothelial cells (CD34+, red) are lining hematopoietic cells (CD43+, green). 
 
hESC differentiation protocols are mainly based on two methods: stroma based 
differentiation methods (74, 75, 86) and embryoid body (EB) differentiation methods 
(76-78). For the first method, undifferentiated PSC colonies are fragmented and 
transferred onto a stromal cell layer, known to support hematopoietic differentiation. 
Examples of such cell lines are the OP9 cell line (derived from the bone marrow of 
op/op mice) (87) and the S17 cell line (generated through long-term culture of bone 
marrow from BALB/cAN mice) (88). For the EB method small fragments of 
undifferentiated hESC, or a suspension of single cells, are allowed to re-aggregate in 
a small clump and are subsequently allowed to differentiate. 
In standard differentiation protocols, feeder cells of murine origin are used or media 
containing components of animal origin are used for culture. Most of these protocols 
generate blood cells with relatively low efficiency with 1-10% CD45+ cells. If PSC-
derived hematopoietic cells are to be used in a clinical setting, so called xeno-free 
protocols are needed. Xeno-free protocols are devoid of any component of animal 
origin and make use of recombinant growth factors. To date, few of these methods 
have been described (79, 89).  
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In vitro hematopoietic hESC differentiation seems to closely mimic the steps through 
which in vivo hematopoiesis occurs (Figure 5) (64). Upon differentiation of the hESC, 
these go through a mesodermal stage, before they generate hemangioblast cells, 
which have the potential to form endothelial and hematopoietic cells. The subsequent 
stages during in vitro hematopoiesis can be easily distinguished by two markers: 
sialomucin gp105-120 (CD34) and leukasialin (CD43) (Figure 8) (90). CD34 marks 
endothelial cells and hematopoietic progenitor cells, while CD43 is the earliest pan 
hematopoietic marker found in hESC differentiation cultures. 
 
Figure 8: Kinetics of in vitro hESC hematopoiesis. 
Representative dot plots are shown for EB’s analyzed after 7, 11 and 14 days of 
culture. Cells were stained with the endothelial cell and progenitor cell marker CD34, 
the early pan hematopoietic marker CD43 and the late pan hematopoietic marker 
CD45. 
After 5-6 days of culture, endothelial cells can be detected in these cultures. These 
are marked by strong expression of CD34 and lack of CD43 (Figure 8). After 7-8 
days, the first erythroid and megakaryocytic cells can be detected and these are 
negative for CD34 but positive for CD43. Subsequently definitive type hematopoietic 
progenitors can be found which increase in numbers from day 10 onwards and are 
marked by expression of both CD34 and CD43. Later on in culture, blood cells start 
to express the late pan hematopoietic marker CD45. The structures generated in 
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these cultures show high resemblance to the blood islands found in the YS, where 
hematopoietic cells are lined by endothelial cells. The general concept that 
hemogenic endothelial cells give rise to hematopoietic cells, also holds true for in 
vitro hematopoiesis of hESC (91, 92). Culture of purified CD34+CD43-CD45- 
endothelial cells readily generate hematopoietic cells, however the frequencies of 
these cells remain low.  
Several reports have claimed generation of hematopoietic progenitor cells capable of 
engraftment from hESC in vitro (93, 94). However, clear differences can be found 
between these hESC-derived multipotent progenitor cells and somatic HSC. While 
CFU progenitor frequencies have been described to be similar between somatic HSC 
and hESC-derived hematopoietic precursor cells (HPC), the hESC-derived HPC 
show a skewed CFU potential towards granulocytic cells compared with the potential 
of somatic HSC (93). After intrafemoral injection of hESC-derived HPC, engraftment 
remains low in the bone marrow compared with somatic HSC (10-100 fold lower). 
The bone marrow was found to contain ~0.1-1% human blood cells upon engraftment 
of hESC derived HPC (94). In these reports no evidence is provided for multilineage 
repopulation (93, 94). In a more recent report, hESC were differentiated towards 
hematopoietic cells on different stromal cell lines derived from murine urogenital 
ridges (UG), AGM and FL (75). This led to engraftment of hESC-derived HPC in the 
contralateral femur after intrafemoral injection. Human cells were found to constitute 
around 2% of bone marrow cells and peripheral blood contained around 16% human 
blood cells. Again, ample evidence is provided for multilineage repopulation, and the 
authors themselves claim that they cannot rule out the presence of long lived myeloid 
cells. 
Taken together, these reports do show engraftment of hESC-derived hematopoietic 
cells, but with low efficiency. Cells which can be serially transplanted and are capable 
of generating all blood cell lineages have not been unequivocally described. 
Moreover, hESC-derived HPC all seem to show the tendency to differentiate towards 
myeloid progenitors upon injection. Therefore, to date no convincing evidence has 
been provided for the in vitro generation of cells with HSC properties.  
Recent reports have described the generation of lympho-myeloid precursors (LMP) 
and erythro-myeloid precursors (EMP) cells during early definitive YS hematopoiesis 
in the murine system. In addition, striking similarities between the timing of 
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hematopoiesis and the potential of the cells generated during in vitro hESC 
differentiation and in vivo human hematopoiesis have been described (64). It might 
thus not be illogical to hypothesize that in vitro hESC hematopoietic differentiation 
might mimic YS definitive hematopoiesis, without the formation of HSC. 
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5. Research focus of part I 
 
PSC have the capacity to generate every cell type of the body. Not soon after the 
derivation of embryonic stem cells, protocols were published to differentiate these 
cells into hematopoietic cells. As almost every hematopoietic cell type has been 
generated starting from pluripotent stem cells, a common misconception is that a 
HSC must lie at the basis of these different cell types. 
This presumptive generation of HSC, led to several publications claiming successful 
engraftment of PSC derived HSC in immune deficient animals. Together with the 
description of iPSC from patient derived somatic cells, this has raised high hopes in 
generating patient specific transplantable HSC for the clinic. 
Study of hematopoiesis in the murine system is uncovering the hematopoietic system 
to be even more complex than previously appreciated. Before a cell with HSC 
properties is formed in the embryo, a whole array of hematopoietic precursors is 
generated in the YS and the AGM/splanchnopleura. These precursors have limited or 
no engraftment capacity. In the YS, which is the extra-embryonic part of the 
developing fetus, progenitors are formed which are able to generate erythroid, 
myeloid and lymphoid cells. The fact that all hematopoietic cell lineages are found in 
culture, therefore, in no way implies the presence of a HSC. 
We hypothesized that during in vitro PSC derived hematopoiesis one of the former 
two types of hematopoiesis could occur. Either a cell with HSC characteristics is 
formed (AGM-like hematopoiesis), or more restricted progenitors are formed (YS-like 
hematopoiesis). Previous studies addressed this by testing the engraftment capacity 
of the cells generated, albeit with limited success. In the study described here, we 
used an alternative in vitro strategy. We based our hypothesis on the essential role 
which has been described for the transcription factor MYB in the function of HSC. 
MYB has been described to be expressed at high levels in HSC, and expression 
levels decrease during differentiation towards lineage progenitors. On the other hand, 
YS-based hematopoiesis has been described to be independent of MYB. We thus 
put forward that expression of MYB during the formation of hematopoietic progenitor 
cells would allow us to discriminate between the emergence of a MYB+ HSC or a 
MYB- YS-like precursor. 
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To this end we have generated a MYB-eGFP human embryonic stem cell line and 
assessed the latter hypothesis during in vitro hESC differentiation.  
The results of this study call for a critical re-assessment of previously published 
papers, as we found no cells with HSC characteristics, expressing high levels of MYB. 
Rather, hematopoiesis in these cultures seems to closely resemble YS based 
hematopoiesis, with the formation of tissue macrophages. The only MYB signal that 
could be detected, was during granulocytic commitment of these progenitors. 
We believe that use of a reporter cell line as the one we described, and adaptation of 
culture protocols, will aid the field in the search for factors which induce the 
generation of HSC from pluripotent stem cells. 
Given the recent insights in hematopoietic development both in vitro and in vivo, and 
the data generated in our study, we discuss the relevance of these findings for gene 
therapy of hematological diseases. 
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Abstract 
 
Although hematopoietic precursor activity can be generated in vitro from human 
embryonic stem cells, there is no solid evidence for the appearance of multipotent, 
self-renewing and transplantable hematopoietic stem cells. This could be due to short 
half-life of hematopoietic stem cells in culture or, alternatively, human embryonic 
stem cell-initiated hematopoiesis may be hematopoietic stem cell-independent similar 
to yolk sac hematopoiesis, generating multipotent progenitors with limited expansion 
capacity. Since Myb was reported to be an excellent marker for hematopoietic stem 
cell-dependent hematopoiesis, we generated a MYB-eGFP reporter human 
embryonic stem cell line to study formation of hematopoietic progenitor cells in vitro. 
We found CD34+ hemogenic endothelial cells rounding up and developing into 
CD43+ hematopoietic cells without expression of MYB-eGFP. MYB-eGFP+ cells 
appeared relatively late in embryoid body cultures as CD34+CD43+CD45-/lo cells . 
These MYB-eGFP+ cells were CD33 positive, proliferated in IL-3 containing media 
and hematopoietic differentiation was restricted to the granulocytic lineage. In 
agreement with data obtained on murine Myb-/- embryonic stem cells, bright eGFP 
expression was observed in a subpopulation of cells, during directed myeloid 
differentiation, which again belonged to the granulocytic lineage. In contrast, CD14+ 
macrophage cells were consistently eGFP- and were derived from eGFP- precursors 
only. In summary, no evidence was obtained for in vitro generation of MYB+ 
hematopoietic stem cells during embryoid body cultures. The observed MYB 
expression appeared late in culture and was confined to the granulocytic lineage. 
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Introduction 
 
During embryogenesis, hematopoietic development is spatiotemporally organized in 
different waves. During the first, so-called primitive wave of hematopoiesis, nucleated 
erythrocytes and macrophage-like cells are generated in the yolk sac (YS). 
Subsequent waves generate multipotent progenitor cells, first in the YS and, finally, 
in the aorta-gonado-mesonephros region (AGM) where hematopoietic stem cells 
(HSCs) are generated (1).  
Members of the MYB transcription factor family are important transcriptional 
regulators throughout embryonic development. One of these three family members, 
MYB, is differentially expressed during embryonic hematopoietic development (2). 
While Myb transcripts have been detected at low levels during early waves of 
hematopoiesis, this process is not MYB-dependent. In contrast, HSC-dependent 
hematopoiesis appears to strictly rely on MYB as loss of function mutants of MYB 
lead to embryonic lethality due to failure of fetal liver hematopoiesis (3, 4). In the 
zebrafish, transgenic animals expressing eGFP under control of myb regulatory 
elements have been used for visualization and analysis of HSC generation from 
aortic blood forming hemogenic endothelium (5). 
In postnatal life, long term repopulating hematopoietic stem cells (LT-HSC) were 
found to express the highest levels of Myb and levels decrease progressively in short 
term repopulating HSC (ST-HSC) and in the multipotent progenitor population 
(MPP)(6, 7).  
MYB-independent hematopoiesis consists largely of short-lived precursors and 
mature blood cells.  However, the mononuclear phagocyte system (MPS), consisting 
of brain microglial cells, hepatic Kupffer cells and skin Langerhans cells, seems to be 
derived from MYB-independent hematopoietic progenitor cells (HPC) rather than 
bone marrow-derived MYB-dependent HSC. Recently, Schulz and colleagues have 
shown that two parallel pathways of macrophage differentiation can be distinguished 
by their inherent dependence on MYB (8). MYB-independent cells originate in the 
yolk sac around E7.5-E8.5, possibly from an erythro-myeloid restricted precursor 
(EMP), while MYB-dependent macrophages originate from bone marrow HSC.   
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Gene therapeutic strategies for inherited immune deficiencies or other genetic 
diseases of the blood rely on the assumption that HSC can be generated in vitro from 
pluripotent stem cells(9). In these approaches, patient-specific induced pluripotent 
stem cells are generated and the defective gene is corrected by homologous 
recombination subsequent to targeting the gene defect by zinc-finger nucleases (ZFN) 
or TALENs. Once the genetic defect is corrected, “cured” HSC are generated by an 
appropriate in vitro differentiation protocol before infusion. However, current protocols 
have failed to convincingly demonstrate the generation of HSC in pluripotent stem 
cell differentiation cultures.  
To investigate whether during in vitro human embryonic stem cell (hESC) derived 
hematopoiesis HSC are formed or rather, hematopoiesis from hESC depends on the 
emergence of a myb independent EMP-like cell, we generated a MYB reporter line 
using random integration of a bacterial artificial chromosome (BAC) reporter 
construct in which eGFP expression is under control of the MYB regulatory DNA 
sequences.  
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Methods 
 
Cell lines, culture of cell lines and isolation of primary cells 
All experiments were approved by the Medical Ethical Committee of Ghent University 
Hospital (Belgium).  The WA01 (National Institutes of Health code: WA01) human 
embryonic stem cell (hESC) line was used in all experiments. Further methods 
describing used cells and culture of cells can be found in supplemental materials.  
Hematopoietic differentiation of hESC in spin embryoid bodies (EB)  
To differentiate hESC into hematopoietic cells, the protocol from Ng et al. was used 
with minor modifications(10). In brief, 5x103 single cell-adapted hESC were spun at 
480 g into each well of a 96-well low attachment plates and subsequently cultured in 
APEL medium containing 10 µM Rock inhibitor Y-27632 (Selleckchem, Houston, TX, 
USA), 40 ng/ml SCF (Peprotech, Rocky Hill, NJ, USA), 2 ng/ml BMP4 (R&D, 
Minneapolis, MN, USA) and 20 ng/ml VEGF165 (Peprotech), further referred to as 
“EB mix”. After 4 days, spin EB were transferred on an OP9 cell layer and further 
cultured in EB mix for  a total of 7-14 days. Half of the medium was changed on day 
7, with APEL medium containing EB mix cytokines, unless a different combination of 
cytokines is specified. These cytokines were added at following concentrations: 50 
ng/ml IL-3 (R&D), 50 ng/ml Flt3-L (R&D), 10 ng/ml TPO (Peprotech) and/or 50 ng/ml 
IL-6 (R&D).  
For myeloid differentiation, spin EBs were dissociated at day 11 and transferred onto 
OP9 cells in MEM-a with 20% FCS, supplemented with 50 ng/ml SCF (Peprotech), 
50 ng/ml TPO (Peprotech), 10 ng/ml IL3 (R&D) and 20 ng/ml IL-6 (R&D). For erythro-
megakaryocytic differentiation, spin EBs were dissociated and transferred onto OP9 
cells in MEM-a with 20% FCS, supplemented with 50 ng/ml SCF (Peprotech), 50 
ng/ml TPO (Peprotech) and 50 ng/ml EPO (eBioscience, San Diego, CA, USA).  
Flow cytometry and cell sorting 
Flow cytometric analysis was performed on a LSR II system (BD biosciences, San 
Jose, CA, USA). Cell sorting was performed with a FACS ARIA IIIU system (BD 
Biosciences). A list of antibodies used  can be found in supplemental materials. 
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Real time RT-PCR 
Cells were lysed and cDNA was synthesized using the SYBR power cells-to-Ct 
system (Ambion, Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Primer sequences can be found in supplemental Table 
S1. PCR reagents and SYBR GreenI master were obtained from Roche (Roche, 
Penzberg, Germany) and used according to the manufacturer’s instructions. The 
reactions were run on a lightcycler480, 384well system (Roche).  
 
 
Statistical analysis 
All statistical analyses were performed using SPSS V22.0 (IBM, New York, USA). 
Significance was assessed using Mann-Whitney U statistical analysis with 
significance level set at p ≤ 0.05. 
Additional materials and methods are provided in supplemental materials and 
methods file. 
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Results 
Generation of MYB-eGFP transgenic reporter hESC. 
To study MYB expression during hematopoietic differentiation, we generated a MYB-
eGFP reporter hESC line using random insertion bacterial artificial chromosome 
(BAC) transgenesis (supplemental figure 1).  
 
Figure 1: Functional validation of MYB-eGFP reporter hESC. 
A) MYB FISH analysis (green) on metaphase nuclei (DAPI stain in grey); inset shows 
chromosome 11 only; B) ArrayCGH showing amplification of the genomic region within the 
BAC plasmid. A relevant portion of chromosome 6 is shown; c) Validation of selection 
cassette removal, as assessed by PCR ranging from eGFP to the first exon of MYB (upper 
gel)  or ranging from pPGK to the first exon of MYB (lower gel); D) MYB-eGFP reporter 
hESCs differentiated towards the hematopoietic lineage were analyzed for eGFP expression. 
CD34+CD43- endothelial and CD43+ hematopoietic populations are depicted. Both floxed and 
non-floxed cell lines are shown; E) Confocal fluorescence microscopy of a day 20 EB culture 
in EB mix showing bright eGFP positive round cells, scale bare measures 100µM; F) MYB 
qPCR analysis of eGFP sorted hematopoietic cells from EB differentiation culture. 
Expression is shown relative to the mean of GAPDH and YWHAZ expression. Error bars 
indicate standard deviation (SD) of the mean (n=4). 
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After nucleofection of hESC and neomycin selection, neomycin-resistant hESC 
colonies were obtained. In figure 1, data are shown of clone 5, which gave highest 
eGFP expression and was used in all experiments. Besides the endogenous MYB 
loci on chromosome 6q, a clear hybridization signal on chromosome 11q was 
detected on FISH analysis, confirming successful integration of the BAC reporter 
vector (Figure 1 A). High-resolution arrayCGH shows integration of the BAC plasmid 
from +84.6 kbp 5’ of the MYB start codon to -39.3 kbp 3’ of the start codon. This 
region encompasses the complete MYB gene and upstream regulatory elements 
(Figure 1 B). 
Hematopoietic differentiation of the MYB-eGFP cell line, before removal of the 
selection cassette, showed eGFP expression by CD43+ hematopoietic cells as well 
as by CD34+CD43- endothelial cells (Figure 1 D). As no MYB transcripts could be 
found by qPCR analysis in the CD34+CD43- population (supplemental figure 2), 
aberrant expression due to interference of the pGK promotor was hypothesized. 
Therefore, the pGK promotor-driven selection cassette was removed through 
transient transfection with a Cre recombinase-encoding plasmid (Figure 1 C). After 
removal of the selection cassette, no eGFP expression was observed in non-
hematopoietic cells (Figure1 D). Although the expression of eGFP found at this point 
in time was relatively weak, prolonged culture, clearly showed strong eGFP+ cells as 
determined by confocal microscopy analysis of d20 EB differentiation cultures (Figure 
1 E).  
Fidelity of the random integration reporter cell line was validated by qPCR analysis 
for MYB expression. eGFP-, eGFPlow and eGFPhi cells were sorted from d14 
hematopoietic differentiation cultures in the presence of SCF, TPO, IL-3 and IL-6 and 
MYB mRNA levels were shown to correlate with eGFP protein expression in the 
sorted populations (Figure1 F and supplemental figure 2). Note that the eGFP- cells 
are not completely negative for MYB mRNA. This indicates that the reporter line is 
not as sensitive as RT-qPCR for MYB expression. However, this does not preclude 
the detection of HSC as these cells are supposed to express high levels of Myb(6). 
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Endothelium-derived early hematopoietic precursors are MYB-eGFP negative. 
Spin EB cultures were set up and screened daily for the appearance of 
hematopoietic eGFP+ cells. Expression of CD43, the earliest marker for 
hematopoietic cells, was first observed in our cultures at day 7. Few eGFP+ cells 
became apparent from day 11 onwards, forming a clear population on day 14. As 
shown in Figure2 A-B, these eGFP+ cells were contained within the CD34+CD43+ 
population, which has been reported to contain progenitors of multiple hematopoietic 
lineages. On the other hand the CD34+CD43- endothelial and CD34+CD43lo 
emerging HPC populations were consistently negative for eGFP expression (Figure 2 
B). As expression was also found highest in the CD34+CD43+ population within the 
CD45low population (supplemental figure 2), we hypothesized this population to have 
the highest possibility of containing MYB+ multipotent progenitors. 
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Figure 2: MYB-eGFP+ HPC are generated relatively late in EB cultures. 
A) Gating strategy for assessment of eGFP expression, a representative plot of EB day 11 
culture is shown; B) Flow cytometric analysis of day 11 and day 14 embryoid body cultures in 
EB mix. Wild type hESC are presented as control for eGFP signal in all populations. 
Percentages of cells in each quadrant are shown.  
 
To assess whether the eGFP+CD43+ hematopoietic cells were emerging directly from 
hemogenic endothelium, day 11 CD34+CD43- endothelial cells were sorted and 
replated on OP9 stromal cells in medium containing SCF, BMP4 and VEGF. After 6 
days of culture a distinct CD45+ population was apparent, however no eGFP+ cells 
were seen at this timepoint. After 11 days of culture, eGFP+ cells became apparent 
(supplemental figure 3 A). As this assay might miss the emergence of transient 
eGFP+ cells directly from hemogenic endothelium, we analyzed using a similar set-up, 
the emergence of hematopoietic cells from endothelium by live confocal imaging. 
During live confocal imaging, adherent eGFP-CD34+CD43- endothelial cells were 
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found to round up and form cells with hematopoietic appearance. These cells 
subsequently upregulated CD43 and proliferated extensively over the course of 72 
hrs. We could not detect eGFP expression during the whole process of blood cell 
generation and subsequent proliferation, suggesting MYB-independent generation of 
HPC (Figure 3 and Supplemental Movie S1). Similar experiments initiated with sorted 
eGFP-CD34+CD43- endothelial cells derived from earlier (day 7) or later time points 
(day 14) of EB cultures were much less potent in the generation of hematopoietic 
cells and generated only few blood cells.  
 
Figure 3: Hematopoietic cells are generated directly from hemogenic endothelium, 
without and eGFP+ intermediate. 
Time-lapse confocal analysis of replated day 11 hemogenic endothelium. A single frame is 
depicted every two hours starting from the defined starting point. Cropped images are shown 
for every channel. Arrows depict a single endothelial cell at the starting point of analysis and 
the progeny thereof at later points in time. Scale bar measures 100 µM; At 72h, the cells 
have rapidly proliferated and generated two clusters of 8 cells. These cells have 
downregulated CD34 and upregulated CD43. Scale bar measures 100µM. 
 
To verify whether other or additional growth factors were required for the generation 
and/or expansion of the eGFP+ CD34+CD43+CD45-/lo population, EB-derived 
hematopoietic cells were cultured in different cytokine combinations of SCF, TPO, 
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Flt3L, IL-3 and IL-6. It was found that eGFP+CD34+CD43+CD45-/lo cells expanded 
most efficiently in conditions containing IL-3. As shown in Figure 4A, the mean of 
absolute numbers of eGFP+CD34+CD43+CD45-/lo per EB was about six fold higher 
than those in conditions without IL-3. This suggests that the 
eGFP+CD34+CD43+CD45-/lo  cells are responsive to IL-3, as has been reported 
previously (11).   
 
 
Figure 4: Phenotype of MYB-eGFP+ HPC. 
A) Absolute cell number of eGFP+ cells within the CD34+CD43+ population of  day 14 
embryoid body cultures. Error bars indicate standard deviation (SD) of the mean (n=3); B) 
Flow cytometric analysis of day 14 MYB-eGFP EB, cultured in the presence of different 
cytokine mixes as indicated. Dot plots are gated on CD34+CD43+. Cells within the eGFP+ 
gate are depicted in the histograms. Shaded histograms show isotype control stained 
samples for the indicated marker. Representative plots of 3 independent experiments are 
shown; 
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Characterization of eGFP negative and eGFP positive subsets. 
To further define the eGFP+ cells generated in these cultures, we analyzed these 
cells for expression of the stem cell phenotype CD38-, CD90+, CD49f+ and CD45RA- 
as previously described by Notta et al., the myeloid lineage markers CD33 and 
CD123, and erythro-megakaryocytic lineage markers CD41a and CD235a. As shown 
in figure 4B, eGFP+CD34+CD43+CD45-/lo cells expressed low levels of CD45RA, 
were negative for CD38 and CD90 and expressed CD49f. This CD34+CD45RA-
CD38-CD49f+ phenotype was present in all conditions including the conditions 
containing IL-3, and is similar to the long term engraftable HSC described by Notta et 
al(12) (Figure 4B). However, the eGFP+ cells in our cultures also showed clear 
expression of CD33 and CD123, while erythroid lineage markers were negative, 
suggesting myeloid lineage commitment of these cells. The phenotype was very 
similar independent of the cytokines added, except for the condition in EBmix + TPO 
+ Flt3-L, where CD38 was upregulated. CD235 and CD41a were consistently absent 
on these populations, arguing against erythroid commitment of 
eGFP+CD34+CD43+CD45-/lo cells. The eGFP-CD34+CD43+CD45- cells, on the other 
hand, contained mainly erythroid committed cells, while the CD45+ population, 
consisted of cells expressing myeloid lineage markers (data not shown). The eGFP+ 
cells derived from eGFP- hemogenic endothelium, also phenotyped as 
CD45lowCD33+CD14- cells, consistent with the data obtained on bulk cultures 
(supplemental figure 3 B) 
 
We assessed myeloid, erythroid and megakaryocytic differentiation capacity of the 
different populations obtained in the cultures with various growth factor mixes to 
assess multipotency. Results were qualitatively similar for all growth factor conditions. 
In figure 5 A, the results are shown of sorted cell populations from d14 spin EB 
cultures expanded with EBmix plus IL-3 and Flt3-L, and subsequently assayed under 
conditions optimal for either myeloid, erythroid or megakaryocytic differentiation. The 
eGFP-CD34+CD43+CD235a/CD41a-CD45- population clearly contained progenitors 
giving rise to myeloid, erythroid and megakaryocytic cells, while the 
eGFP+CD34+CD43+CD235a/CD41a-CD45-/lo population was shown to give rise to 
granulocytic lineage myeloid cells only, with complete absence of monocytic, 
erythroid and megakaryocytic precursor potential. On the other hand, eGFP-
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CD34+CD43+CD235a/CD41a+ cells gave rise mainly to erythroid and megakaryocytic 
cells, although some myeloid precursor activity was also observed. eGFP-
CD34+CD43+CD235a/CD41a-CD45+ cells were able to give rise to CD11b+CD14- 
granulocytic lineage cells, CD11b+CD14+ macrophage lineage cells, CD71+CD235+ 
erythroid and CD41+ megakaryocytic cells (Figure 5 A).   
 
 
Figure5: MYB-eGFP+ HPC show commitment towards the granulocytic lineage. 
A) Flow cytometric analysis of differentiation cultures towards granulocytic, monocytic, 
megakaryocytic and erythroid cells. Day 14 MYB-eGFP hESC-derived precursors with 
indicated phenotypes were isolated from IL-3 and Flt3-L expanded EB; representative plots 
of at least 3 independent experiments are shown; B) qPCR analysis for lineage commitment 
genes on indicated populations, isolated from day 14 MYB-eGFP hESC EB expanded in 
presence in IL-3 and Flt3-L. Expression is shown relative to the expression of GAPDH. Error 
bars indicate standard deviation (SD) of the mean (n=3).  
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To assess expression of genes associated or determining commitment towards the 
different lineages, RT-qPCR was performed for MPO, GATA1, PU.1 and MPL on the 
same sorted populations as in Figure 5 A. MYB was assessed as a control and 
showed high expression in the eGFP+ population as expected (Figure 5 B). In line 
with the multipotent precursor capacity, the eGFP-CD34+CD43+CD45- cells 
expressed only low levels of the various genes analyzed. In contrast, the eGFP-
CD34+CD43+CD45+ cells had significantly higher levels of PU.1 suggesting that 
together with the acquisition of CD45, the cells become committed to the 
macrophage lineage.  As expected, the eGFP-CD34+CD235a/CD41a+ express high 
levels of GATA1 and MPL, emphasizing their erythro-megakaryocytic commitment. In 
contrast, the eGFP+CD34+CD43+CD45-/lo cells show high expression of MPO and low 
levels of PU1 suggestive for granulocytic lineage commitment. GATA1 expression 
was also detected in the eGFP+CD34+CD43+CD45-/lo population, in agreement with 
granulocytic lineage commitment 
To study the generation of the eGFP+ precursor at the clonal level, CFU assays and 
single cell sorting followed by liquid culture were performed on d11 and d14 EB 
cultures (figure 6). The day11 eGFP-CD34+CD43+ cell population gave rise to CFU-
GEMM, CFU-GM, CFU-G, CFU-M, BFU-E and CFU-E. These colonies were 
analyzed microscopically for eGFP expression and it was observed that the CFU-GM, 
CFU-G and CFU-GEMM contained eGFP positive cells whereas the CFU-M, CFU-E 
and BFU-E were consistently negative (figure 6 A). Similarly, using single cell culture 
and flow cytometric analysis, we found that d11 and d14 eGFP-CD34+CD43+ 
progenitors consisted of GEMM, GM, G, M, E precursors. A marked skewing towards 
the myeloid lineage was observed on d14 of culture. In agreement with the CFU 
assays, eGFP+ cell containing wells were confined to the wells containing G, GM and 
GEMM precursor cells, whereas the wells lacking eGFP expression contained E and 
M precursors (figure 6 B and 6 C). These data clearly show, that the MYB-eGFP+ 
precursors is a more committed myeloid precursor derived from a multipotent MYB-
eGFP- hematopoietic precursor cell. 
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Figure 6: Clonal progeny analysis of CD34+CD43+ progenitors. 
A) Representative microscopic images of  eGFP-CD34+CD43+ d11 EB derived progenitor 
CFU assay, analyzed after 14 days of liquid culture. A representative image for each colony 
type is depicted. Both eGFP and brightfield channels are shown; B) Representative analysis 
of single cell (clonal) cultured CD34+CD43+ EB derived progenitors, analyzed after 7 days of 
culture. CD235a/CD41a- cells are depicted in the center and right panels. Scoring gates are 
indicated with E (erythroid/megakaryocytic), M (monocytic) and G (granulocytic). 
Combination of these gates led us to determine colony type as G, M, E, GM or GEMM as 
indicated for the representative plots. Representative progeny of  eGFP+CD34+CD43+ EB 
derived progenitors are depicted in the dotted box; C) Frequency of progenitor types within 
CD34+CD43+ EB derived progenitors at the indicated time points. Absolute numbers of 
colonies are indicated between brackets. The progeny of eGFP-CD34+CD43+ are depicted in 
the panels below as fractions of wells containing eGFP+ cells or wells lacking eGFP+ cells; all 
wells were scored as shown in panel B. 
 
While macrophage development is MYB-independent, MYB marks granulocytic 
lineage differentiation.  
As MYB was described to be dispensable for the generation of YS derived 
macrophages, we studied the role of MYB during myeloid lineage choice. When EB 
cultures were grown under myeloid differentiation conditions, a homogenous 
population of CD45+CD33+ was obtained after 4 days of culture (Figure 7 A). To 
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further define both eGFP- and eGFP+ populations, we analyzed both populations by 
flow cytometry, cytospin and qPCR.  
 
Figure 7: Myeloid cells show strong expression of MYB-eGFP upon granulocytic 
lineage differentiation. 
A) Flow cytometric analysis of myeloid-directed differentiation of day 11 MYB-eGFP hESC 
embryoid bodies, after 5 days of myeloid culture. Representative plots of at least 3 
independent experiments are shown; B) phenotypic analysis of eGFP+ (upper panels) and 
eGFP- (lower panels) populations in myeloid directed differentiation cultures of day 11 MYB-
eGFP embryoid bodies after 5 days of myeloid culture. All cells shown in histograms are 
gated on CD45. Shaded histograms show control staining for the depicted marker. 
Representative plots of 3 independent experiments are shown; C) May-Grünwald-Giemsa 
staining of cytospin samples of myeloid-directed differentiation of day 11 MYB-eGFP hESC 
embryoid bodies, eGFP-CD14+CD11b+ and eGFP+CD14- populations are depicted; D) qPCR 
analysis for lactoferrin (LTF) and MYB expression in indicated populations. Expression is 
shown relative to the mean of GAPDH and YWHAZ expression. Error bars indicate standard 
deviation (SD) of the mean (n=2).  
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The eGFP+ population was found to be CD45lo and positive for CD33, weakly 
expressing the myeloid markers CD11c, CD11b, CD123 and CD13. The granulocytic 
marker CD15 was found absent. This phenotype is in line with the surface phenotype 
of myelocytes, a precursor of the granulocyte lineage. Macrophage markers CD14, 
CD16, CD115, HLA-DR and CD86 were consistently negative. On the other hand, 
the eGFP- population was found to be CD45hi, CD33+. These cells were CD11chi, 
CD11bhi, CD14+, HLA-DR+, CD86+ compatible with a activated macrophage 
phenotype. CD115, the receptor for M-CSF, was found only weakly positive. The 
cells expressed CD16, which is normally expressed on tissue macrophages (Figure 7 
B).  
On cytological analysis using May-Grünwald-Giemsa staining, eGFP+CD14- cells 
show a granulocytic cytoplasm compatible with myelocytic granulocyte lineage cells, 
whereas the eGFP-CD14+ cells have a morphology compatible with tissue 
macrophages (Figure 7 C).  This was confirmed by qPCR analysis showing these 
eGFP+ cells to express the granule protein lactoferrin (LTF), eGFP- cells on the other 
hand were devoid of lactoferrin expression (Figure 7 D). As expected, MYB 
expression levels were high in eGFP+CD14- cells (Figure 7 D).   
To analyze whether the generation of these macrophages from hematopoietic 
precursor cells was MYB-independent, we sorted eGFP-CD34+CD43+CD45+ 
committed precursor cells, cultured these in myeloid conditions on OP9 stromal cells 
and analyzed them daily for the expression of eGFP. After 4 days, a population of 
CD14+ cells was already clearly visible. These cells were negative for eGFP as 
assessed by flow cytometry (Figure 8 A). Further culture of these cells for up to 11 
days, showed clear eGFP positive populations at all analyzed time points. However, 
at no time point were eGFP+CD14+ cells observed. After 11 days of culture, virtually 
all eGFP- cells were CD14 positive (Figure 8 A).  
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Figure8: Macrophages develop without expression of MYB-eGFP and show 
characteristics of yolk sac -derived tissue macrophages. 
A) Flow cytometric analysis of myeloid-directed differentiation of day 11 MYB-eGFP hESC 
EB-derived CD34+CD43+CD45+eGFP- precursors, after 4, 8 and 11 days of myeloid culture; 
B) Time-lapse confocal analysis of live stained cultures. CD34+CD43+CD45+eGFP-CD14- 
cells were cultured in myeloid differentiation cultures. Samples were live stained with CD14-
PE for confocal analysis. eGFP+ myeloid cells are shown as reference. Single channel 
panels are shown every hour starting from 11.30 h after plating onwards. Scale bars 
measure 10 µM. 
 
To determine whether an eGFP+CD14- intermediate stage gave rise to the eGFP-
CD14+ macrophage cells, sorted day 11 eGFP-CD34+CD43+CD45+CD14- committed 
HPC were cultured under myeloid conditions and analyzed using live confocal 
microscopy to track cells becoming CD14+. We did not observe eGFP expression in 
cells acquiring CD14 expression (Figure 8 B and Supplemental Movie S2). These 
data suggest that the generation of CD14+ macrophage cells from hESC is MYB-
independent.  
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Discussion 
 
We here show evidence that multipotent  HPCs expressing high levels of MYB are 
not generated in human EB cultures initiated with hESC. We therefore conclude that 
the hematopoietic cells generated in vitro from hESC using current in vitro protocols, 
emerge through an endothelial intermediate, and are precursors with limited stem cell 
activity that resemble yolk sac hematopoietic progenitors.  In addition we show that 
the first progenitors derived from endothelial cells are eGFP-CD34+CD43+ cells, 
which then develop into eGFP+CD34+CD43+ granulocyte committed progenitors. 
Multipotency and self-renewal are two hallmark characteristics of HSC. With regard 
to multipotency: almost all hematopoietic cell types can be generated from hESC-
derived hematopoietic precursors, including erythrocytes(13), megakaryocytes(14), 
granulocytes, monocytes(15), NK cells(16) and T cells(17, 18). Although, to our 
knowledge, it has not been demonstrated that a single hESC-derived hematopoietic 
precursor cell is able to form all of the aforementioned cell types, the absence of 
these reports may be due to technical issues associated with precursor cells of 
limited proliferative capacity. The fact that T cells, can be generated from fetal HPC 
does not in itself prove the presence of multipotent progenitors or HSC, since it has 
been shown that T cells can be generated from YS precursors that arise before HSC 
are generated(19, 20). Self-renewal of HSC is evaluated by their ability to 
reconstitute immune deficient mice. Previous studies have reported repopulation by 
in vitro hESC-derived HPC(21, 22). Wang et al. reported multilineage hematopoietic 
repopulation upon intrafemoral injection of HPC(22). However, hESC-derived HPCs 
had limited proliferative and migratory capacity compared with somatic HSCs. In 
another study by Ledran et al., whole hESC differentiation co-cultures with stromal 
cells derived from murine fetal tissues were injected intrafemorally in mice. These 
cells were reported to repopulate bone marrow of the non-injected femur as well as 
the spleen. In addition, secondary engraftment was reported. However, the engrafted 
cells were not fully defined. The phenotype shown is compatible with myeloid cells 
(CD33+CD13+). As it is known that tissue macrophages have a long lifespan, and are 
found lifelong in the adult, without a need for HSC to replenish them, chimerism may 
have been caused by non-HSC dependent cells. Evidence for engraftment of CD34+ 
cells in the bone marrow was lacking. 
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In a recent article by Amabile et al. hESC were injected in mice to form teratoma. The 
authors show that in these teratoma, also hESC derived CD34+ hematopoietic cells 
are formed. Upon isolation and transplantation of these CD34+ HPC into 
immunodeficient mice, engraftment of human cells was found, including CD34+ cells 
in the bone marrow. This in vivo differentiation model therefore suggests that HSC 
can be generated from human pluripotent stem cells (23).  
In conclusion, based on these data it remains questionable whether HSC can be 
formed from  ESC using currently available in vitro differentiation protocols, although 
it is clear that multipotent progenitors are formed. Changes to the culture conditions, 
such as other cytokine mixtures or the use of more appropriate feeder lines may 
result in HSC generation. The MYB-eGFP cell line that we generated will be very 
helpful in screening for such conditions. Which factor(s) are missing to generate HSC 
is unknown to date. However, recent publications using reprogramming of specified 
cells are starting to shed light on this issue (24-26). Recently it was reported that 
overexpression of 5 factors in hESC-derived HPC confers short-term engraftment 
potential to these hESC-derived cells(24). One of the factors which was required for 
in vivo engraftment was characterized as MYB. A similar strategy was used for 
reprogramming murine hematopoietic cells toward transplantable HSC (26). Although 
the reprogramming factors needed for conferring HSC properties have not yet 
reached consensus, this approach may prove to be an alternative method for 
generating HSC from pluripotent stem cells. 
An alternative hypothesis could be that HSC are continuously generated in vitro, but 
lack necessary signals that are present in vivo, and thus quickly degenerate to 
restricted precursor cells, losing their self-renewal capacity. Fetal, newborn and adult 
HSC are known to lose the capacity to self-renew within days of in vitro culture(27-
29).  
To study the emerging HPC in vitro, we isolated CD34+ CD43- endothelial cells and 
studied the characteristics of hematopoietic cells generated from them through time-
lapse microscopy. We did not observe generation of MYB-eGFP expressing cells, 
that subsequently lose MYB expression in vitro. This is in line with the reported 
generation of hematopoietic cells directly from hemogenic endothelium from Myb-/- 
murine ESC, showing MYB to be dispensable for endothelial to hematopoietic 
transition(30). Instead, we observed either cells that remained MYB negative, or cells, 
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which up regulated MYB over the course of several days and were further 
characterized as granulocyte lineage cells. In the murine system, strong evidence 
was provided that MYB is essential for HSC function. Transplantable HSC were 
shown to express high levels of Myb (6). This is strengthened by the fact that Myb-/- 
mice die around fetal day 15 due to lack of transplantable HSC (4), moreover, 
conditional deletion of Myb leads to exhaustion of the stem cell pool and failure to 
engraft upon transplantation of LSK cells (6).We can therefore conclude that it is 
unlikely that HSC are generated in these spin EB cultures. 
Conditional MYB knockout models show a marked decrease in granulocytic 
development, suggesting an important role for MYB in granulocytic development(7). 
In addition, hematopoietic differentiation cultures set up with  Myb-/- murine ESC also 
showed defective granulocyte lineage differentiation (30, 31).  Clarke et al. reported a 
similar potential to generate CFU-E and CFU-M between wildtype and Myb-/- mESC 
in short term cultures, however, later on, the numbers of CFU-E and CFU-GM were 
decreased. Sakamoto et al. compared wild type with Myb-/-  mES cells and knock out 
mES cells that expressed Myb under control of a tetracyclin-inducible promotor. They 
reported similar numbers of hematopoietic cells generated by wild type and knock out 
cells, whereas induction of Myb during hematopoietic differentiation resulted in vastly 
higher cell numbers. Similar to Clarke et al., they report a reduced differentiation 
towards erythroid and granulocytic lineages, whereas the monocytic differentiation is 
unaffected. The relative absence of these lineages in mESC cultures reflects the 
MYB dependency of a lineage restricted erythroid-megakaryocytic and erythro-
myeloid precursor rather than the generation of MYB-dependent HSC. These data 
thus point towards a differential requirement of MYB during macrophage/granulocyte 
commitment, as is also apparent in our experiments. 
Recent studies suggest that tissue macrophages belong to a separate lineage 
derived from MYB- independent precursors. These are derived from YS derived EMP 
and persist by local proliferation of terminally differentiated cells or precursors into 
adult life independent from the bone marrow .The MYB-eGFP- macrophage cells 
generated in our cultures, co-express CD14 and CD16, a phenotype previously 
described for tissue macrophages(32, 33).  
In conclusion, we have shown that hematopoietic precursor cells that arise from 
endothelial cells in EB cultures are MYB negative. MYB-positive precursors arise 
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later in the cultures and are granulocyte lineage restricted. These data therefore 
provide evidence that bona fide HSC are neither generated nor maintained in these 
cultures. Rather,  yolk sac-like hematopoietic precursors are formed.  We here 
describe that granulocytic lineage committed progenitor diverge thereof, and that this 
process is accompanied by the upregulation of MYB. In this light reinvestigation of 
Myb signal in YS precursors might be advised. In addition, we have described a Myb 
reporter cell line which may be helpful to screen for conditions which can generate 
HSC from hemogenic endothelium in vitro. 
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Abstract 
 
Gene therapy for inherited hematopoietic disease is currently applied using viral 
overexpression systems in hematopoietic stem cells. Using retro- or lentiviral vectors, 
a copy of the functional gene is introduced in hematopoietic stem cells and 
constitutive expression of the corrected gene is obtained. These transduced 
hematopoietic stem cells are then transfused back into the patient. While successfully 
used in the clinic, these methods hold some major limitations both at the safety and 
efficacy level. Recently, methods to generate patient specific induced pluripotent 
stem cells (iPSC) from somatic cells were devised. In combination with recent 
advances in nuclease mediated genetic correction, iPSC technology seems mature 
for rapid clinical application, especially as gene therapy for hematologic diseases. 
Combining these technologies, the affected gene could be corrected by replacing the 
defective gene by a wild type copy in the patient-derived iPSC. These cells can be 
screened for correct integration and subsequently differentiated towards 
hematopoietic stem cells or different types of hematopoietic cells. During recent 
years, the efficiency of genetic modification and in vitro hematopoietic differentiation 
of human PSC has greatly increased. However, protocols for generating bona fide 
hematopoietic stem cells are still lacking. For this reason, we believe that iPSC based 
gene therapy can be used in conditions where long lived hematopoietic cells mediate 
the therapeutic effect such as T cells in IL2RG deficiency and tissue macrophages in 
mucopolysaccharidoses.  In this review we give an overview of current protocols and 
advances in in vitro hematopoiesis starting from pluripotent stem cells and evaluate 
these in the light of gene therapy for hematologic diseases. 
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Gene Therapy; Hematopoiesis; IPSC; hESC; Pluripotent Stem Cells, Tailored 
Nucleases, Hematological Diseases; Stem Cells.   
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1. Genetic correction of hematopoietic stem cells 
In 2000, the group of Fischer described the successful genetic correction of the most 
common form of severe combined immunodeficiency (SCID-X1) by using retroviral 
overexpression vectors [1, 2]. These patients have an inherited defect in the 
interleukin 2 common gamma chain (IL2RG gene), leading to a non-functional 
receptor for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. SCID-X1 patients have low to 
absent numbers of T cells and NK cells, in the case of an IL-7 or an IL-15 defect 
respectively. Also, T dependent B cell responses are defective. These defects lead to 
severe immunodeficiency with recurrent and life threatening infections. Occurrence of 
such infections starts a few months after birth and does not resolve despite antibiotic 
therapy. SCID-X1 patients are treated with allogeneic stem cell transplantation, if a 
HLA identical sibling is available. However, patients without such a donor may be 
treated with genetically modified autologous hematopoietic stem cells (HSC).  
For treatment with genetically modified autologous HSC, CD34+ cells are isolated 
from bone marrow of the patient. These CD34+ cells are then transduced with a 
retroviral vector expressing the IL2RG encoding cDNA and reinfused (Figure 1A). 
This therapy was successful in all patients treated and had similar results to 
hematopoietic stem cell transplantation from matched siblings. It has to be noted 
however, that 5 out of 20 patients developed T cell acute lymphoblastic leukemia (T-
ALL). This oncogenic transformation was caused by transactivation of LMO2 or 
CCND2 proto-oncogenes. Transactivation was induced by viral integration in close 
proximity of these latter genes [3-5]. In fact, most of the oncogenic events upon 
retroviral transduction can be traced back to insertion of the retroviral vector near 
proto-oncogenes. This poses a particular problem for patients who are especially 
susceptible to the development of cancer. Increased susceptibility for oncogenic 
transformation could be detected in aforementioned SCID patients or Wiskott-Aldrich 
syndrome patients [6].  
To alleviate problems related to transactivation of neighboring genes, self-inactivating 
(SIN) retroviral vectors were used for the treatment of SCID-X1. These SIN vectors 
lack viral promoter and enhancer activity in their 3′ long terminal repeat (LTR) and 
cannot activate neighboring genes. In this study, patient derived CD34+ cells were 
transduced with a SIN vector expressing the IL2RG encoding cDNA. In these 
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patients successful engraftment of HSC was detected and functional gene corrected 
peripheral-blood T cells were found in the blood. This thus shows that use of SIN 
retroviral vectors is an adequate alternative to the use of conventional viral vectors. 
The use of SIN retroviral vectors may reduce the risk of oncogenic transformation 
compared to the use of regular retroviral vectors. 
Alternatively, SIN lentiviral vectors can be used. Such vectors have the advantage 
that they readily integrate into the genome of non-dividing cells, in contrast to 
retroviral vectors. In patients with the Wiskott-Aldrich syndrome such vectors were 
used for the correction of mutations in the WASP gene [7]. This method has also 
been used to treat patients with adrenoleukodystrophy (ALD) and β-thalassemia 
without reports of oncogenic transformation to date [8, 9]. 
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Figure 1: Hematopoietic stem cell based gene therapy for hematological diseases  
 
a) Standard gene therapy using retroviral transduction of hematopoietic stem cells (HSC). 
Patient derived HSC are transduced with a retroviral expression vector encoding the 
corrected gene. Upon successful transduction, gene corrected HSC are generated; b) Gene 
therapy using tailored nucleases to obtain gene corrected HSC.  
 
In conclusion, gene therapy using SIN LTR vectors seems much less likely to induce 
oncogenic transformation. However, patient follow up is still short. While the LTR 
used are self-inactivating, integration of the viral vector is still at random. If the viral 
vector is integrated in regulatory sequences or coding sequences of proto-oncogenes, 
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insertional mutagenesis is still likely to occur. In combination with clonal selection that 
occurs during development of T cells, malignant transformation remains a constant 
threat. Thus, while SIN vectors have been successfully applied in the clinic [1, 7-12], 
possible adverse effects related to random integration remain a major concern. In 
addition, expression levels of the corrected gene are not dynamically regulated 
during differentiation of gene corrected HSC. Constitutive gene expression may in 
itself enhance malignant transformation, especially in cases where the 
overexpressed corrected gene is a growth receptor such as the IL2RG.  
 
2. Use of tailored nucleases for genetic correction of HSCs.  
 
During recent years, different genetic engineering methods have made their way into 
standard laboratory protocols. These strategies all rely on a similar basic strategy, 
where sequence specific DNA nucleases are targeted to the genomic DNA sequence 
to be modified. The nuclease associated DNA binding proteins are either Zinc Finger 
motifs (ZFN)[13], transcription activation like effectors (TALEN)[14] or CRISPR 
associated proteins (Cas) [15] (for review see Gaj T, Trends in Biotech, 2013[16]). 
Upon successful binding to the target genomic DNA, the associated nuclease will 
induce a double stranded DNA break (DSB). This DSB is then repaired by the cell in 
one of two ways: by ligating both ends together by a process called non homologous 
end joining (NHEJ), alternatively the other DNA strand is used as a template to 
correct the induced mutation, in a process called homologous recombination (HR). 
This latter process of HR can be hijacked to introduce the corrected genomic 
sequence into the chromosome. This hijacking is induced by providing an excess of a 
“donor plasmid” carrying the corrected DNA sequence to be introduced.  
Proof of concept that this method can be applied in the clinic was recently provided 
by Genovese et al.[17]. They showed successful gene correction of the IL2RG locus 
in hematopoietic stem and progenitor cells (HSPC) from SCID patients through HR 
(Figure 1B). In this study CD34+ HSPC were isolated from patient bone marrow. To 
induce genetic correction, these HSPC were electroporated with mRNA encoding 
ZFN targeting the IL2RG genomic DNA after lentiviral transduction to introduce the 
donor construct. This integrase-deficient lentiviral vector encoded the IL2RG gene 
In vitro studies on human hematopoiesis  Stijn Vanhee 
!
98 | 
!
and served as a homologous recombination donor cassette. The authors show that 
about 3-11% of the HSC successfully integrated the corrected IL2RG gene, as 
assessed through expression of the associated fluorescent marker that was present 
in the targeting vector. Off note, less differentiated CD34+CD133+CD90+ HSC were 
found to be targeted with lower efficiency compared to more committed 
hematopoietic stem cells, suggesting that relatively few long term repopulating stem 
cells are corrected. In addition, the corrected stem cells are only a minority of the 
HSC and should therefore be able to successfully compete with non-corrected cells 
for gene therapy to be successful.  
The use of tailored nucleases for clinical applications is a relatively new technology 
and thus warrants thorough safety analysis. To this end, both efficiency and 
specificity of the tailored nucleases are of utmost importance. The use of the ZFN 
method in ex vivo HSC was found to be highly efficient in this study [17]. Upon 
targeting with ZFN, insertion or deletion of bases (indel) in the IL2RG locus were 
found in around 50% of the cells. This high rate of indels shows that the IL2RG 
specific ZFN nuclease targets the IL2RG locus with high efficiency. However, 
homologous recombination is the limiting factor for efficient integration of the 
corrected gene since only 3-11% of the cells were corrected by homologous 
recombination. To evaluate ZFN specificity, targeting of potential off-target sites of 
these ZFN was addressed. Upon sequencing of these presumptive off-target sites 
the rate of mutation was found to be about 0.7-1.7%. This proves the high specificity 
of the ZFN used, with potential off-target sites being targeted with only low 
efficiencies. Although successful gene correction efficiencies are low, in the case of 
IL2RG correction in the HSPC, T and NK cells derived from corrected HSPC are 
expected to have a selective advantage over their non-corrected counterparts [17].  
Although this study is promising, genetic modification of human stem cells still 
remains far from being routine practice. Successful genetic modification using 
tailored nucleases depends on a number of limiting prerequisites: 1) efficiency of 
transfection and adequate survival of the cells during the transfection process, 2) 
successful homologous recombination and 3) the availability of an in vivo or in vitro 
method for selection of the corrected cells.  
The first two require active cycling of the targeted cells, which poses a major problem, 
as HSC are quiescent and do not readily divide. Induction of HSC cycling requires 
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addition of ex vivo cytokines. This causes HSC to commit to hematopoietic lineages 
and differentiate, reducing their use for transplantation.  
With newer technologies, efficiencies of nuclease genome editing are readily 
increasing. The main problem for gene correction thus remains the low efficiency of 
homologous recombination in non-cycling human cells. In the case of X-SCID the 
gene-corrected cells are supposed to have a selective advantage in vivo, however 
this is not the case for other diseases such as WAS or β-thalasemia. In those cases 
where the corrected gene does not impose a selective advantage, corrected HSC 
would need to be selected in vitro. Such methods generally rely on selection using an 
antibiotic for several days, or cell selection is based on a co-expressed membrane 
marker. Ex vivo selection inevitably requires prolonged culture, which would further 
cause differentiation of the corrected HSC.  
Another major drawback is the impossibility to screen for off-target mutations or 
integrations. As shown, such off-target effects do not occur with high efficiency, but 
hold oncogenic potential nonetheless [17].  
 
3. Advances in generation and genetic modification of pluripotent stem cells for 
clinical applications. 
 
The group of James Thomson first derived human embryonic stem cells (hESC) in 
1998 [18]. These hESC are derived by culture of human pre-implantation embryos 
[19]. hESC possess the ability to generate virtually every cell type of the human body, 
a characteristic termed “pluripotency”. Pluripotency is evidenced by the generation of 
teratomas, which are generated upon injection of hESC in immune deficient mice. 
These teratomas contain cells derived from all three germ layers, and thus prove the 
pluripotent properties of hESC [18]. Another hallmark characteristic of these cells is 
their ability to be propagated indefinitely in vitro. This latter characteristic thus allows 
unlimited expansion of hESC without differentiation.  
 
hESC, however,  remain topic of ethical debate and are of low applicability in the 
clinic as these are allogeneic to the patient. With the description of human induced 
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pluripotent stem cells (hiPSC) generation, the group of Shinya Yamanaka 
revolutionized the field by showing that fully differentiated adult cells can be 
“reprogrammed” towards fully pluripotent cells [20]. iPSC cells show close similarity 
to hESC on transcript level, on the morphological level and have similar properties as 
do hESC. Similar to hESC, hiPSC are pluripotent and can be expanded indefinitely 
during in vitro culture [20]. hIPSC were initially generated by reprogramming of 
fibroblasts obtained from skin biopsy. In these reports, reprograming was obtained by 
retroviral transduction of the fibroblast cells with only four factors: Oct3/4, Sox2, Klf4 
and c-Myc. Recently, less invasive sources than fibroblasts obtained through skin 
biopsy have been used for somatic cell reprogramming. Among these cell types are 
circulating white blood cells and hematopoietic progenitor cells (HPC) derived from 
cord blood and adult peripheral blood [21-26]. 
In the Yamanaka paper retroviral vectors were used for somatic cell reprogramming. 
These integrating retroviral vectors contain known oncogenes such as cMyc. This 
may render reprogrammed cells prone to oncogenic transformation. To alleviate 
these safety issues, alternative reprogramming strategies were developed. Instead of 
using integrating viral vectors, successful reprograming was obtained using non-
integrating techniques. Among these techniques are transfection of mRNA [27], 
transfection of protein [28] or transduction with non-integrating Sendai viral particles 
[29]. All these methods circumvent the use of potentially oncogenic viral integration 
techniques.  
Patient derived iPSC can be corrected using the aforementioned methods. As iPSC 
can be cultured indefinitely, the potential gene corrected iPSC can be easily 
screened and clonally expanded. This allows for exclusion of cells where off-target 
effects occurred, and would even allow for functional assessment of  the gene 
correction in iPSC-derived cells upon differentiation. 
As iPSC can be derived without the need for donor human embryos, ethical issues 
have become less of a problem. iPSC technology enables us to generate patient 
derived autologous pluripotent cells, which can be differentiated to every cell type of 
the human body. The use of autologous cells could alleviate immunologic issues 
upon transplantation, at least for acute rejections [30]. For clinical purposes, hiPSC 
can be derived from the patient itself, or, alternatively allogeneic histocompatible 
iPSC could be obtained from a public iPSC bank [31]. Such a public iPSC bank may 
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circumvent the need for reprograming, correction and screening of patient derived 
cells, although in this case it is likely that lifelong immunosuppressive therapy should 
be prescribed. 
In conclusion, it is currently possible to generate patient specific pluripotent stem 
cells (PSC). These can be derived from starting material obtained by minimally 
invasive methods, such as peripheral blood, cord blood or skin biopsies. iPSC could 
then be subjected to genetic correction and differentiated towards HSC or specific 
types of blood cells suited for transplantation (Figure 2). 
 
 
!
Figure 2: Pluripotent stem cell based gene therapy for hematological diseases  
 
Gene therapy using tailored nucleases to obtain gene corrected hematopoietic cells derived 
from patient specific pluripotent stem cells. Somatic cells are reprogramed towards induced 
pluripotent stem cells (iPSC), in which the affected gene is then corrected. After in vitro 
hematopoietic differentiation of iPSC, the obtained cells can be transfused back to the patient. 
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4. Pluripotent stem cell derived blood cells 
 
During the last decade, different protocols to generate blood cells from PSC  in vitro 
have been described [32-38]. In general, two types of strategies are used to initiate 
hematopoiesis from pluripotent stem cells: embryoid body (EB) based and stromal 
cell line (feeder) based differentiation methods. The former method relies on the 
aggregation of small fragments of PSC or a single cell suspension of PSC into a 
small clump. This re-aggregated clump is differentiates into an “embryoid body” and 
contains PSC differentiated to different cell types. The latter method relies on transfer 
of fragments of pluripotent stem cells onto a feeder layer. Generally feeder cells of 
animal origin are used in combination with media containing components of animal 
origin. Use of xenogeneic feeder cells renders the PSC-derived cells inadequate for 
use in patients. In addition, the efficiency of blood cell generation remains low in most 
of these protocols, with only a few percent of input cells leading to hematopoietic 
cells. Of these differentiated cells, cells expressing CD34+ or CD45+ are generally 
found with frequencies between 1 -50%.  
For patient use, differentiation protocols are needed which are devoid of any 
component of animal origin. This can be obtained by omitting xenogeneic feeder cells, 
using serum-free medium and using recombinant growth factors. To date, few of 
these so called “xeno-free” methods have been described [35, 37, 38]. Of these 
protocols, the ones described by the group of Andrew Elefanty appear promising. 
With this method about 1:500 of the input pluripotent cells generates cells with 
hematopoietic potential. These cultures give rise to over 20% CD34+ cells. However, 
it should be noted that this population is not a pure hematopoietic progenitor cell 
population. By the end of culture, around 30% of the cells express CD45. In this 
protocol, a fixed number of single-cell adapted hESC are differentiated towards 
hematopoietic cells using the EB methodology. These re-aggregated hESC clusters, 
are then grown for up to 12 days in xeno-free APEL-medium supplemented with SCF, 
BMP4 and VEGF. Addition of extra factors such as APELIN, further increases the 
hematopoietic differentiation efficiency, but also induces rapid differentiation of 
hematopoietic progenitors [38]. The upside of this method is that it is highly scalable 
and differentiation is consistantly induced with limited variability. 
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In mice, successful in vivo reconstitution of irradiated mice with murine PSC-derived 
hematopoietic progenitors was shown after transduction of these hematopoietic 
precursor cells with HOXB4 [39]. This led to the belief that HSC generation from PSC 
for clinical purpose should be possible. 
As addressed earlier, PSC have the inherent ability to form any cell type of the body 
in vivo. Also in vitro, many hematopoietic cell types have been generated from hESC 
and hIPSC. NK cells [40], T cells [41, 42], megakaryocytes [43], erythrocytes [44], 
monocytes and granulocytes [45] have all been generated from PSC in vitro. 
However to date the generation of a bona fide HSC from PSC has not been reported 
unequivocally. The gold standard for the demonstration of human HSC properties 
such as self-renewal remains the repopulation assay in immune deficient animals. 
This assay was developed by John Dick to test the hematopoietic properties of 
postnatal hematopoietic cell populations [46]. For this assay a HSC containing 
suspension is injected intravenously or intrafemorally in sublethally irradiated 
recipients. Upon successful engraftment these animals have human CD45+ cells in 
the blood and bone marrow for up to 12 weeks. Human cells consist of myeloid cells, 
B cells and NK cells. In addition, human cells repopulate the thymus and generate 
human T cells. Secondary transfer of bone marrow cells from these repopulated mice 
into novel recipient mice should again result in repopulation.  
However, when testing fetal or ESC-derived populations for HSC activity, care has to 
be taken that long lived cells other than HSC derived cells do not interfere with the 
assay. For this reason, we think that this assay should show: 1) chimerism in the 
blood or spleen of these animals, 2) the human cells consist of at least erythroid, 
myeloid and lymphoid lineages, and 3) the bone marrow should contain human 
CD34+ cells which upon purification and secondary transfer give rise to multilineage 
reconstitution. 
The first reports showing generation of HPC from hESC capable of SCID 
repopulation were published by the groups of Mickie Bhatia [47] and Dan Kaufman 
[48]. Both these groups have shown successful in vitro differentiation of hESC 
towards hematopoietic cells, and in addition, repopulation in vivo. However, both also 
show clear differences between these hESC-derived multipotent progenitor cells and 
somatic HSC.  
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In the publication by the group of Mickie Bhatia [47] the CFU progenitor frequencies 
were reported to be similar between somatic HSC and hESC-derived (HPC). 
However, the hESC-derived HPC showed a skewed CFU potential towards 
granulocytic cells as compared with the potential of somatic HSC. To test HSC 
properties of the hESC derived hematopoietic progenitors, cells were intravenously 
injected into immune deficient mice. After injection approximately 60% of mice died 
due to formation of lung emboli, induced by factors in murine serum. As somatic HSC 
do not cluster in these same conditions, this is another indication for differences 
between both types of progenitor cells. Using flow cytometry, the hESC-derived stem 
cells clearly show higher expression of CD45 and display a higher granularity.  
Intrafemoral injection of the hESC-derived HPC cells alleviates the problem of lung 
emboli formation, and resulted in engraftment of human cells. The authors show the 
presence of human cells in the bone marrow after injection, although it is not clear 
how long they remain detectable after injection. These cells show expression of 
CD33 and CD19, which points towards lineage commitment. However, the CD34 
expression profile of the successfully engrafted cells is not shown. It has to be noted 
that engraftment remains low in bone marrow compared to somatic HSC (10-100 fold 
lower). Interestingly, when gene expression was analyzed and compared between 
somatic HSC and hESC-derived HPC, clear differences were shown. Main 
differences were found in clusters regulating cell replication, transcription, cell-cell 
contact and migration. Also the pattern of homeobox (HOX) genes was markedly 
different, further indicating the differences between both types of HPC [47]. 
The group of Dan Kaufman [48], reported similarly low levels of engraftment with 
hESC-derived HPC (~0.1-1%). Engraftment was more pronounced when recipient 
NK cells were largely eliminated by treatment with anti-ASGM1 antiserum. The 
authors were able to show expression of human CD34 on cells injected into the bone 
marrow, but no evidence is provided for multilineage repopulation. These 
publications also fail to show successful secondary repopulation of the hESC derived 
HPC. 
In a publication by the group of Majlinda Lako [33], hESC are differentiated towards 
hematopoietic cells on different stromal cell lines derived from murine urogenital 
ridges, aorta-gonado-mesonephros region (AGM) and fetal liver (FL). The AM20.1B4 
cell line, derived from the AGM region, was best in supporting the generation of 
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hematopoietic cells from hESC capable of engraftment. Upon intrafemoral injection of 
hESC derived progenitors an average engraftment in the contralateral femur was 
found to be around 2%. In the peripheral blood human cells were 16% of the total of 
hematopoietic cells. The cells found in the peripheral blood and bone marrow 
expressed CD33, CD13, CD2 and CD19 and were high in forward scatter, showing 
the large size of these cells. The authors remark themselves that despite the 
presence of lymphoid markers (CD2 and CD19) they cannot exclude that these are 
myeloid committed cells. 
Taken together, these reports do not show solid evidence for the presence of HSC in 
PSC derived cultures. The long term presence of human cells was demonstrated, 
however no multilineage reconstitution was shown, nor is there solid evidence for 
engraftment of CD34+ cells in the bone marrow responsible for primary and 
secondary reconstitution. It is possible that these long-term surviving human cells are 
contaminating non-hematopoietic cells or HSC independent myeloid cells such as 
tissue macrophages. 
In a recent publication by Amabile et al. undifferentiated hESC were injected in 
immunodeficient mice. Here these hESC readily form teratomas, containing cell types 
of all germ layers. The authors show that in these teratomas also hESC derived 
CD34+ hematopoietic cells are formed. These develop under the influence of factors 
originating from the injected hESC or from the recipient mouse. Upon isolation and 
transplantation of these CD34+ cells into immunodeficient mice, engraftment of 
human hematopoietic cells was found. These cells also hold multilineage 
reconstitution capacity, but it has to be noted that they show lineage skewing towards 
the myeloid lineage after transplantation. This is in contrast to CB derived CD34+. 
While these data support the inherent pluripotent potential of hESC, the factors 
leading to the generation of HSC remain unexplored and elusive. Further research on 
these factors will certainly provide more insight in the complex ontogeny of the 
hematopoietic system. 
The properties of HPCs formed in these cultures remain poorly understood. 
Expansion of the PSC-derived CD34+ population without apparent commitment, 
would be an excellent way to remediate the low cell numbers generally obtained. 
However, while able to replicate in a burst like fashion, expansion of these PSC-
derived cells is rapidly exhausted. Upon expansion, the HPC rapidly commit to the 
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erythroid or myeloid lineage and give rise to terminally differentiated cells. In addition, 
the lack of successful engraftment and multilineage reconstitution capacity of 
pluripotent stem cell derived HPC thus hampers the use of these generated CD34+ 
cells for direct transplantation in a clinical setting. To understand the generation and 
properties of progenitor cells in vitro, it is essential to understand the ontogeny of the 
hematopoietic system in the embryo. 
 
5. In vivo murine hematopoiesis  
 
In the embryo, hematopoiesis occurs at different locations, both extra-embryonic and 
inside the embryo. During decades of research, hematopoiesis has been 
conceptualized as the formation of the hematopoietic system in largely two distinct 
waves: a first “primitive” wave and a second “definitive” wave. During the brief wave 
of primitive hematopoiesis the developing embryo forms blood cells in the yolk sac. 
All hematopoiesis beyond this wave is termed “definitive” hematopoiesis. During 
definitive hematopoiesis, blood cells are generated at different sites, both extra-
embryonic (in the yolk sac or YS) as intra-embryonic (in the aorta-gonado-
mesonephros or AGM region). After these waves hematopoiesis shifts to other, more 
specialized hematopoietic organs. HSC generated in the AGM, will migrate to the 
fetal liver, where they will mature and vastly expand. These mature HSC will then 
populate the bone marrow, where they sustain lifelong hematopoiesis (Figure 3A). 
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Figure 3: schematic overview of hematopoiesis  
 
a) Ontogeny of the hematopoietic system in the mouse. A first wave of primitive 
hematopoiesis occurs in the yolk sac at embryonic day 7.5 (E7.5). Here primitive 
erythrocytes and megakaryocytes are generated. Subsequently a definitive wave of 
hematopoiesis is initiated between E8.5 and E9.5, during which erythro-myeloid progenitors 
(EMP) and lympho-myeloid progenitors (LMP) are formed. Hematopoietic stem cells (HSC) 
are generated in the embryo at E10.5 in the aorta-gonado-mesonephros (AGM) region. 
These cells will then migrate to the fetal liver, where they further develop and expand; b) 
Development of hematopoietic cells in vitro from human embryonic stem cells. In analogy 
with the in vivo situation, during a first primitive wave after 5-7 days of differentiation, 
primitive erythrocytes and megakaryocytes are generated. Later on in culture, between day 
10 and 14, erythro-myeloid progenitors (EMP) and lympho-myeloid progenitors (LMP) are 
generated. Whether these cultures proceed to the generation of an AGM-like hematopoietic 
process has not been established. 
 
 
 
 
A.!
B.!
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5.1 Different waves of hematopoiesis 
 
5.1.1 Primitive yolk sac based hematopoiesis 
 
During the development of the embryo, oxygenation of tissues by diffusion is unable 
to cope with the increasing need for oxygen during growth. At this time, the embryo is 
in urgent need of a functional cardiovascular system carrying oxygen to the 
developing organs. To this end a primitive hematopoietic system is triggered to form 
immature cells, which are able to sustain oxygenation of the tissues.  
The first hematopoietic cells that are formed in the extra-embryonic tissues around 
E7.5 are in close proximity of the endothelial cells lining the “blood islands” of the YS. 
These first, primitive, blood cells generated within the blood islands are marked by 
their large size and expression of both embryonic and fetal hemoglobin chains [49]. 
During primitive hematopoiesis no hematopoietic stem cells are formed. This concept 
was established by determining that at E7.5-E8.25 no transplantable HSC can be 
derived from the YS, nor are multipotent progenitors generated at this timepoint [50] 
(Figure 3A).  
 
5.1.2 Definitive yolk sac based hematopoiesis 
 
After the primitive wave of hematopoiesis, the definitive wave of hematopoiesis is 
initiated. This wave occurs in both YS and AGM/para-aorta-splanchno pleura (PAS) 
regions. During early definitive hematopoiesis, the YS gives rise to multiple types of 
hematopoietic (progenitor) cells, which do not show HSC properties. In zebrafish and 
mice, these multipotent cells have been termed erythro-myeloid precursors (EMP) 
and give rise to erythroid cells and all types of myeloid cells [51] and reviewed in [52] 
(Figure 3A). 
E8.5 YS-derived progenitors give rise to cells of the mononuclear phagocyte system 
(MPS). The monocytes generated here sustain lifelong and are independent of a 
bone marrow HSC. Recently Schulz and colleagues have shown that two parallel 
pathways of macrophage differentiation can be detected. These parallel pathways 
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can be distinguished based on their differential dependence on MYB [53]. The cells 
of the MPS system originate in the YS from MYB independent precursors. These 
precursors give rise to tissue macrophages such as liver Kupffer cells and skin 
Langerhans cells. This is in contrast with HSC based hematopoiesis, which is strictly 
MYB dependent. Ginhoux et al. have shown in a similar fashion that microglia have 
an origin in E7.5 YS hematopoiesis which is HSC independent [54].  
Recent reports also show that E9.5 YS definitive hematopoiesis contributes to 
lymphopoiesis (Figure 3A). This suggests the existence of a possible lympho-myeloid 
restricted precursor (LMP) already before the initiation of AGM HSC based 
hematopoiesis. In the publication by Yoshimoto et al. [55] evidence is presented for 
lymphoid potential in both YS and para-aortic-splanchno pleura (PAS) at E9.5, before 
emergence of HSC at E10.5. To further strengthen the fact that lymphoid cells are 
autonomously generated in the YS, experiments were performed using NCX1-/- mice, 
which lack active circulation. This excludes passive migration of AGM-derived HSC to 
the yolk sac. It was shown that cells expressing VE-Cadherin (marking endothelium) 
and lacking CD41 (marking the first hematopoietic cells) were the precursors of these 
YS-derived T cells. T precursor cells derived from this YS endothelium were able to 
reconstitute fetal thymus and were found to be functional. Moreover, these cells gave 
rise to both TCRγδ and TCRαβ T cells, which were of polyclonal nature. It has to be 
noted that in this report lymphoid progenitors cells were generated in vitro. The 
observation that lymphoid progenitors could be found prior to the emergence of HSC 
in vivo was studied in more detail by Böiers et al [56]. The authors use a Rag1-GFP 
reporter mouse to trace the earliest cells having lymphoid potential. These cells were 
defined as being Lin-Kit+Flt3+IL7Ra+, and were found in the YS as early as E9.5. At 
this timepoint the embryo proper lacks lymphoid potential. These cells were found to 
be CD45+ and in contrast to the report by Yoshimoto et al., these co-expressed CD41. 
The cells reported by Böiers et al do not show MegE potential, but are able to form T, 
B and NK cells. Also these cells seem to contribute to myeloid lineages. As these 
cells are found as early as E9.5, this excludes their origin in AGM derived HSC. 
However, it remains to be defined whether these cells derive from multipotent YS 
progenitors or whether they originate as lymphoid lineage restricted progenitors 
directly from hemogenic endothelium in the YS, as suggested by the data of 
Yoshimoto et al. [55] 
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Together, these recent data thus underscore the previously under-appreciated 
potential of HSC independent YS based hematopoiesis. 
 
5.1.3 Definitive AGM based hematopoiesis 
 
The hematopoietic stem cell is first detected in the AGM region. The “true” 
hematopoietic stem cell, capable of reconstitution of an adult mouse, is formed here 
at a later time point than the onset of definitive hematopoiesis in the YS (Figure 3A). 
Medvinsky and Dzierzak [50], using explant cultures, elegantly showed that HSC 
formation is initiated in the E10.5 AGM region. At this time point the YS lacks any 
transplantable activity. Immature HSC are formed in the ventral aspect of the E10.5 
AGM directly from the endothelial lining, a concept also found in other model 
organisms such as the zebrafish [57, 58]. However, HSC generated in the AGM do 
not directly acquire their full potential, but first require functional maturation and 
expansion in the fetal liver [59]. These mature HSC will then seed the spleen and 
bone marrow to sustain lifelong HSC-dependent hematopoiesis. The embryo 
becomes dependent on HSC-dependent hematopoiesis around E15. Deficiencies in 
HSC specific genes such as Myb and Meis1 are lethal around E15 [60, 61]. This is in 
contrast with hematopoietic specific genes such as Runx1 and Lmo2 which are lethal 
around E9-11, when the embryo becomes dependent on the blood circulation for 
oxygen transport [62, 63].  
Adding to the complexity of HSC biology, fetal-type HSC are markedly different from 
mature adult HSC. From FL hematopoiesis at ~E14 until 3-4 weeks after birth in the 
bone marrow, fetal HSC can be isolated which have higher proliferative activity and 
can give rise to specific types of γδ-T cells and B1 marginal B cells [64, 65]. These 
cells seem to be regulated by a, to date unraveled, specific genetic program which 
gradually shifts towards the mature HSC program and tips over between week 3 and 
week 4 after birth. In this process Lin28b has been shown to be a key regulator of the 
fetal HSC program [66]. 
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Thus, it is clear that hematopoiesis is a complex and stepwise system, giving rise to 
multiple progenitor cells with different capacity arising at different time points and 
locations. The molecular mechanisms underlying these steps still remain to be 
unraveled. Currently, the only true functional test of the generated cells remains 
assessment of their functionality, by engraftment or in vitro multi-lineage 
differentiation.  
 
Acknowledging the temporal changes during in vivo hematopoiesis, starting with a 
wave of primitive hematopoiesis in the yolk sac, followed by a wave of definitive 
hematopoiesis in the yolk sac and finally a wave of HSC formation in the AGM, one 
might hypothesize that in vitro hematopoiesis from hESC may follow a similar path 
(Figure 3B). 
  
6. Generating pluripotent  stem cell derived HSC – where are we now? 
 
Based on the data mentioned above, it is unclear whether HSC are generated in 
PSC differentiation cultures. Alternatively, it is possible that HSC do arise  but rapidly 
disappear or differentiate due to lack of supportive culture conditions.  
 
To address this question, we generated a MYB reporter hESC line, to mark 
emergence of MYB dependent HSC in the in vitro cultures [67]. The use of a MYB 
reporter line, allows for discrimination of YS MYB-independent hematopoiesis or fetal 
liver HSC-based MYB dependent hematopoiesis. We have shown, using this MYB-
eGFP reporter hESC line that the generation of blood cells from hemogenic 
endothelium occurs without the progression through a MYB-eGFP positive stage. 
The first CD34+CD43+ MYB-eGFP+ cells occur relatively late in these cultures, 
around day 14. These cells express a CD34+CD45RA-CD38-CD49f+ stem cell 
phenotype, however, the myeloid surface markers CD33 and CD123 are also 
expressed by these cells. Adding to this, these cells are readily expandable in media 
containing IL-3, further suggesting myeloid commitment. Using rt-qPCR, we were 
able to show commitment of the eGFP+CD34+CD43+CD45-/lo populations towards the 
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granulocytic myeloid lineage, through expression of high levels of MPO and GATA1. 
This was reflected in their lineage potential, as these were limited to generate 
granulocytic committed myeloid cells. The first multipotent hematopoietic cells 
generated in these cultures therefore do not pass through a MYB positive stage. 
CD34+ cells expressing this marker show commitment towards the granulocytic 
lineage rather than multipotency. Upon closer investigation of the monocytic cells 
generated here, we were able to show that these cells are reminiscent of tissue 
macrophages. In vivo, these tissue macrophages derive from MYB independent YS 
precursors, without dependence of HSC, as discussed earlier. Between day 10 and 
day 12 of culture, lymphoid precursors that give rise to T and NK cells also arise. This 
thus suggests that these cells are also formed from a MYB-eGFP yolk sac ELP-like 
cell. 
Based on our experimental results, we hypothesize that in vitro hematopoiesis from 
hESC mimics definitive YS EMP and LMP based hematopoiesis and that bona fide 
HSC are not generated (Figure 3B). 
 
Although reports have published the generation of CD34+ stem cells from hESC 
capable of engraftment, there is no solid proof for in vitro generation of HSC based 
on functional assays. As evidence is accumulating that HSC are not formed in vitro 
using current differentiation protocols, it is becoming clear that the goal of generating 
transplantable HSC from pluripotent stem cells for clinical practice is not yet 
achieved. Using reporter cell lines, such as our MYB-eGFP hESC reporter line, 
experimental conditions could be identified which do generate MYB+ progenitor cells 
with HSC properties during in vitro pluripotent stem cell differentiation culture. 
7. Towards clinical application of human pluripotent stem cells – the road ahead. 
 
As we have discussed, generation of bona fide HSC from PSC has not been 
successful to date, however current PSC differentiation methods do allow for 
generation of patient specific cells that may be suitable for transplantation (figure 4).  
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Figure 4: Generation of hematopoietic cells from pluripotent stem cells with clinical 
applicability.  
 
Gene corrected induced pluripotent stem cells (iPSC) derived blood cells can either be 
reprogrammed to generate gene corrected induced HSC (iHSC) and transfused into the 
patient,  alternatively, iPSC can be directly differentiated towards end cells for transplantation. 
Suitable cases would be the transplantation of gene corrected T cells for treatment of 
Wiskott-Aldrich syndrome (WAS) or severe combined immunodeficiency syndrome (SCID) 
and transplantation of macrophages for the treatment of Hurler syndrome 
 
 
We were the first to show that hESC differentiation cultures give rise to mature and 
functional T cells [41]. In vitro differentiation culture of PSC to T cells  could be 
applied for lymphoid cell diseases, such as the aforementioned X-SCID and Wiskott-
Aldrich syndrome. T cells are long lived, and vastly expand during development and 
upon recognition of their ligand. Thus transplantation of gene corrected T cell 
precursors generated in vitro might provide a sufficient basis for reconstitution of T 
cell immunity.  
Another type of long-lived YS-like cells that can be generated from PSC are tissue 
macrophages, as we have shown [67]. These cells may be ideal for transplantation in 
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the case of mucopolysaccharidoses (MPS) such as MPS I. MPSI, also known as 
Hurler syndrome, is a multisystemic disease caused by accumulation of carbohydrate 
polymers [68]. One of the affected cell types are tissue macrophages, among which 
are liver Kupffer cells and brain microglia [69]. As these cells are long lived and are 
easily generated from pluripotent stem cells, transplantation of patient specific gene 
corrected macrophage precursors could provide a highly efficient and safe alternative 
therapy to transplantation of hematopoietic stem cells, especially to prevent central 
nervous system complications.   
However, for broad applicability of PSC technology for the treatment of inborn 
hematologic diseases, generation of functional HSC is required. 
Advances towards generation of HSC from PSC will inevitably be made in the coming 
years based on increased understanding of in vivo hematopoietic processes. 
Knowledge of the factors, which are essential to induce definitive hematopoiesis at 
the different time points and anatomical locations during development, can be 
translated to the in vitro system. While no formal proof for HSC formation from hESC 
has been provided, knowledge of in vivo hematopoiesis has greatly advanced in vitro 
hematopoietic differentiation. 
One of the first reports regarding hematopoietic induction from hESC, was by 
Chadwick et al [34]. Here it was shown that upon addition of hematopoietic cytokines, 
a mix containing SCF, Flt3-L, IL-3, IL-6 and BMP4, generation of hematopoietic 
(progenitor) cells was greatly increased. The percentage of CD34+ cells was 
increased by almost twofold by addition of these cytokines, while total cell numbers 
remained stable. This suggests increased efficiency of hematopoietic differentiation. 
Also the number of CFU was vastly increased.  
Woll et al. [70] describe both increased kinetics of differentiation upon addition of 
Wnt1 containing conditioned medium to these cultures. The percentage of hemato-
endothelial cells was also increased. However, the authors used differentiation 
protocols using stromal cells and undefined serum component, hampering direct 
conclusions about the effect of Wnt1 signaling itself. In a more recent paper by 
Gertow et al.[71] the effect of Wnt signaling was addressed in defined media 
conditions. Here the authors conclude that Wnt3a signaling in itself is insufficient for 
successful induction of mesodermal differentiation, and that additional BMP signals 
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were needed. Upon addition of these factors, increased generation of HPC was 
found. Also, the authors point at the importance of timing of addition of these factors. 
In a report by Wang et al. [72], different signaling inhibitors and activators were 
assessed for generation of CD43+ HPC from hemogenic endothelium. Here it was 
shown, that inhibition of TGFβ signaling, activation of FGF signaling or retinoic acid 
signaling, greatly advances the generation of HPC.  
It has to be noted that none of these reports assessed true stem cell properties and it 
remains questionable whether the HPC generated in this way will be useful as such. 
It is clear that addition of factors, which play an essential role during in vivo 
hematopoiesis, positively influence the generation of HPC from hESC.  
Another option is the forced induction of HSC properties, by overexpression of factors 
which regulate them (figure 4), so called hematopoietic reprogramming. This has 
been successfully achieved by over-expression of HOXB4 in murine ESC-derived 
hematopoietic cells [39]. This method is based on the observation that HOXB4 
expression enhances engraftment when overexpressed in bone marrow progenitors 
and the fact that this factor regulates HSC properties. Upon transduction of YS 
progenitors with ectopic HOXB4, it was shown that these cells also acquired HSC 
properties. Using an inducible expression system, the same HSC properties were 
conferred to ESC derived progenitors. This shows, that brief induction of HOXB4 is 
sufficient for conferring HSC properties. These cells were not only able to be 
successfully engraft, but also show multilineage commitment in vivo. Adaptation of 
this method to hESC did not confer similar properties to hESC-derived HPC [47].  
Given the success of reprogramming somatic cells towards PSC [20], multiple 
research groups pursued along a similar line. Several attempts were made to directly 
reprogram cells towards HSC. This reprogramming can be initiated by directly 
inducing the desired cell characteristics, through overexpression of lineage specific 
genes. This has been successfully described for reprogramming of fibroblasts 
towards cardiomyocytes, which serves as a proof of concept [73]. In a report by 
Szabo et al [74], overexpression of OCT4 only reprograms fibroblasts to 
hematopoietic cells. These cells expressed the panhematopoietic marker CD45 and 
seemed to bypass the pluripotent state, as the obtained CD45 cells were shown to 
be unable to form teratomas in vivo. This proves that overexpression of OCT4 alone 
did not direct the fibroblasts towards a pluripotent state, but directly induced 
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hematopoietic properties. The authors were able to show that these cells could 
differentiate towards myeloid, erythroid and megakaryocytic lineages. However 
lymphoid differentiation was not addressed. Hematopoietic engraftment potential was 
found when injecting these cells into sublethally irradiated mice. As also evidenced in 
other reports generating CD34+ cells from PSC, these cells were of myeloid lineage, 
arguing against true HSC properties of the injected cells. To obtain hemogenic 
endothelium, a more controlled hematopoietic reprogramming was described. Here, 
murine fibroblasts were reprogrammed to hemogenic endothelium using 
overexpression of four factors, namely Gata2, Gfi1b, cFos and Etv6 [75]. 
Recently Doulatov et al. [76] have shown that overexpression of five hematopoietic 
factors effectively confers short term engraftment and expansion capacity to HPC 
generated in vitro. Here, HPC were derived from hESC, which were transduced with 
inducible vectors expressing ERG, HOXA9 and RORA. Upon induction of these 
factors, a transcriptional program quite similar to that of HSC was activated. However, 
expression of these factors was insufficient for successful engraftment of these 
hESC-derived cells. Through reverse screening, the authors were able to determine 
that only cells that were dependent on two additional factors, SOX4 and MYB, were 
capable of short-term engraftment.  
Finally, Riddell et al [77] reported the feasibility of direct reprogramming of committed 
hematopoietic cells to HSC in the murine system (termed induced HSC or iHSC). 
After isolation of mature blood cells and transient expression of Run1t1, Hlf, Lmo2, 
Prdm5, Pbx1, Zfp37, Meis1 and Mycn, HSC properties were conferred to these cells. 
These cells were able to reconstitute immune deficient mice. Upon secondary 
transfer, hematopoietic reconstitution was again observed. 
Currently, the changes in genetic program underlying this reprograming are not well 
understood. However, this proof of concept shows the feasibility of reprograming 
approaches to HSC as well as PSC. Based on the cited reports, there is no 
consensus on the factors needed for successful hematopoietic reprogramming. Also, 
it might be that these factors differ between man and mouse.  
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8. Conclusion 
 
Although major advances have been made towards generating gene corrected 
pluripotent stem cells for therapy, current protocols generating hematopoietic stem 
cells from these cells are lacking. Further understanding of the mechanisms 
underlying embryonic hematopoiesis will inevitably broaden our understanding of the 
in vitro differentiation processes and may result in efficient generation of HSC from 
PSC. Direct reprogramming of somatic cells such as fibroblasts towards 
hematopoietic stem cells using defined factors is currently an exciting alternative and 
a major advance in the field of in vitro hematopoiesis.  
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7. Discussion of the research in part I 
 
The research described in part I aimed at assessing whether bona fide hematopoietic 
stem cells (HSC) are formed during in vitro hematopoiesis from human pluripotent 
stem cells (PSC). The formation of HSC in vitro could be of great applicability for the 
clinic, where compatible grafts are often limited or not available.  
 
7.1 Can hematopoietic stem cells be generated from pluripotent stem cells? 
 
During the last decade, different protocols have been described that reproducibly 
induce hematopoietic differentiation from PSC. However, it is unclear whether bona 
fide HSC are generated in these cultures  
As described in the introduction, a bona fide HSC should fulfil three criteria: it should 
be multipotent, it should be able to self-renew and it should be able to engraft a 
sublethally irradiated host (upon secondary transplant). 
Evidence is accumulating that all types of hematopoietic cells can be generated from 
lineage restricted multipotent progenitor cells which are derived from hemogenic 
endothelium, rather than from HSC: recent reports show that the embryo develops all 
blood cell lineages before the formation of a HSC during the definitive wave of YS 
hematopoiesis (1, 2). While erythro-myloid restricted precursors (EMP) and lympho-
myeloid precursors (LMP) are lineage restricted precursors, cumulatively these 
precursors form all types of blood cells. EMP have been shown to give rise to 
erythroid cells, megakaryocytic cells, granulocytes and monocytic cells (such as 
Kupffer cells and microglia), while LMP give rise to myeloid cells and lymphoid cells, 
such as NK, T and B cells (1, 2).  
Often CFU assays are used to assess the potential of hESC derived hematopoietic 
progenitors (3). From these data multipotent CFU-GEMM progenitors are estimated 
to constitute 0.4% of CD34+ progenitors and 4% of CD34+CD43+ progenitors (4, 5). 
However, this assessment of multipotency does not include lymphoid differentiation 
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potential (T, NK, B cell precursor activity) and thus lacks proof for the presence of all 
blood lineages among the progeny of a single hematopoietic progenitor.  
Taken together, multipotency, presumed by the generation of all types of blood cells 
is no formal proof for the occurrence of HSC.  
Several research groups have taken the engraftment capacity of PSC-derived 
multipotent progenitors as proof for the presence of HSC (6-8). All these reports do 
show presence of human CD45 expressing hematopoietic cells in the blood or in the 
bone marrow of engrafted mice. However, no formal proof for the presence of a HSC 
that has all three aforementioned properties has been given.  
In the study described in this thesis, an alternative approach was used to address 
whether HSC are formed during in vitro hESC differentiation and at the same time 
identify them. We reasoned that if HSC are formed in  hESC culture, these cells 
should express high levels of MYB. MYB is expressed in fetal as well as postnatal 
HSC. In addition, MYB is absolutely required for HSC function as gene deletion 
mutant mice do not survive beyond E15, the point at which fetal hematopoiesis 
becomes HSC dependent (9, 10). This is in sharp contrast with YS-based 
hematopoiesis, which is MYB independent (1). We found that during in vitro hESC 
differentiation, no eGFP-marked MYB+ cells are formed that are capable of 
multilineage differentiation. This suggests that hematopoiesis in culture is HSC 
independent (5). In addition, in these cultures macrophages are formed that closely 
resemble the tissue macrophages generated during YS hematopoiesis. Based on 
data from previous reports and our finding that no multipotent MYB+ cells could be 
found, we concluded that in vitro hESC differentiation resembles YS HSC 
independent hematopoiesis. 
In conclusion, it is clear that pluripotent stem cells are able to form every type of 
hematopoietic cell. If conditions and cues are right, HSC can be generated, as has 
been show by the generation of HSC in teratomas (11). However, the generation of 
HSC from pluripotent stem cells in vitro using current protocols has not been shown 
conclusively. 
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7.2 Can transgenic pluripotent stem cell lines be used for optimization of the in vitro 
generation of HSC? 
 
Reporter cell lines, such as the MYB-eGFP hESC line we generated (5), can be used 
for the optimization of in vitro protocols to generate HSC. Use of such a reporter line 
provides a direct read-out for emergence of cells that express a key HSC marker. In 
combination with defined surface markers, this provides a powerful tool to screen for 
HSC formation.  
In the murine system, the combination of reporter strains has led to the detailed 
description of several hematopoietic progenitor stages. One example is the 
combination of PU.1 and GATA1 reporters (12), which allowed for definition of 
precursors of common lymphoid progenitors (CLP) and common myeloid progenitors 
(CMP). Combination of such lineage specific transgenic markers provides a tool to 
track progenitor commitment. An example of a reporter strain to identify and isolate 
HSC is the Fgd5 reporter, which was recently described (13). In the case of PSC 
differentiation, HSC specific markers could be combined with lineage specific 
markers. For example, the MYB-eGFP reporter we generated could be combined 
with an erythroid marker (e.g. GATA1 or a globin locus) and a myeloid marker (e.g. 
PU.1 or MPO). This would allow the definition of conditions that do not induce lineage 
skewing of the generated progenitors. 
As tailored nuclease technologies were still rapidly evolving when we designed our 
study, we circumvented these technical issues by using random BAC integration.  
The study was conceptualized in 2009-2010. At this time ZFN were a developing 
technology for genome editing, and reports showing successful endogenous 
integration of transgenes were still ample (14). Also, this technique was of low 
efficiency for many loci and flexibility in transgene design was low. Adding to this that 
homologous recombination in hESC remains cumbersome, we chose to use a 
random transgenic reporter method as was previously publishes in both the murine 
and human system. More flexible and efficient methods, such as the TALEN and 
CRISPR systems, only became available later on during the project (2012-2013) (15, 
16). 
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The use of a BAC reporter, which is integrated at random, has been described and 
validated before, both in the murine and in the human system (17-20). It can be 
argued that random integration might influence faithful expression of the transgene 
(21). However, we found complete integration of the full BAC plasmid (200kbp) in the 
genome. This large integration should sufficiently isolate the MYB transgene from 
neighboring genomic sequences to ensure physiologic expression. eGFP expression 
was validated by showing a correlation between MYB mRNA levels and eGFP 
expression in multiple sorted populations.  
Undoubtedly, the field will see the emergence of more transgenic PSC lines with the 
description and implementation of the new and highly efficient transgenic methods, 
such as CRISPR technology and it’s derivatives.  
 
7.3 Is there an advantage in using PSC derived cells to current gene therapy for 
hematologic diseases? 
 
Currently, HSC transduced with retro- or lentiviral overexpression vectors are used 
for gene therapy for hematological diseases such as SCID-X1 and WAS (22-24). 
SCID-X1 patients carry a genetic defect in the interleukin 2 common gamma chain 
(IL2RG gene. These patients have low numbers of T and NK cells, as a defective 
common gamma chain  leads to defective signaling for IL-2, IL-4, IL-7, IL-9, IL-15 and 
IL-21. Patients suffer from severe immunodeficiency with recurrent life threatening 
infection (25).  In the case of WAS, a genetic defect in the WASp protein (Wiskott-
Aldrich syndrome protein), causes defective acting polymerization. This is essential 
for T cell activation and effector functions. Like SCID-X1 patients, WAS patients also 
suffer from severe immunodeficiency (26). These genetic defects are thus ideal 
candidates for gene therapy, as introduction of a functional copy of the gene should 
alleviate disease symptoms. A major drawback of this approach is the risk of 
oncogenic transformation (27, 28). This is largely due to the insertional mutagenesis 
induced by transcriptional enhancers encoded within the viral sequences. These 
enhancers can induce aberrant expression of nearby genes, causing oncogenic 
transformation in the case of proto-oncogenes. These issues have been largely 
alleviated by use of later generation viral vectors, in which these enhancing 
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sequences become inactivated upon integration (29). However the use of promoters, 
which induce a constitutive increase in gene expression in HSC might still impose 
problems for the correction of proto-oncogenic genes. 
Recently Genovese et al. reported a proof of principle for genetic engineering using 
tailored nucleases to correct a mutation in patient-derived HSC (30). The advantage 
of this method is that the corrected gene is inserted into its endogenous genomic 
locus. Expression of the corrected gene is thus dynamically regulated and expression 
levels are within a physiologically relevant range. The fact that no additional promoter 
sequences or viral sequences need to be inserted alleviates possible issues 
regarding insertional mutagenesis. While this is a promising advance for the field, this 
method  holds some limitations: endogenous targeting of HSC is relatively inefficient 
and HSC in which off-target cutting or integration has occurred cannot be removed.  
These limitations are circumvented when autologous  iPSC are used for targeting 
instead of HSC.  
Corrected iPSC can be cultured indefinitely without differentiation. This not only has 
the advantage that an infinite amount of cells could be provided for transplantation, it 
also allows for thorough screening of the manipulated iPSC. Using iPSC, cells can be 
screened and expanded in a clonal manner. In this way, cells in which off-target 
cutting of the nucleases, off-target integration of the donor cassette or in which no 
correction has occurred can be excluded. The corrected pluripotent stem cells can be 
stored in iPSC banks. This might render the search for suitable donors obsolete. 
Generation of patient specific iPSC, their genetic correction and the generation of 
sufficient number of cells for transplantation requires valuable time and efforts. 
Herefore use of histocompatible iPSC banks might prove a more feasible alternative 
and provide a rapidly accessible source of gene corrected PSC.  
For the generation of HSC from PSC, one option would be to further optimize in vitro 
PSC differentiation protocols. Study of the ontogeny of the hematopoietic system has 
already identified several essential factors for generation of HSC. Among these are 
BMP-signaling (31, 32), Wnt-signaling (33) and Notch signaling (34, 35). The effect of 
these factors has been tested in hESC differentiation cultures without significant 
improvements to the generation of HSC in these cultures (36-38). However, the 
signals that regulate hematopoiesis might prove to be more complex than initially 
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thought, as essential non-hematopoietic cell types which act on the developing 
hematopoietic system are located outside of the site of hematopoiesis or are needed 
before the onset of hematopoiesis. Such an example was provided in the murine 
system, where catecholamines produced by the sympathetic nervous system 
influence HSC generation in the AGM region (39). In the zebrafish model, Wnt 
signaling early in ontogeny was found essential for expression of notch ligands by the 
somites. This signaling was shown to be essential for the specification of hemogenic 
endothelium in the AGM region  (40).  
To increase the efficiency of hESC derived definitive hematopoiesis, efforts have 
been undertaken to block the primitive hematopoietic wave during hESC 
differentiation using chemical compounds. By blocking activin-nodal signaling, which 
promotes Wnt signaling, the efficiency of definitive type hematopoietic cell generation 
improves. This increase in definitive type hematopoietic progenitors improved the 
efficiency of T cell generation in these cultures (41).  
Even when improved culture methods become available which favor HSC generation 
from PSC, maintenance of these cells in vitro might prove problematic resulting in 
rapid differentiation of the cells. Currently no culture conditions are described which 
can sustain and expand HSC properties. Al of the described HSC culture conditions 
induce rapid differentiation of LT-HSC (42-44). It has to be noted that the field has 
made advances in retaining HSC properties upon short-term culture by blocking the 
mTor pathway and stimulating the Wnt pathway. These HSC are cultured in absence 
of cytokines, which might induce differentiation (45). The question is whether such an 
approach could be integrated with differentiation of pluripotent stem cells, which 
depends on instruction of cytokines for generation of hematopoietic cells. 
 
Thus in conclusion, while the generation of cells for gene therapy using PSC remains 
promising, the generation of bona fide transplantable HSC has not been described. 
For this reason, the current applicability of PSC derived cells remains limited to cases 
where long lived hematopoietic cells can be transplanted (T cells or macrophages, in 
the case of SCID-X and Hurler syndrome respectively).  As methods for the in vitro 
differentiation of PSC are increasing in efficiency, this might provide feasible for 
clinical application.  
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In vitro generation of innate lymphoid cells from hematopoietic stem cells 
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1. Summary of part II 
 
The immune system is composed of two components, the innate and adaptive 
immune system. The innate immune system provides a rapid, broadly effective 
response to infection, while the adaptive immune system is highly specific and 
effective in clearing infection later on. Both systems rely on the function of specific 
types of immune cells.  
While the first member of the innate lymphoid cell (ILC) family, the natural killer cell 
(NK cell) was described 30 years ago, several previously unidentified members were 
recently added to this family. ILC have important roles in both health and disease. NK 
and ILC1 aid in the immune defense against viruses and malignant cells. Other types 
of ILC are essential to develop specific lymphoid organs and maintain gut 
homeostasis, lymphoid tissue inducer cells (LTi) and ILC3 respectively. Another type 
of ILC has been described to be involved in the development of asthma and defense 
against parasites (ILC2). 
As most members of the ILC family have only been described during the last decade, 
the development of these cells from HSC is not studied in detail. Progress in 
understanding the nature and development of ILC has been made in the murine 
system. Here, key transcription factors, environmental cues involved in ILC 
development, and the lineage relationships between different types of ILC have been 
largely, although not completely, elucidated. Some reports have described plasticity 
of ILC subsets during their development, as certain types of ILC were described to 
give rise to others. This suggests a flexible model, where ILC can change their 
function upon environmental cues. However, other reports have argued against such 
a model, and were not able to find this plasticity. 
In the human system, development of different ILC remains elusive, and reports 
generally rely on ex vivo culture of distinct developmental stages found in secondary 
lymphoid tissues (SLT). Using such a system, plasticity of ILC3 and NK cells was 
described. Here ILC3 were able to develop into NK cells, upon loss of stimulation of 
the aryl hydrocarbon receptor (AHR). Another report, which used an in vitro 
differentiation system of cord blood CD34+ progenitors argues against this plasticity, 
as ILC3 were not found to generate NK cells in absence of strong AHR stimulation. 
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As the developmental stages of ILC3 have not been elucidated in the human system, 
this might simply reflect the differences in plasticity of different stages of ILC3 
development. 
In our study, we set out to define the developmental stages through which NK and 
ILC3 progress. We found that as in SLT, stage 3 NK precursors could be detected, 
defined by a CD34-CD94-CD117+ phenotype. We describe that within this stage 3 
population, ILC3 can be distinguished from true stage 3 precursors, as ILC3 display a 
CD117hiIL1R1+NKp44+ phenotype, while stage 3 precursors are CD117dimNKp44-. 
Within the CD117dim population, both IL1R1- and IL1R1+ precursors could be found. 
These IL1R1- stage 3 precursors seem primed towards the NK lineage, as assessed 
by the expression of high levels of Tbet and absence of RORγt, while IL1R1+ stage 3 
precursors show ILC3 lineage priming evidenced by downregulation of Tbet and 
upregulation of RORγt. This priming is also reflected in the lineage potential of these 
cells. Although the IL1R1- stage 3 population gave rise to some IL1R1+ stage 3 cells 
and ILC3, these cells rapidly and predominantly generated NK cells. On the other 
hand IL1R1+ stage 3 cells rapidly developed into ILC3 cells, but retained NK 
developmental potential. Upon addition of FICZ, a strong AHR agonist, development 
of NK cells IL1R1+ stage 3 cells was hampered, and development of ILC3 promoted. 
The progeny of IL1R1- stage 3 cells was largely the same in the presence or absence 
of FICZ. 
These data thus show, that early in development, ILC3 precursors retain the potential 
to develop into NK cells and vice versa. Here, strong signaling through the AHR is 
essential for ILC3 to develop further. This finding might thus unify the views on ILC3 
lineage plasticity. 
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2. Samenvatting van deel II 
 
Het immuunsysteem bestaat uit twee componenten, het aangeboren en het 
verworven immuunsysteem. Het aangeboren immuunsysteem zorgt voor een snelle 
respons op infectie, met een brede werking.  Het verworven immuunsysteem 
daarentegen is hoog specifiek en klaart de infectie efficiënt, hetzij met enige 
vertraging. Beide systemen zijn gebaseerd op de functie van specifieke soorten 
immuuncellen. 
De eerste soort aangeboren lymfoïde cel (innate lymphoid cell, ILC), de natural killer 
cell (NK cel) werd 30 jaar geleden beschreven. Recent werden verschillende soorten 
ILC aan deze familie toegevoegd, die voorheen niet beschreven waren. De 
classificatie van ILC binnen het aangeboren en verworven immuunsysteem is niet zo 
eenvoudig, en ILC worden vaak beschreven als de brug tussen beide componenten 
van het immuunsysteem. ILC hebben een belangrijke rol in verschillende 
ziektebeelden, maar zijn ook essentieel in het behoud van immunologisch evenwicht 
in afwezigheid van infectie. NK cellen en ILC1 hebben een belangrijke rol in de 
immuun respons tegen virussen en belemmert kwaadaardige ontwikkeling van cellen. 
Andere types ILC zijn belangrijk voor de ontwikkeling van bepaalde lymfoïde organen 
en voor het behoud van het immunologisch evenwicht in de darm, deze worden 
respectievelijk lymphoid tissue inducer cells (LTi) en ILC3 genoemd. Een ander type 
ILC met een rol in de ontwikkeling van ,onder andere, astma werd beschreven (ILC2). 
Gezien de meeste leden van de ILC familie tijdens het laatste decennium werden 
beschreven zijn er nog vele vragen omtrent hun ontwikkeling. Door middel van 
onderzoek in het muismodel werden reeds inzichten verkregen in de eigenschappen 
van ILC en hun ontwikkeling. Zo werden de transcriptie factoren, omgevingsfactoren 
nodig voor ILC ontwikkeling en de verwantschappen tussen verschillende soorten 
ILC grotendeels, maar niet volledig, beschreven. Sommige artikels beschrijven het 
bestaan van plasticiteit van verschillende types ILC tijdens hun ontwikkeling, gezien 
uit sommige ILC andere soorten kunnen worden gegenereerd. Dit is suggestief voor 
een flexibel model, waarin ILC hun functie kunnen veranderen onder invloed van 
omgevingsfactoren. Andere publicaties beweren echter het tegendeel, en konden 
deze plasticiteit niet aantonen. 
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Bij de mens is de ontwikkeling van ILC nog niet volledig in kaart gebracht, en de 
artikels die deze ontwikkeling beschrijven zijn gebaseerd op de kweek van ILC types 
buiten het lichaam. Meestal worden bepaalde ontwikkelingsstadia uit secundaire 
lymfoïde organen (secondary lymphoid tisses, SLT) geïsoleerd en in kweek gebracht. 
Door middel van dergelijk model, kon plasticiteit tussen ILC3 en NK cellen worden 
aangetoond. ILC3 waren in staat om NK cellen te vormen, als stimulatie van de aryl 
hydrocarbon receptor (AHR) wegviel. In een andere publicatie die gebruik maakte 
van een in vitro differentiatiesysteem van CD34+ precursoren geïsoleerd uit 
navelstrengbloed kon deze plasticiteit niet worden aangetoond. Gezien de 
verschillende stappen in de ontwikkeling van ILC3 nog niet beschreven zijn bij de 
mens, is het mogelijk dat deze verschillen in plasticiteit te wijten zijn aan verschillen 
in de differentiatie van deze cellen. 
Onze studie had als doel de stappen in de ontwikkeling van NK  en ILC3 te 
beschrijven. We vonden dat stadium 3 NK cel precursoren aanwezig waren in deze 
kweken, net als in SLT. Deze konden geïdentificeerd worden op basis van de 
expressie van volgend oppervlaktemerker profiel: CD34-CD94-CD117+. We 
beschreven dat binnen deze stadium 3 populatie, een onderscheid kan worden 
gemaakt tussen ILC3 en echte stadium 3 precursoren, gezien ILC3 een 
CD117sterkIL1R1+NKp44+ oppervlaktemerker profiel vertonen. Binnen de CD117zwak 
populatie konden zowel precursoren met een IL1R1-NKp44- als een IL1R1+NKp44- 
fenotype worden gedetecteerd. De IL1R1- stadium 3 precursoren leken eerder aan te 
leunen bij NK cellen, gezien deze Tbet sterk tot expressie brengen, maar geen 
RORγt expressie vertonen. Anderzijds verlagen IL1R1- stadium 3 precursoren hun 
expressie van Tbet, maar verhogen de expressie van RORγt. Het aanleunen bij een 
bepaald celtype kon ook worden aangetoond door de analyse van de dochtercellen 
van deze precursoren. Ook al waren IL1R1- stadium 3 precursoren beperkt in staat 
om IL1R1+ stadium 3 precursoren te vormen en later ILC3, toch vormden deze 
precursoren vooral snel NK cellen. Anderzijds ontwikkelen IL1R1- stadium 3 
precursoren zich snel tot ILC3, maar behielden toch het potentieel om NK cellen te 
vormen. Na toevoeging van FICZ, een sterke agonist van de AHR, werd de 
ontwikkeling van NK cellen uit IL1R1+stadium 3 precursoren tegengewerkt en werd 
de ontwikkeling van ILC3 bevorderd. De dochtercellen van de IL1R1- stadium 3 
precursoren waren gelijkaardig in de aan- of afwezigheid van FICZ. 
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Deze data tonen dus aan dat ILC3 precursoren hun potentieel behouden om NK 
cellen te vormen tijdens vroege ontwikkeling, en omgekeerd. Tijdens deze 
ontwikkeling is sterke stimulatie van de AHR noodzakelijk voor de verdere 
ontwikkeling van ILC3. Deze bevinding kan mogelijk de verschillende visies op ILC 
plasticiteit samenbrengen. 
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3. Introduction of part II 
 
3.1 The immune system 
 
The human body is constantly engulfed by a wide variety of commensal and 
pathogenic bacteria, fungi and viruses. However, infection is a rare event. Pathogens 
are prevented from entering the body by potent physical, microbial and chemical 
barriers which are under control of the immune system. When the pathogen 
succeeds in crossing these barriers, infection is usually rapidly cleared by the 
immune system and does not lead to disease.  
When pathogens enter the body, tissue resident macrophages come in to action. The 
first cells that fight the infection will engulf the invading pathogens. These cells will 
then rapidly attract different types of more specific immune cells. Through secretion 
of cytokines and chemokines, this leads to a process called inflammation. The first 
cells that arrive at the site of infection are cells of the innate immune system, while 
the second wave consists of cells of the adaptive immune system. 
 
3.2 The innate immune system 
 
The innate immune system is evolutionarily conserved and is found in both 
vertebrates and invertebrates. The innate immune system has the ability to rapidly, 
selectively and efficiently target invading pathogens through the action of a humoral 
and cellular component. This causes a first line of defense during the first hours/days 
after infection.   
One of the modes of action of the innate immune system, is activation of the 
complement system. The complement system is part of the humoral innate immunity 
and consists of multiple complement factors circulating in the blood in an inactive 
state. The enzymatic function of the complement factors is activated upon their 
cleavage at the site of infection. Here complement factors elicit one of three major 
actions: 1) they bind to the pathogen and trigger their engulfment by phagocytic cells, 
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2) they act as chemo-attractants for immune cells such as neutrophils and monocytes 
and 3) they create pores in bacterial cells, leading to their direct killing (1). 
The cellular part of the innate immune system is activated upon recognition of 
pathogens in several manners. One of these is the recognition of pathogen-
associated molecular patterns (PAMP’s). PAMP’s are molecular structures, which are 
conserved on a wide range of different pathogens. Examples of PAMP’s are 
lipopolysaccharides of gram-negative bacteria and lipotechoic acid of gram-positive 
bacteria (2). These structures are essential for the function of pathogens, and are 
thus not prone to mutational diversity. Targeting of such conserved sequences 
prevents the occurrence of mutants that can escape the immune system. It also 
allows the innate immune system to be highly effective against a wide range of 
pathogens, by expression of germline-encoded receptors. These germline-encoded 
receptors are called pattern recognition receptors (PRR)(3). PAMP’s trigger PRR on 
the tissue resident immune cells and on cells that form the barrier of the body, such 
as epithelia. One example of such a receptor is the TOLL-like receptor expressed on 
macrophages and neutrophils, which will lead to activation of the NFkB pathways 
upon triggering (2). Activation of macrophages and neutrophils, leads to the 
production of chemokines and cytokines that promote the differentiation and 
expansion of immature innate immune cells. Also, additional innate immune cells are 
activated and attracted through this mode of action.  
The cellular innate immune system is composed of several cellular components. 
These include macrophages, mast cells, dendritic cells, various granulocytes and 
natural killer (NK) lymphocytes (figure 1).  
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Figure 1: Key components of the immune system. 
The immune system consist of two components, the innate and adaptive immune 
system. The innate immune system provides a rapid response to infection, through 
the action of complement factors, granulocytes, natural killer cells, macrophages and 
mast cells. The adaptive immune system functions through the action of B and T 
cells, which carry highly specific  immune receptors. (Figure adapted from Dranoff G 
et al. (4)) 
 
The first cells that fight infection are macrophages, which are attracted to the site of 
infection and eliminate pathogens or damaged cells by phagocytosis. The ingested 
particle is encompassed into a phagosome. Once inside the cell, the phagosome will 
fuse with a lysosome and form the phagolysosome. The factors contained therein, 
such as hydrogen peroxide and hydroxyl radicals will kill the contained pathogen or 
cell (2). Another innate cell type, the dendritic cell, arises from the same precursor as 
the macrophage. The naïve dendritic cells take up pathogens through engulfment. 
The DC process the ingested proteins into peptides, which are then presented on the 
major histocompatibility complex (MHC) to the T lymphocytes of the adaptive immune 
system.  
While macrophages are often the first to detect the presence of pathogens, the 
readily attract other types of immune cells. Granulocytes, such as neutrophils, are 
attracted to the site of infection and will extravasate from the blood stream into the 
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tissues. Alternatively blood borne pathogens can trigger endothelial cells to recruit 
neutrophils to the site of infection. Neutrophils play an important role in clearing 
infections. These can directly kill bacteria and fungi by release of their toxic granular 
content (myeloperoxidase and lysozyme), in a process called degranulation and take 
up the encountered pathogens by phagocytosis. Phagocytocis is mediated through 
recognition of complement or recognition of antibody through FcγR. Patients having 
mutations in any of these pathways fail to efficiently clear infection (reviewed by 
Witko-Sarsat (5)). In addition, neutrophils also interact with several parts of the 
adaptive immune system (reviewed by Nauseef et al (6)). 
Natural killer (NK) cells do not directly target the invading pathogens, but rather target 
cells of the body that are infected with intracellular bacteria and viruses or which have 
undergone oncogenic transformation. NK cells express an array of activating and 
inhibitory receptors, and the balance of the signals through these receptors triggers 
killing of the infected cell. Among these activating receptors are the C-type lectin 
receptors CD94-NKG2C, NKG2D, NKG2E/H and NKG2F, the natural cytotoxicity 
receptors (NCR) NKp30, NKp44 and NKp46, and the killer cell immunoglobulin-like 
receptors (KIRs) KIR-2DS and KIR-3DS and FcRγIIIa (CD16). Inhibiting receptors 
consist of CD94-NKG2A/B heterodimers and KIR-2DL and KIR-3DL (7, 8). One of the 
major mechanisms of NK cell triggering is recognition of non-self (Figure 2). NK cells 
receive signals through their activating receptors, priming them to kill infected cells. 
However they also constantly “scan” for the level of MHCI molecules expressed on 
the surface of the cells of the body. Healthy cells express high levels of MHCI, which 
causes triggering of the KIRs on the NK cells, and subsequently inhibits killing of the 
healthy cell. When MHCI levels drop, which is frequently induced by viral infection, 
the strength of these inhibitory signals drops and triggers the NK cell to kill the 
infected cell (1, 9). This process is called “missing-self recognition” (figure 2). Another 
method of action is the process of “non-self-recognition”. Here the NK cell recognizes 
molecules that are not expressed by host, but are encoded by the infecting pathogen. 
Alternatively, pathogens or malignant transformation might cause upregulation of the 
expression of self-molecules, which are otherwise not expressed, or can only be 
detected at low levels. This leads to the process of “stress-induced self-recognition” 
(figure 2) (7-9). 
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Figure 2: Methods of natural killer (NK) cell activation.  
Activation of NK cells is regulated by the balance of signaling through inhibitory and 
activating receptors. If inhibitory signals (e.g. recognition of self through MHCI 
detection) exceed the strength of activating signals, NK cell function is inhibited. If 
upon infection, inhibitory signals cease, or if activating signals increase, NK cells 
become activated (Figure adapted from Vivier, E et al. (9)). 
 
Together, these mechanisms effectively fight bacterial or viral infection during the first 
hours and days after infection. In cases where the infection is not successfully 
cleared, it is usually sufficiently contained until the adaptive immune system clears 
the infection. 
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3.3 The adaptive immune system 
 
The adaptive immune system is a slow but very powerful system to fight and clear 
infection. The adaptive immune system has evolved during vertebrate evolution. In 
this system, each cell has a unique receptor. The specificity of these is generated 
through rearrangement of the germ line DNA encoding immune receptors. This 
occurs by the merit of “recombination activating” enzymes (RAG) mediate in 
rearrangement of the genetic sequence, as described further. The immune receptor 
that is the result of this rearrangement is different for each cell, which leads to an 
immense diversity within the pool of immune cells. These cells are collectively able to 
recognize a wide variety of pathogens. Different types of adaptive immune cells 
come into action upon infection: B cells provide immunity through antibody 
production and T cells by direct killing of infected cells or by regulation of immune 
responses by other immune cells.  
When a cell with a specific immune receptor recognizes a pathogen, it expands in a 
clonal manner. This cellular proliferation takes days or even weeks. The adaptive 
immune response is therefore inherently slow to develop, but, once the cells are 
generated, provides a more efficient mechanism than the innate immune system, and 
is able to clear infection. In addition, cells which have been successful in recognizing 
and eliminating pathogens or infected cells will survive and generate an 
immunological ”memory”, that can rapidly come in to action upon re-infection. 
 
3.3.1 T cell immunity 
 
T cells are characterized by the expression of a hetero-dimeric T cell receptor (TCR). 
T cells are subdivided into cells that express a TCRαβ heterodimeric receptor or a 
TCRγδ heterodimeric receptor.  
T cells also express co-receptors, which aid binding of the TCR to the MHC complex. 
Two types of co-receptors exist, namely CD4 or CD8 co-receptor molecules. TCRαβ 
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T-cells are subdivided into helper T-cells (CD4+), cytotoxic T-cells (CD8+) and 
regulatory T cells. 
CD4+ TCRαβ+ cells will help to activate other immune cells, such as B cells, CD8+ 
effector T cells and macrophages, while CD8+ TCRαβ+ effector cells will directly kill 
infected cells. Regulatory T cells (Treg) are a subtype of CD4+ T cells that control 
autoimmunity, through limitation of the activity of immune cells after they have 
exerted their function. Treg have also been described to play a role in preventing 
allergy and asthma. On the other hand, Treg also exert negative effects, as they 
suppress immune responses against different cancers (10-12). They are generally 
characterized as CD4+ cells expressing high levels of CD25 and the Forkhead 
transcription factor Foxp3 (13).  
After clonal expansion and the elimination of infection, T cells go into apoptosis 
(contraction) and only a pool of memory T cells survive, which can be rapidly 
activated an expanded upon re-infection. T cell memory is subdivided into central 
memory (Tcm) and effector memory (Tem), while the first migrate to secondary 
lymphoid tissues (SLT) and are expanded upon antigen triggering, the latter readily 
go to infected tissues to exert their effector function (14). 
Cells carrying a TCRγδ are mainly found in mucosal tissues, for example as intra 
epithelial lymphocytes (IEL) in the gut, where they take part in the first line of defense 
against invading pathogens (15, 16). 
Although the precursor that generates T cells originates in the bone marrow (17), T 
cells develop in a specialized organ, called the thymus. Herein all necessary cues, 
such as Notch signaling and interleukin-7 (IL-7), are provided for commitment to the 
T cell lineage and subsequent development (reviewed by Taghon and Rothenberg 
(18)). After selection on the basis of their functionality, cells exit the thymus and 
home to the secondary lymphoid tissues.  
Development of T cells is characterized on the molecular level by rearrangement of 
the T cell receptor genes and expression of surface molecules such as CD4 and CD8. 
Generally, T cell development is divided into consecutive stages, during which the 
developing T cell undergoes three essential processes. These will be described in 
the following paragraphs: 1) β -selection, 2) positive selection and 3) negative 
selection. 
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T cells develop through several steps defined by the expression of their co-receptors 
and T cell receptor (figure 3). During the double negative (DN) stage cells are defined 
by the lack of expression of a TCR and are negative for CD4 and CD8. At this stage, 
the T cell precursor will either further differentiate along the TCRαβ or the TCRγδ 
lineage. After this stage, TCRαβ differentiating cells enter the immature single 
positive stage (ISP), which is CD4+CD8-. During the ISP stage, the selection of a 
successfully rearranged β-TCR chain occurs through the process of β-selection. After 
successful progression through this stage, cells upregulate the CD8 molecule and 
become double positive (DP). In the end, a DP T cell will develop into either a single 
positive CD4+ T cell  (T helper cell) or CD8+ T cell (cytotoxic T cell)(reviewed by 
Singer et al. (19)). 
 
Figure 3: Stages in T cell development.  
During the development of T cells, a CD4-CD8- (double negative, DN) precursor, will 
upregulate CD4 and CD8 expression, to become a CD4+CD8+ (double positive, DP) 
precursor. This DP precursor will either develop into a CD4 single positive T cell or a 
CD8 single positive T cell (Figure adapted from Singer et al. (19)).  
 
Each T cell expresses a unique T cell receptor, and only recognizes one specific 
antigen. However, together the pool of these T cell receptors recognizes an 
extensive array of different antigens. Through this mechanism, they form an effective 
means to clear infection by different pathogens. This clonal specificity is achieved by 
rearrangement of the T cell receptor gene loci during their development. The TCR 
are encoded by 3 TCR loci, which consist of different gene segments. The gene 
segments consist of multiple variable (V), diversity (D), domain (J) gene segments 
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encoding the variable domains and one or two gene segments encoding the the 
constant domain (C). The V-D-J segments are “recombined” by two enzymes called 
“recombination activating genes” RAG1 and RAG2. These interact with one-another 
and “cut-and-paste” V-J or V-D-J segments in a random fashion. This generates a 
random diversity in antigen recognition. Adding another layer to the diversity, endo- 
and exonucleases remove or add several nucleotides between these VDJ gene 
segments. This process generates unique T cell receptors which recognize one 
single antigen (1). 
The process of recombination is a process of trial and error and cells with 
unsuccessful TCR-locus rearrangement will fail to develop further. During 
development, the cell is submitted to several quality control mechanisms. One of the 
quality control steps during αβ T cell development is control of successful β chain 
rearrangement, in a process called β-selection. During β-selection a cell that has 
successfully rearranged the TCRB encoding genomic locus will dimerize with a pre-
Tα chain, a germline encoded surrogate for the TCRα chain, to form a pre-TCR. If the 
pre-TCR is formed, cells will be selected for further development.  
 
Once the TCRα chain is rearranged, the generated TCR will be screened for weak 
interaction with self-MHC complexes, which is essential for immune function. 
Through this process, double positive cells will develop into either a MHCI restricted 
(CD8+ single positive T cells) or MHCII restricted (CD4+ single positive T cells).  
 
After β-selection and positive selection, the T cells generated are subjected to one 
final test before it exiting the thymus: negative selection. This mechanism excludes 
cells that recognize self-antigens, which would otherwise lead to autoimmunity. 
 
 
 
3.3.1.1 T helper responses. 
 
CD4+ T cells have a role in promoting antibody production and induction of CD8+ 
cytotoxic T cell responses. These CD4+ cells are subdivided into different helper 
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subsets, based on the cytokines they produce and the immune response they elicit 
(figure 4). 
 
 
Figure 4: Different types of T helper responses.  
T helper responses are divided into different subtypes: the TH1, TH2 TH17 and TFH 
response. During a TH1 response, type I cytokines are produces, such as interferon 
gamma (IFN-γ) and IL-2. The TH2 response on the other hand leads to production of 
type2 cytokines such as IL-4, IL-5 and IL-13. The Th17 response leads to production 
of  TNF, IL-17 and IL-22, while T follicular helper (TFH) responses lead to IL-4 and IL-
21 production (Figure adapted from Craft et al. (20)) 
 
Classically, T helper subsets are subdivided into T helper 1 (TH1) and T helper 2 
(TH2) responses. TH1 cells produce type1 cytokines such as interleukin 2 (IL-2), IL-
3, interferon gamma (IFN-γ), and granulocyte-macrophage colony stimulating factor 
(GM-CSF). TH2 cells produce IL-3, IL-4 and IL-5. TH1 and TH2 responses protect 
against intracellular pathogens and extracellular pathogens, respectively. Another T 
helper subset, the TH17, produces TNF, IL-17 and IL-22. TH17 cells provide 
protection against bacteria and fungi. The TFH response, produced IL-4 and IL-21 
provides survival and differentiation signals for B cells (20). 
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3.4 Bridging innate and adaptive immunity – innate lymphoid cells 
 
Various cell types have been described that bridge innate and adaptive immunity. 
Among these are  γδ T cells, natural killer T cells (NKT) and B1 B cells. While these 
have re-arranged immune receptors, except for γδ T cells, these receptors display 
limited diversity (21, 22). These cell types play an important role in the rapid 
responses to particular pathogens. Another type of lymphoid cells that bridges the 
innate and adaptive immune system are closely related to NK cells, but have effector 
functions similar to T cell subsets (figure 5). These are collectively termed “innate 
lymphoid cells” or ILC. During recent years this “innate counterpart” of T-helper 
subsets has been the focus of intense investigation (23).  
 
 
Figure 5: Analogy between adaptive T helper subsets and innate lymphoid cell 
subsets.  
Innate lymphoid cells (ILC) have been divided in three separate subsets based on 
their cytokine production profile. Group 1 ILC contain natural killer (NK) and ILC1 
cells, group 2 ILC contain ILC2 and group 3 ILC contain lymphoid tissue inducer cells 
(LTi) and natural cytotoxicity receptor (NCR) positive and negative ILC3 (Figure 
adapted from Walker et al. (24)). 
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ILC secrete immunoregulatory cytokines, similar to their T-counterparts. The main 
difference between innate lymphoid cells (ILC) and T cells is the absence of 
rearranged T cell receptor, ILC produce cytokines in an antigen receptor independent 
manner. Different types of ILC have been described to have a function in mucosal 
immunity, repair of damaged tissues and the generation of lymphoid organs. 
 
3.4.1 Types and characteristics of innate lymphoid cells 
 
As several research groups described ILC’s simultaneously, these have been given a 
myriad of names. Recently a more uniform nomenclature has been proposed by 
Hergen Spits and James Di Santo (23). Here, for clarity, only this nomenclature will 
be used. 
Using this classification, the family of ILC consists of different subsets defined by 
their cytokine secretion profile in analogy with T-helper subsets. These three subsets 
are called group 1 ILC, group 2 ILC and group 3 ILC (24) (table I and figure 6 and 7).  
In brief, group 1 ILC contain conventional NK cells and type 1 ILC (ILC1) Group 2 ILC 
contain type2 ILC (ILC2) while group 3 ILC are constituted of type3 ILC (ILC3) and 
lymphoid tissue inducer (LTi) cells. 
TableI: different subsets of innate lymphoid cells and their cytokine production profile 
(based on Spits and Di Santo (23)). 
Class Cell type Cytokines 
produced 
Group 1 ILC NK TNF-α, IFN-γ, 
perforin, 
granzyme 
ILC1 IFN-γ 
Group 2 ILC ILC2 IL-5, IL-9, IL-13 
Group 3 ILC NCR+ ILC3 IL-22 
NCR- ILC3 IL-17, IL-22 
LTi IL-17, IL-22 
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3.4.1.1 Group 1 ILC 
 
- NK cells have an important function in killing infected or transformed cells. NK cells 
exert their function through release of perforin and granzymes. NK cells also have 
immunoregulatory functions by the release of pro-inflammatory cytokines such as 
tumor necrosis factor α (TNF-α) and interferon γ (IFN-γ) (25).  
- ILC1 cells have been described to produce IFN-γ, but lack cytotoxic activity. Based 
on their capacity to secrete type1 cytokines, these cells were classified as group1 ILC 
However it is still not clear to which lineage these cells belong: as progeny of cells 
generated from ILC3, as an induced functional state of ILC3 or as a sub-class of NK 
cells, as will be described lower in section 3.4.3.2 (26).  
3.4.1.2 Group 2 ILC 
 
ILC2 cells were first described in the murine system to fight Helminth infection in 
absence of B and T cells (27). Human ILC2 have also been described since (28). 
These cells produce IL-5, IL-9 and IL-13, similar to T helper 2 cells (28). ILC2 cells 
are found in tonsils, blood and intestines, where their main function is the elimination 
of extracellular parasites. 
 
3.4.1.3 Group 3 ILC 
 
- LTi cells are essential for the development of secondary lymphoid tissues such as 
lymph nodes and Peyers patches. These cells lack expression of the natural 
cytotoxicity receptors (NCR) NKp46 and NKp44 (29) (see tableII). LTi have a major 
role during fetal development, but have also been described in secondary lymphoid 
tissues after birth (30).  
- ILC3 express NCR (NKp44 and NKp46), but lack expression of other NK cell 
markers, such as KIRs, CD16 and CD94 (31). They do not produce TNF-α and IFN-γ, 
but are a main source of IL-17 and IL-22. ILC3 are found mainly in the small and 
large intestine, where they provide mucosal immunity and form a barrier against 
invading pathogens  (32). 
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While it is becoming clear that ILC2 arise through a different developmental pathway 
than ILC1 and ILC3 subsets. The relationships between group 1 and group 3 ILC, or 
different group 3 ILC subtypes remain a matter of debate. It is possible that these 
different subsets represent the same cell type that produces different cytokines or 
expresses different surface markers depending on different environmental cues. 
 
3.4.2 Phenotype of innate lymphoid cells 
 
A range of surface markers have been described which could enable isolation of 
different types of ILC and discrimination from other lymphoid cell types (table II). NK 
cells are generally defined by expression of CD94, natural cytotoxicity receptors 
(NCR) such as NKp44 and NKp46 and positivity for CD56. Group 1 ILC can be 
discriminated from other types of ILC, by the absence of IL1R1 expression. ILC1, in 
contrast to NK cells do not express NCR. Group 3 ILC are also positive for IL23R, 
CD117 and some subtypes express NCR. Among these group 3 ILC, ILC3 can be 
defined by expression of CD56, NKp44 and NKp46, while LTi are negative for the 
latter two. Group 2 ILC can be discriminated by expression of CRTH2, a marker 
uniquely expressed on this subset. 
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Table II: Phenotype of innate lymphoid cells ( taken from Spits et al. Nature Reviews 
Immunology, 2013 (23)). 
Marker 
Group 1 ILCs Group 2 ILCs Group 3 ILCs 
NK cells ILC1s ILC2s 
LTi 
cell
s 
NCR+ 
ILC3s* 
CD4 − − − − − 
CD25 −/+‡ low low ND low 
CD56 + − ND − 50% 
CD117 (also known as KIT) − − +/− + + 
CD127 (also known as IL-7Rα) −/+§ + + + + 
CD161 −/+§ +/− + +/− + 
NKp44 (also known as NCR2) −/+* − − − + 
ICOS low + + ND + 
NKp46 (also known as NCR1) + − − − + 
CRTH2 − − + − − 
IL-1R − + + + + 
IL-23R − − ND + + 
IL-12Rβ2 + + − − − 
ST2 (a subunit of IL-33R) − − + − − 
IL-17RB (a subunit of IL-25R) − − + − − 
CRTH2, chemoattractant receptor-homologous molecule expressed on TH2 cells; ICOS, inducible 
T cell co-stimulator; IL, interleukin; ILC, innate lymphoid cell; LTi, lymphoid tissue-inducer; NCR, 
natural cytotoxicity triggering receptor; ND, not determined; NK, natural killer.  
*Also referred to as NK22 cells.  
‡CD56hiCD16− cells express CD25.  
§Not on all cells.  
*NKp44 is expressed by activated but not resting NK cells.  
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3.4.3 Development of innate lymphoid cells  
 
Innate lymphoid cells develop from a common lymphoid progenitor (CLP), which is 
dependent on the transcriptional repressor Id2 and will develop into a presumptive 
common ILC precursor. Induction of Id2 is crucial for this differentiation as it inhibits 
the function of E proteins. This is important to block T- and B cell development from 
this common precursor, as both T- and B cells rely on function of E proteins for their 
commitment (33). From this common precursor, differentiation into the different types 
of innate lymphoid cells depends on the expression of specific transcription factors. 
These are in common with the factors regulating differentiation of their adaptive 
counterparts (figure 5 and figure 6).   
 
Figure 6: Innate lymphoid cell subsets and the queues regulating their development. 
Different groups of ILC develop from a common ID2+ precursor through induction of 
different transcription factors. Group 1 ILC develop under the influence of IL-15 
signaling (NK cells) and IL-7 (ILC1), during their development T-bet and Eomes are 
key transcription factors. Group 2 ILC develop through induction of the transcription 
factors RORα and GATA3, and depend on IL-7 and Notch signaling. Group 3 on the 
other hand strictly depend on RORγt signaling for their development, and develop in 
the presence IL-7 and  aryl hydrocarbon receptor (AHR) signaling (Figure adapted 
from Spits et al. (23)). 
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3.4.3.1 Development of conventional NK cells 
 
The development of human conventional NK cells has been divided into 5 different 
stages and has been largely based on the work of the group of Michael Caligiuri. 
It has been established that NK cells develop from a precursor common to T and B 
cells. This common lymphoid precursor (CLP) is derived from bone marrow HSC. 
The human CLP has been defined as a CD34+CD38+CD45RA+CD10+ cell (figure 7) 
and can be detected both in the BM and the SLT (34). The CLP then differentiates 
into a stage 2 NK cell precursor, which is marked by the loss of CD10 expression and 
upregulation of CD117 expression. This cell then differentiates into a stage 3 
precursor, which loses expression of CD34. This stage 3 precursor is highly 
heterogenous, containing precursors of NK cells and innate lymphoid cells. The bulk 
of stage 3 precursors is minimally defined by a CD94-CD117+ surface phenotype. 
From this stage 3 precursor, conventional NK cells will develop, and upregulate 
CD94 expression (stage 4 and stage 5). Stage 4 NK cells are defined by a 
CD94hiCD56bright phenotype and have a more cytokine producing profile. From this 
stage 4 NK cell, although still under debate, stage 5 NK cells will develop, which 
have a more cytotoxic profile (35-37). 
 
 
Figure 7: A schematic overview of human NK cell development.  
NK cell development has been divided into separate stages based on surface 
markers and functionality. From a hematopoietic stem cell (HSC), NK cells develop 
towards through several progenitor stages (stage 1-3) to become CD56brightCD94hi 
stage 4 NK cells, which have a cytokine producing profile. These can then develop 
into stage 5 CD56dimCD94low NK cells, which have a cytotoxic profile (Figure adapted 
from Freud et al. (38)). 
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3.4.3.2 Lineage relationships between innate lymphoid cells 
 
Whether NK cells and other types of ILC derive from a common ILC precursor or 
whether they diverge at the CLP stage remains a matter of scientific debate (figure 8).  
 
Figure 8: a schematic overview of innate lymphoid cell development.  
All ILC develop from the common lymphoid progenitor (CLP). From this stage 
different environmental  cues divert cells into the ILC lineage, and block T and B cell 
differentiation. The exact lineage relationships between these different subsets and 
the stages through which they develop, have not been described in detail. Whether 
ILC1 are a subset of NK cells, or develop from ILC3 remains topic of debate. 
In the murine system it was shown that all ILC, except NK cells, derive from a 
common precursor (39). This common precursor was defined within the Lin-IL-
7Rα+α4β7-integrinhigh population, and was found to express high levels of the 
transcription factor PLZF (39). This was strengthened by the publication by Klose et 
al. (40), where a common precursor for all ILC types, except NK cells was described. 
It has been proposed that NK and ILC3 have a different origin using adoptive transfer 
experiments and tracing of the lineage of RORγt expressing precursors (a key 
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transcription factor during type 3 ILC development) (41, 42). In a report by Crellin et 
al. (31), a different precursor for NK and ILC was proposed on the basis of 
expression of CD127 (IL-7 receptor) and both were detected in human SLT. Here the 
CD127+ precursor gave rise to ILC3 cells, while the CD127- precursor gave rise to 
NK cells. This adds to the evidence for a separate precursor of ILC3 and NK. 
 
Whether there is plasticity between ILC3 and NK cell subsets remains a matter of 
debate. Using cord blood CD34+ in vitro cultures, human NK and ILC3 cells were 
described to be fully committed cells without plasticity (43). In contrast, plasticity of 
SLT derived NK cells and type 3 IL-22 producing ILC was described ex vivo (34, 44).  
A different origin of RORγt+ LTi and RORγt+ ILC3 has been described based on 
expression of α4β7-integrin. Sawa and colleagues have shown that in fetal liver 
RORγt+ α4β7-integrin+ precursors give rise to LTi, while their α4β7 integrin negative 
counterpart gives rise to ILC3 (45). On the other hand it was shown that NKp46- ILC 
(presumptive LTi-like cells) can give rise to NKp46+ ILC (ILC3), which would argue for 
a common origin of both cell types (42). Also in the human system, ex vivo NKp44-
CD117+ LTi were shown to be able to differentiate into NKp44+ ILC3 when stimulated 
with IL-2, IL-23 and IL-1β in culture (26).  
This thus warrants further research to define the exact lineage relationships of ILC 
subtypes and the different stages in their respective development. 
 
3.4.3.3 Transcriptional control of innate lymphoid cells 
 
Group 1 ILC develop by induction of the transcription factor T-bet, while NK cell 
development diverges from the CLP by up regulation of EOMES induced by IL-15 
signaling (46, 47). NK cells are also dependent on E4BP4/Nfil3 and TOX for their 
differentiation. While these genes were thought to uniquely drive NK cell 
development, recently Seillet et al. and Geiger et al. provided evidence for an 
important role of E4BP4/Nfil3 in ILC2, LTi and ILC3 development (48, 49). Also, TOX 
was shown to play a role in LTi development, next to its role in NK development (50). 
Developmental plasticity has been described between group 3 ILC and ILC1 when 
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cultured in presence of IL-12 and IL-18 , which questions ILC1 to be a distinct cell 
type. These data argue for a common origin of both cell types or alternatively might 
reflect alternative activation stages of a highly plastic common ILC. Therefore, 
environmental cues may downregulate RORγt in response to IL-12 and IL-23 (42). 
However, whether ILC1 and ILC3 are truly the same cell type remains a question and 
requires further research. 
ILC2 have been described to depend on a different set of transcription factors, which 
are thought to be unique for ILC2 during development of innate lymphoid cells:  
RORα (51) and GATA3 (52). Again, this remains subject of debate, as GATA3 
signaling has also been described to be important for ILC3 development (53). 
In conclusion, while key transcription factors regulating development of innate 
lymphoid cell subsets have been defined, the exact relationships between these 
subsets, their plasticity, and the interplay between factors involved has not been fully 
clarified.  
 
3.4.3.4 Extracellular signals regulate innate lymphoid cell development 
 
The cues that direct the development of ILC are being unraveled. NK cells were 
shown the be dependent on IL-15 signaling for their development, while all other 
types of ILC rely on IL-7 signaling (41, 43). Essential for ILC3 development is 
signaling through the AHR. Genetic knockout of this receptor leads to abolishment of 
ILC3 expansion and failure to clear Citrobactor rodentium infection in the murine 
model (54, 55). In a recent report by Hughes et al (56), it was shown that stimulation 
of AHR blocked differentiation of human secondary lymphoid tissue derived ILC3 
towards NK cells. Similarly, IL-1β signaling has also been described to block NK cell 
development from these ILC3 (57). 
Within group 3 ILC, Notch signaling has been described to be important for postnatal 
ILC3 development, while LTi development has been described to be Notch 
independent (58). Similarly, ILC2 are dependent on Notch signaling for their 
development (59). ILC2 cells are closely related to T cells, as thymic DN1 and DN2 
precursors can still develop into ILC2 cells. The key factor blocking T cell 
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development at this point has again been shown to be Id2 (60). Here, the strength of 
Notch signaling seems to influence the choice between T and ILC2 lineage 
development from a common thymic progenitor, where weak notch signals drives 
these precursor towards the T lineage and strong Notch signals give rise to ILC2 
cells (59). 
 
3.4.4 Function of innate lymphoid cells 
 
In contrast to NK cells, which constitute approximately 15% of peripheral blood 
lymphocytes, other types of ILC are generally not detected in the circulation (0.01-0.1% 
of circulating cells) (61). These are found to be tissue resident and reside in tonsils, 
thymus, gut and skin (62).  
While the key role of NK cells in the immune system has been established, the roles 
of other types of ILC are only just being elucidated.  
 
3.4.4.1 Type 1 ILC 
 
The function of type 1 ILC is similar to that of TH1 T cells, and these produce type 1 
cytokines such as IFNγ and TNF. NK cells have an important role in the 
immunological defense against viral infections (63). They also have a protective role 
against cancer development (64). NK cells act through several mechanisms to exert 
their effects. MHCI expression is reduced upon malignant transformation, to evade 
the action of T lymphocytes. However, this causes NK cells to elicit a missing-self 
response and attack the malignant cells. Alternatively, several oncogenic 
malignancies have been described to upregulate molecules that trigger NK cell 
activation through NKG2D, even on cells with normal MHCI levels (65). Some 
cancers also express ligands for the NKp30 activating receptor (66). 
While evidence is limited, ILC1 have been described to have a protective role against 
extracellular parasites (40). It has also been shown that a specified ILC1 in the 
human system, which has no characteristics of ILC3 or NK cells, is able to produce 
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IFNγ upon bacterial infection of the gastro-intestinal tract. A rapid antibacterial 
response is hereby provided (26).  
 
In the case of inflammatory bowel disease, an increased number of ILC1 cells were 
found in the intestine of patients with Crohn’s disease (67). These ILC1 can then 
produce IFNγ in a TH1-like response, causing increased inflammation of the intestine. 
 
3.4.4.2 Type 2 ILC 
 
Type 2 ILC have been described to have a protective role against gastrointestinal 
parasites such as Helminths through the production of IL-25 by epithelial cells. IL-25 
will trigger ILC2 to produce IL-5 and IL-13, eliciting TH2 immune responses and 
attraction of eosinophils (68).  
In the case of asthma, PRR expressed on airway epithelial cells are triggered by 
PAMPs, leading to production of cytokines, chemokines and antimicrobial peptides. 
This causes attraction of immune cells, of which monocytes play an important role. 
These monocytes will differentiate into dendritic cells, which will activate specific TH2 
T cells in the lymph nodes (69).  
Among the cytokines produced after endothelial cell PRR triggering, are IL-25 and IL-
33. These latter two cytokines trigger ILC2 to produce IL-5 and IL-13. IL-5 will lead to 
the attraction of eosinophils, which cause basement membrane deposition (70). One 
characteristic of asthma is an increase in goblet cells (goblet cell metaplasia or GCM), 
which is induced by IL-13 signaling on endothelial cells (71). 
 
3.4.4.3 Type 3 ILC 
 
 
While ILC mainly have immune protective functions, some reports have described a 
cancer-promoting role of ILC3 through an IL23 induced mechanism. Herein cancer 
development is promoted by production of IL-17 and IL-22 (72). Chronic inflammation 
of the intestine has been shown to lead to colorectal cancer, through downregulation 
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of IL-22 binding protein (IL22BP) production. IL22BP neutralizes soluble IL22, and 
thus maintains a subtle balance of IL-22 levels in homeostasis (73). 
ILC3 have been described to play and essential role in infections of the gastro-
intestinal tract. In mouse models infection with Citrobacter rodentium leads to 
upregulation of IL-22 by ILC3 and mice lacking ILC3 die because of this bacterial 
infection (74). IL-22 stimulates the gastro-intestinal epithelial cells to produce anti-
microbial peptides and defensins, which will clear bacterial infection (75).  
As innate lymphoid cells play a role in intestinal mucosa homeostasis, it is maybe not 
surprising that a role for ILC has been described in intestinal bowel disease (IBD). 
TH17 responses have been described to play a role in sustaining inflammatory bowel 
disease (76, 77), thus a similar role for ILC3 has been proposed. Indeed, NCR- ILC3 
have been found in increased levels in the colon of patients with Crohn’s disease 
(78). IL-22, produced by ILC3, can trigger signaling on epithelial cells, which causes 
STAT3-related signaling. This has important anti-inflammatory roles and causes 
restitution of goblet cells in colitis (79).  
 
In addition, innate lymphoid cells have been described to play a role in the 
development of inflammatory immune diseases such as psoriasis (80) and asthma 
(81). Psoriasis is caused by deregulated immune responses of the skin. Here skin-
resident dendritic cells produce IL-12 and IL-23. This leads to a pro-inflammatory 
TH1 and TH17 response, which induces production of IFNγ, TNFα, IL-17 and IL-22. 
These cytokines promote inflammation and increase keratinocyte proliferation. 
Interestingly, while IL-23 has been described to promote growth and activation of 
ILC3, IL-12 has been described to alter ILC3 development towards ILC1 type cells 
(26), which produce IL-17 and IL-22 and IFNγ and TNFα respectively. 
 
IL-22 producing innate lymphoid cells have been described to play an essential role 
in protecting against graft-versus-host disease (GVHD) related intestinal 
inflammatory damage. Frequency of ILC and the levels of IL-22 were both reported to 
be lower upon GVHD (43). 
It was recently described that innate lymphoid cells interact with cells of the adaptive 
immune system. Next to their role as cytokine producers, ILC3 have been described 
to present peptides in MHCII molecules (29, 82, 83). This might provide a novel 
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mechanism of antigen presentation, but understanding this specific function requires 
further research. 
In conclusion, future research will certainly unravel more immune functions of ILC 
and elucidate their role in both protective immunity and in disease. Finally, this could 
lead to therapies directly targeting innate lymphoid cells. 
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5. Research focus of part II 
 
Innate lymphoid cells (ILC) have been recently discovered as the innate counterpart 
of T helper adaptive lymphoid subsets. These cells were described to have an 
essential role in maintaining mucosal homeostasis and play important roles in 
stimulating the immune system upon infection. Understanding of the differentiation of 
immune cells, the transcription factors and extracellular signals involved, is essential 
in understanding the immune system in both health and disease.  
The exact developmental intermediates through which ILC differentiate remain a 
matter of scientific debate and it remains to be established whether conventional NK 
cells and other types of ILC originate from a common precursor, and whether there is 
lineage plasticity between these lineages.  
The in vitro differentiation of cord blood progenitors towards ILC enables analysis of 
stepwise development through different intermediates. Thorough understanding of 
ILC development will provide the field with insights into pathogenesis of ILC related 
diseases and might provide novel therapeutic targets. The efficient generation of 
different types of ILC in vitro can also provide cells which are suitable for 
transplantation. 
We thus set out to define the lineage relationships between conventional NK cells 
and group 3 ILC using this in vitro study. As plasticity has been described and refuted 
between these ILC subtypes, we hypothesized that this could be due to differences in 
the lineage commitment during differentiation of these cells. We thus assessed the 
earliest progenitors of the cells which arose in vitro for their lineage potential, and 
defined whether AHR signaling is necessary at any one of these stages and is able 
to influence in vitro ILC3 versus NK cell commitment. 
In the presented work, we describe the stepwise differentiation of progenitors in vitro 
similar to the stages described in ex vivo studies. We show that during this 
differentiation both IL1R1+ and IL1R1- stage 3 NK precursor can be detected. These 
either develop into a IL1R1+ ILC biased precursor or retains its phenotype to become 
an NK primed precursor. This IL1R1+ stage 3 cell presents itself as a bipotent 
conventional NK and ILC3 precursor. Signaling through the AHR receptor can 
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enforce commitment towards ILC3 cells. We found that the IL1R1- stage 3  NK 
committed precursor  cannot be diverged from the NK developmental pathway.  
The research presented here unifies different models of NK and ILC development, 
and presents the field with a novel tool for study of ILC and NK development, which 
allows for stepwise analysis of the genes and cues involved in the development of 
these cell types. 
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Abstract 
 
During recent years, the phenotype and function of innate lymphoid cells has been 
unraveled both in the murine as in the human system. However, the exact 
developmental pathways of NK cells and ILC3 remain elusive. Here, using in vitro 
differentiation of human cord blood CD34+ cells, we describe how the earliest NK and 
ILC3 precursors diverge at the stage 3 NK developmental stage. The stage 3 
population contains both IL1R1- and IL1R1+ precursors. The IL1R1+ fraction is 
strongly RORγt+ but displays some remnant Tbet expression, in contrast to fully 
mature ILC3 cells. The IL1R1- fraction is RORγt-, and contains cells which express T-
bet and low levels of Eomes. These IL1R1- cells partially remain IL1R1 negative and 
become NK cell primed precursors, while the remaining part gives rise to an IL1R1+ 
stage 3 intermediate. This IL1R1+ stage 3 intermediate either upregulates CD94, to 
generate NK cells, or further upregulates CD117 and NKp44, to become RORγt+ 
ILC3. Addition of AHR agonist to these cultures diverts differentiation of the IL1R1+ 
stage 3 precursor toward ILC3 development and hampers development of NK cells In 
contrast, differentiation of the IL1R1- stage 3 precursor towards the NK lineage was 
not influenced by AHR signaling. These data provide a novel insight in the early 
developmental decisions during the development of innate lymphoid cells and NK 
cells.  
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Introduction 
 
The family of innate lymphoid cells (ILC) bridges innate and adaptive immunity. In 
contrast to immune cells of the adaptive immune system, ILC lack expression of a 
rearranged immune receptors, such as the T cell receptor (TCR) or B cell receptor 
(BCR). ILC produce immunoregulatory cytokines that act on mucosa and other types 
of immune cells. Different subsets of ILC have been described according to their 
respective cytokine production profiles. This divides the ILC family in three major 
groups: group 1, group 2 and group 3 ILC (1, 2). Group 1 ILC contain conventional 
NK cells (NK) and ILC1, which are both IFN-γ producing cells. Group 2 ILC contain 
only one member, ILC2, which produces IL-5, IL-9 and IL-13. Group 3 ILC contain IL-
22 and IL-17 producing cells and is constituted of lymphoid tissue inducer cells (LTi) 
and ILC3.  
 
ILC develop from a common lymphoid progenitor (CLP), which is dependent on Id2. 
Id2 function is key for differentiation of ILC at this stage as it inhibits the function of E 
proteins. This is important to block B cell and T cell potential from the CLP (3). The 
human bone marrow CLP has been defined by the CD34+CD38+CD45RA+CD10+ 
surface marker profile. Upon induction of an NK developmental program, the CLP 
differentiates into a stage 2 NK cell precursor and is marked by the loss of CD10 
expression and upregulation of CD117 expression. These stage 2 NK cells 
subsequently differentiate into a stage 3 precursor, which loses expression of CD34. 
This population of stage 3 precursors is minimally defined by a CD34-CD94-CD117+ 
surface phenotype and is highly heterogeneous and contains precursors of both NK 
cells and ILC. From this stage 3 precursor, conventional NK cells will develop, and 
upregulate CD94 expression to generate stage 4 and stage 5 NK cells. Stage 4 NK 
cells are defined by a CD94+CD56bright phenotype. These cells have low cytotoxic 
capacity and mainly produce cytokines. From this stage 4 NK cell, although still under 
debate, stage 5 CD94+CD56dim NK cells may develop, which have a more cytotoxic 
profile (4). 
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How different ILC populations develop and how their development fits in the 
aforementioned 5-stage NK cell development model remains elusive. In the human 
system, Hughes et al. described RORγt+ ILC3 isolated from adult secondary 
lymphoid tissues (SLT) to hold lineage plasticity and to be able to differentiate 
towards IFNγ producing NK cells (5). These ILC3 were described to express high 
levels of IL1R1 and it was shown that signaling through the aryl hydrocarbon receptor 
(AHR) was essential to inhibit their differentiation towards NK cells. In contrast, in a 
report by Ahn et al. it was shown that NK cells and ILC3, generated using a protocol 
based on cord blood CD34 differentiation in vitro, are irreversibly committed and do 
not show any lineage plasticity (6). These NK cells were defined by expression of 
LFA1, while IL-22 producing ILC3 do not express LFA1. The LFA1- ILC3 were shown 
to be uniformly positive for IL1R1, while the LFA1+ NK cell precursors are devoid of 
IL1R1 expression. These data are also supported by data in the murine system, 
where using RORγt lineage tracing, NK cells derived from a RORγt+ precursor were 
not detected (7).  
 
We hypothesized that these seemingly contradictive reports might reflect differences 
in the differentiation state of these populations. During early lineage development, 
cells which are not yet fully committed might be present and represent cells with 
higher plasticity. In this study we aimed at defining the developmental relationship of 
NK cells and ILC3 from the earliest stage 3 precursors arising during in vitro NK 
differentiation culture. As ILC3 development is clearly marked by the upregulation of 
IL1R1, while NK cells remain negative for IL1R1, we addressed whether differences 
in expression level at the stage 3 NK precursor population might reflect early skewing 
of these stage 3 precursors. The obtained data provide evidence for bifurcation of 
ILC development within the stage 3 precursor population, which is marked by IL1R1 
expression. At this stage, the IL1R1- precursor is unresponsive to AHR stimulation. 
On the other hand, AHR stimulation of the IL1R1+ stage 3 precursor provides a rapid 
progress into the ILC3 lineage, while hampering development towards the NK cell 
lineage. These data provide a novel insight in the early divergence of the 
developmental pathways of ILC3 and NK cells. 
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Materials and Methods 
 
Isolation of cord blood CD34+ precursors. 
All cord blood samples were obtained from the Cord Blood Bank of the University 
Hospital Ghent following approval by the ethical committee of the Ghent University 
hospital. Cord blood samples were processed by mononuclear cell isolation, through 
ficoll gradient centrifugation (Lymphoprep, Axis-Shield, Oslo, Norway). Subsequently 
CD34+ precursors were isolated using magnetic activated cell sorting (MACS) 
(Miltenyi biotec, Bergisch Gladbach, Germany) according to the manufacturers 
protocol.  MACS CD34 isolation obtained purity >60% on average. To isolate pure 
precursors, cells were FACS sorted for following phenotype CD34+CD45+CD14-CD3-
CD19-CD56- (CD34+lin-) obtaining purities >98%. 
 
Lymphoid differentiation of CD34+ precursors. 
CD34+ precursors were differentiated in vitro as previously described (8, 9). In brief, 
350 CD34+lin- precursors were seeded on mitotically inactive EL08-1D12 feeders (a 
kind gift of professor E. Dzierzak (10)) seeded to confluence. Cells were cultured for 
up to 28 days in DMEM:F12 (2:1) (Gibco, Life Technologies, Carlsbad, CA, USA), 
supplemented with 20% human serum (Innovative research, Novi, MI, USA),  20 
ng/ml Stem Cell Factor (SCF) (Peprotech, Rocky Hill, NJ, USA), 5 ng/ml interleukin 3 
(IL-3) (R&D Technologies, Minneapolis, MN, USA), 20 ng/ml IL-7 (R&D 
Technologies), 10ng/ml IL-15 (Peprotech), 10 ng/ml Flt3-L (R&D Technologies), 
24µM β-mercaptoethanol, 50µM ethanolamine, 20 µg/ml ascorbic acid, 50 ng/ml 
sodium selenite, 1% penicillin+streptomycin, 1% pyruvate and 1% glutamin. Half of 
the medium was changed with fresh medium containing cytokines every 7 days and 
IL-3 was omitted after the first week of culture. 
CD34+Lin- FACS sorted populations were cultured using this protocol and were 
seeded as indicated. For AHR stimulation experiments, cultures were supplemented 
with either 300 nM 6-Formylindolo(3,2-b)carbazole (FICZ) (Enzo Life sciences, 
Farmingdale, NY, USA) or a similar volume of DMSO carrier. 
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Flow cytometric analysis and cell sorting 
Cells were analyzed using a LSRII flow cytometer (BD, Franklin Lakes, NJ, USA) or 
FACS sorted using a FACS ARIA IIIu with ACDU unit. Samples were stained using 
the following antibodies: IL1R1 PE (R&D Technologies), IL1R1 APC (R&D 
technologies), NKp44 APC (eBioscience, San Diego, CA, USA), CD94 PerCP-Cy5.5 
(BD biosciences, San Jose, CA, USA), CD117 PE-Cy7 (eBioscience), CD45 APC-
Vio770 (Miltenyi biotec), CD56 V450 (BD bioscience).  
For intracellular staining, cells were fixed and permeabilized after surface staining 
using the Foxp3 / Transcription Factor Staining Buffer Set (eBioscience) according to 
the manufacturer’s instructions. Following antibodies were used for transcription 
factor staining: RORγt-PE, Tbet-PE and Eomes-PE (all from eBioscience). 
 
Real time RT-PCR 
Cells were lysed using Qiazol lysis reagent (Qiagen, Venlo, Netherlands). RNA was 
extracted using the miRneasy RNeasy micro kit (Qiagen) and cDNA was synthesized 
using superscriptIII reverse transcriptase using random hexamer primers (Life 
Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. PCR 
reagents and SYBR GreenI were obtained from Roche (Roche, Penzberg, Germany) 
and used according to the manufacturer’s instructions. The reactions were run on a 
lightcycler480, 384 well system (Roche). Following primers were used in this study:  
GAPDH fwd: 5’- TGCACCACCAACTGCTTAGC -3’; GAPDH rev: 5’- 
GGCATGGACTGTGGTCATGAG -3’;  
YWHAZ fwd: 5’- ACTTTTGGTACATTGTGGCTTCAA -3’; YWHAZ rev: 5’- 
CCGCCAGGACAAACCAGTAT – 3’;   
RORC fwd: 5’- TCGCCAAAGCATCCTGGCAAAG -3’; RORC rev: 5’- 
ATGGGGTGGAGGTGCTGGAAGA -3’;  
Tbet fwd: 5’- CGCCAGGAAGTTTCATTTGGG -3’; Tbet rev: 5’-
TGGAGGGACTGGAGCACAAT -3’;  
Eomes fwd: 5’- AGCCCTCAAAGACCCAGACTT -3’; Eomes rev: 5’- 
CCAGGGACAATCTGATGGGAT -3’. 
In vitro studies on human hematopoiesis  Stijn Vanhee 
!
190 | 
!
Statistical analysis 
All statistical analyses were performed using SPSS V22.0 (IBM, New York, NY, USA). 
Significance was assessed using the students t test with significance level set at p ≤ 
0.05. 
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Results 
 
ILC3 and conventional NK cells develop in vitro through a stage 3 NK cell precursor. 
 
To analyze the kinetics of human innate lymphoid cell development, CD34+Lin- cord 
blood precursors were cultured for up to 28 days in conditions which favor NK/ILC 
development. After 10 days of development, the majority of cells had acquired a 
CD94-CD117dim phenotype and had downregulated CD34, in agreement with the 
presence of a stage 3 NK cell phenotype (Figure 1A and data not shown). After 14 
days of culture, the first CD94+ NK cells appeared. Simultaneously, CD94-CD117hi 
cells were generated. Within the stage 3 population, part of the cells upregulated 
IL1R1, but remained negative for NKp44 expression. At the following time points, 
both the CD94+ NK cell population and CD94-CD117hi population vastly increased. By 
the end of culture, the CD94+ NK cells were uniformly positive for CD56, but only a 
small fraction expressed NKp44 and IL1R1. In contrast, after 28 days of culture the 
CD94-CD117hi population, uniformly expressed high levels of CD56, NKp44 and 
IL1R1. This latter surface phenotype is compatible with presence of ILC3 (Figure 1A). 
These CD94-CD117hi cells expressed high levels of RORγt, but were negative for T-
box transcription factors Tbet and Eomes. In contrast, the CD94+ NK cell population 
shows weak expression of RORγt and expressed high levels of Tbet and Eomes 
(Figure 1B). 
Thus three clear populations could be discerned during innate lymphoid cell 
differentiation: a CD94+ NK cell population, and within the CD94-CD117+ population a 
CD94-CD117hiIL1R1+NKp44+ ILC3 population and a CD94-CD117dim stage 3 
population. 
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Figure 1: Generation of NK cells and ILC3 in vitro from CD34+ cord blood progenitors. 
A) Flow cytometric analysis of CB differentiation cultures under NK/ILC supportive conditions. 
At day 10,  14,  21 and 28 cells were stained for CD117, CD94, CD56, NKp44 and IL1R1. All 
populations were gated for human CD45 expression or as indicated. Histograms showing 
CD56, NKp44 and IL1R1 are shown as an overlay of the populations as indicated; B) 
Intranuclear staining for RORγt, Tbet and Eomes is shown for the indicated populations. 
Gating was perfomed as in panel A. Marker expression (full line) is shown compared to an 
isotype control staining (dotted line). Representative analysis of 3 experiments are show at 
each time point. 
 
After 14 days of culture, when the stage 3 population was most apparent, this 
population contained both IL1R1+ and IL1R1- cells (Figure 2A). The IL1R1+ stage 3 
and IL1R1- stage 3 population were both negative for NKp44 expression. Within the 
IL1R1+ stage 3 population, some CD56+ cells could be detected (Figure 2A). Low 
levels of RORγt, Tbet and Eomes expression were detected on the protein level in 
the IL1R1- stage 3 population. In contrast, the IL1R1+ stage 3 population expressed 
high levels of RORγt, and expression of Tbet or Eomes was borderline (Figure 2B).  
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Figure 2: Stage 3 NK precursors contain a distinct IL1R1+ and IL1R1- population. 
A) Flow cytometric analysis of day 14 CD94-CD117dim stage 3 cells. Stage 3 cells were 
stained for IL1R1, CD56 and NKp44. All populations were gated for human CD45 expression 
or as indicated. Histograms show CD56 and NKp44 expression (full line). Expression is 
compared to an isotype control (dotted graph); B) Intranuclear staining for RORγt, Tbet and 
Eomes is shown for the indicated populations. Gating was perfomed as in panel A. Marker 
expression (full line) is shown compared to an isotype control staining (dotted line). 
Representative analysis of 3 experiments of each population are shown. 
To confirm the data obtained by flow cytometry, expression levels of these 
transcription factors were assessed by qPCR. Herefore, CD94+ NK, CD94-CD117hi 
ILC3, IL1R1- stage 3 and IL1R1+ stage 3 populations were isolated by FACS sorting 
on day 14 and day 21 of cord blood differentiation culture (Figure 3). As expected, 
NK cells expressed high levels of Eomes and Tbet, at both time points analyzed, 
while being devoid of RORC expression. (Figure 3). RORC was found highest in the 
ILC3 population, while this population was consistently negative for Eomes and Tbet.   
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Figure 3: Expression of key transcription factors during innate lymphoid cell 
development. 
Expression of Tbet, Eomes and RORC was analyzed in the indicated populations by qPCR 
analysis after 14 and 21 days of culture. Expression is shown relative to the mean of GAPDH 
and YWHAZ expression. Data represent the mean of 3 independent cord blood donors. Error 
bars indicate the standard deviation of the mean. 
 
Both at day 14 and day 21 of culture, the IL1R1- stage 3 population expressed high 
levels of Tbet, but was negative for Eomes and RORC. In contrast, the IL1R1+ stage 
3 population expressed low levels of Tbet and RORC, but was negative for Eomes at 
day 14 of culture (Figure 3). 7 days later, expression of Tbet was decreased in 
comparison to the expression on day 14, but RORC expression increased in this 
IL1R1+ stage 3 population (Figure 3). From these data it is clear that ILC3 and IL1R1+ 
stage 3 cells are a distinct population, and while the latter population expresses 
RORC, some remnant expression of Tbet expression could be detected. This 
suggests that the IL1R1+ stage is a transition stage from the IL1R1- stage 3 towards 
the ILC3 phenotype. 
 
To address this hypothesis, IL1R1- and IL1R1+ stage 3 precursors were isolated from 
day 14 cocultures through FACS sorting and recultured for up to 10 days (Figure 4). 
By the end of culture, IL1R1+ precursors generated higher percentages of  ILC3 
(defined as CD94-CD117hiIL1R1+NKp44+) compared to IL1R1- precursors. The 
fraction of CD94+ NK cells was similar between the progeny of both populations 
(Figure 4A). To address whether ILC3 and CD94+ NK cells were generated with 
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altered kinetics, cultures were analyzed after 7 and 10 days of culture (Figure 4B). 
After 7 days, CD94+ NK cells were most apparent in cultures initiated with IL1R1- 
stage 3 precursors, however, low percentages were also detectable in the IL1R1+ 
stage 3 condition. By day 10, CD94+ NK cells had formed from both populations to 
the same extent. This suggests a difference in kinetics of CD94+ NK formation from 
different  stage 3 subpopulations. Upon addressing ILC3 lineage differentiation, it 
was clear that IL1R1+ stage 3 precursors had faster kinetics of ILC3 generation, and 
this fraction constituted a higher proportion of CD45+ cells than the IL1R1- stage 3 
precursor (Figure 4B).  
 
Figure 4: IL1R1+ stage 3 precursors represent ILC3 primed precursors. 
A) Flow cytometric analysis of IL1R1- stage 3 and IL1R1+ stage 3 precursors sorted from d14 
cocultures and recultured for 10 days of culture. Plots show CD45+ gated fractions. 
Representative dot plots from the same donor are shown. B) Analysis of IL1R1- stage 3 and 
IL1R1+ stage 3 progeny after 7 and 10 days of culture. Data are indicated as percentage of 
CD45+ cells and represent the mean of 3 independent cord blood donors. Error bars indicate 
the standard deviation of the mean. 
 
These data thus suggest that IL1R1- stage 3 cells readily differentiate into NK cells, 
or alternatively, differentiate into ILC3 through an IL1R1+ stage 3 intermediate, which 
would explain the delayed kinetics of ILC3 generation. 
 
 
 
In vitro studies on human hematopoiesis  Stijn Vanhee 
!
196 | 
!
Stimulation through the AHR influences lineage commitment of stage 3 precursors. 
To address whether the development of ILC3 cells is influenced by AHR signaling, 
we added either the known high affinity AHR ligand 6-Formylindolo(3,2-b)carbazole 
(FICZ) or DMSO carrier to day 14 bulk cultures and analyzed the phenotype and cell 
number 4 days later (Figure 5). Phenotypically, induction of AHR signaling led to an 
increase of the ILC3 population (defined as CD94-CD117hiIL1R1+NKp44+), but 
showed a reduction of the CD94+ NK population (Figure 5A). Addition of FICZ, did not 
significantly affect the percentage and absolute cell numbers of CD45+ cells 
generated (Figure 5B, C). Although the differences are not significant, the CD94+ NK 
cell population was decreased in the presence of FICZ after 4 days of culture, a 
similar result was found after 7 days of culture (Figure 5D and data not shown). Upon 
addition of FICZ both the percentage and absolute cell number of ILC3 significantly 
increased (Figure 5D, E). Within the stage 3 population, no significant changes could 
be detected upon addition of FICZ, however, the IL1R1+ stage 3 precursors showed 
a tendency to decrease upon AHR stimulation (Figure 5D, E).  
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Figure 5: Stimulation of the aryl hydrocarbon receptor influences the lineage output of 
different stage 3 precursors. 
A-E) Flow cytometric analysis of day 18 cocultures. Cultures were performed in the presence 
of the AHR agonist FICZ (300 nM) or DMSO carrier control from day 14 onwards. A) Plots 
show CD45+ gated fractions. Histograms show marker expression within the stage 3 
precursor population. B, C) Percentage and absolute number of CD45 in day 18 cocultures 
are shown. Data represent the mean of 3 independent cord blood donors. Error bars indicate 
the standard deviation of the mean D,E) Percentage and absolute number of the indicated 
populations in day 18 cocultures are shown. Percentages are shown as proportion of CD45+ 
cells. Data represent the mean of 3 independent cord blood donors. Error bars indicate the 
standard deviation of the mean. F) Day 14 IL1R1+ and IL1R1- stage 3 precursors were sorted 
and recultured for 10 days in  the presence of the AHR agonist FICZ (300nM) or DMSO 
carrier control. Plots show CD45+ gated fractions. Representative dot plots are shown from 
the same cord blood donor.  
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As the increase in ILC3 might reflect rapid differentiation of IL1R1+ stage 3 
precursors towards ILC3, the influence of AHR stimulation on the lineage output of 
the two stage 3 subsets was addressed. Here fore, IL1R1- stage 3 cells and IL1R1+ 
stage 3 cells were FACS sorted from day 14 cocultures. These stage 3 populations 
were subsequently allowed to differentiate for an additional 10 days in the presence 
of FICZ or DMSO carrier (Figure 5F). A subpopulation of IL1R1- stage3 became a 
clear ILC3 population by day 10 (Figure 5F). The IL1R1+ stage 3 population gave rise 
to a population of ILC3 cells which constituted about 50% of CD45+ cells by the end 
of culture. The NK cell population generated from IL1R1+ stage 3 precursors was 
smaller than the population generated from IL1R1- stage 3 precursors (Figure 5F). 
When the AHR was stimulated by addition of FICZ, development of NK cells from the 
IL1R1+ stage3 precursor was hampered, as evidenced by the decrease in the 
percentage of NK cells (Figure 5F). In contrast, NK cell development from IL1R1- 
precursors was largely unaltered (Figure 5F).  
In conclusion,  AHR stimulation diverts differentiation of the IL1R1+ stage 3 precursor 
toward ILC3 development and hampers development of NK cells. In addition, AHR 
stimulation has no effect on the differentiation of  IL1R1- stage 3 precursor towards 
the NK lineage. 
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Discussion 
 
To date the phenotypic intermediates of ILC differentiation have not been clearly 
described. Plasticity between different types of ILC has been proposed. However, 
while some reports have underscored this hypothesis, others have provided evidence 
against it. In the human system, it was shown in a report by Hughes et al. that IL-22 
producing ILC3 found in human secondary lymphoid tissues express high levels of 
IL1R1 (11). In a recent report by Hughes et al., lineage plasticity of this IL1R1+ ILC3 
population was shown. In the absence of AHR signaling, ILC3 cells were able to 
differentiate towards NK cells, while stimulation of AHR blocked this differentiation. 
Also, IFNγ production by NK cells was markedly decreased after AHR stimulation(5). 
In a report by Ahn et al., it was shown that in differentiation cultures initiated with 
human CD34+ cord blood progenitors, ILC3 and NK cells could be distinguished by 
expression of LFA1 after 21 days of culture (6). At this timepoint, the stage 3 
population already contained mature IL-22 producing ILC3 cells and IFNγ producing 
NK cells. Here, no plasticity of the ILC3 population could be detected. These findings 
suggest that late in culture, NK cells and ILC3 are terminally differentiated, and have 
lost their lineage plasticity. 
 
We show here that innate lymphoid cells and conventional NK cells are efficiently 
generated in cord blood CD34 cultures as previously described (6, 12). In addition, 
we show the dynamics of IL1R1 expression during the development of ILC. During in 
vitro differentiation, NK cells and ILC3 are generated through a stage 3 NK cell 
precursor. After 14 days of culture, stage 3 NK cell precursors can be detected which 
express IL1R1 within this population. Both IL1R1- and IL1R1+ stage 3 precursors 
have been shown to be present in secondary lymphoid tissues . These populations 
constituted about 20% and 80% of stage 3 cells, respectively (11). In culture, we 
found these IL1R1+ stage 3 precursors to rapidly progress towards an ILC3 
phenotype. Development of IL1R1- stage 3 cells seemed to preferentially proceed 
towards the NK cell lineage, however, these also gave rise to a small population of 
IL1R1+ stage 3 cells and ILC3 later on (data not shown). These data are suggestive 
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for a model where IL1R1- stage 3 precursors develop into a IL1R1+ stage 3 precursor, 
which subsequently gives rise to ILC3. 
 
In the absence of AHR signaling, IL1R1+ stage 3 cells were found to retain NK 
potential. Upon strong AHR signaling, NK cell development from the bipotent IL1R1+ 
precursor was hampered. NK cell development from IL1R1- stage 3 precursors was 
not influenced by addition of an AHR agonist. These data are in contrast to the report 
of Ahn et al, where NK and ILC3 cells were not found to retain lineage plasticity after 
21 days of culture. Our observations add to these findings that early in culture, NK 
and ILC lineages are diverting, but are not yet fully committed. In addition to the 
report by Ahn et al, it has been described that during development, murine NK cells 
do not develop through a stage of RORγt positivity (7) and that human IL-22 
producing NK cells (ILC3), constitute a stable lineage, unable to generate NK cells 
(13). While these latter reports seem to be in sharp contrast with the reports of 
Hughes et al, where developmental plasticity of RORγt+ ILC3 cells has been 
described (5), this might reflect differences in lineage commitment of ILC found in 
SLT. 
As plasticity between NK and ILC3 is not detected in vivo, the bipotent nature of 
IL1R1+ stage 3 cells might be an in vitro artifact and explain the absence of RORγt 
traced NK cells in vivo. During in vivo development of ILC3, signaling through the 
AHR has proven to be essential (14). In physiological locations of ILC3 development, 
levels of AHR ligand might be sufficiently high to induce ILC3 development from 
IL1R1+ stage 3 cells and block NK cell development (15, 16).  
 
In our study IL1R1+ and IL1R1- stage 3 subsets were found to be different from 
mature NK and ILC3 populations in their transcription factor expression profile. 
IL1R1- stage 3 precursors express Tbet, low level of Eomes and do not upregulate of 
RORC. On the other hand IL1R1+ stage 3 cells express low levels of Tbet, are 
negative for Eomes expression and upregulate expression of RORC. This suggests 
the former to be more NK primed precursors, while the latter seem primed towards 
the ILC3 lineage. This is reflected in the lineage output of these precursors, although, 
lineage plasticity can clearly be detected. While it has been established that RORγt is 
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essential for ILC3 development (17, 18) and that Tbet is needed to sustain NK cell 
populations (19), an essential role for Tbet in NKp46+ IL-22 producing ILC 
development has also been suggested (20). Moreover, Tbet expression was 
detected at high levels in this IL-22 producing subset. As we, and others (5, 6, 21), 
did not detect Tbet expression in ILC3, this might reflect differences between human 
and mouse. NK cells and ILC1 express high levels of Tbet, this thus seems to be a 
specific transcription factor for group1 ILC in the human system. Loss of Tbet 
expression and upregulation of RORγt expression in IL1R1+ stage 3 precursors thus 
suggests a gradual differentiation towards ILC3 cells. On the other hand, IL1R1- 
stage 3 precursors maintain high levels of Tbet and are devoid of RORγt expression, 
which could explain their NK skewed lineage potential. 
 
We here thus provide an explanation for differences in reports on ILC plasticity, by 
showing that during early development, ILC3 primed precursors retain NK potential. 
Within the stage 3 progenitor population, IL1R1- progenitors maintain high expression 
of Tbet to form NK cell primed precursors, or they upregulate IL1R1 to become ILC3 
primed precursors. Differentiation along the ILC3 pathway still holds lineage plasticity, 
and NK differentiation from this precursor can be blocked by strong stimulation of 
AHR early in development. 
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7. Discussion of part II 
!
The research described in part II aimed at elucidating the development of human 
innate lymphoid cells (ILC), by using an in vitro cord blood CD34+ coculture system. 
The first ILC family member that was discovered, was the NK cell in 1975 (1). About 
30 years later, other subsets of innate lymphoid cells have been described (2-4). For 
years, it has been known that NK cells derive from a common lymphoid precursor 
(CLP), together with T and B cells (5). However, with the discovery of a whole new 
family of immune cells, it remained to be seen through which developmental stages 
these cells develop. It has been clearly shown that all ILC subsets derive from the 
CLP, however, their exact developmental pathways and the plasticity between 
different ILC subsets has remained matter of scientific debate. 
In the research we have performed, we provide evidence that could explain the 
seemingly contradictive reports on ILC lineage plasticity. In addition, these insights in 
the development of ILC do not only offer valuable fundamental scientific data, but 
also allow for development of novel targeted therapies. 
 
7.1 Do ILC hold lineage plasticity during development, and do environmental cues 
influence plasticity during differentiation? 
 
The fact that all (innate) lymphoid lineages derive from a CLP in the adult has been 
established (5). However, whether a common ILC precursor exists remains a matter 
of debate. Also, whether there is plasticity between different types of ILC remains to 
be established. 
Secondary lymphoid tissue derived precursors have been described to contain ILC3, 
which retain the ability to generate conventional NK cells (6). Stimulation of these 
ILC3 with IL-1β led to their expansion and caused an increase of IL-22 and AHR 
expression, while decreasing IFNγ production. Moreover, IL-1β signaling negatively 
influenced NK cell differentiation from this IL1R1+ ILC3 (7). Recently, this IL1R1+ IL-
22 producing ILC3 was shown to be responsive to AHR stimulation. Stimulation of 
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AHR signaling promoted ILC3 differentiation and blocked their differentiation towards 
CD94+ NK cells (6). Other reports, both in human and mouse, dispute this plasticity 
and describe a separate lineage of NK cells and ILC3 (8, 9). In the paper by Ahn et al. 
the LFA1+ NK cells and LFA1+ IL-22 producing ILC3 were shown to be stable 
lineages, and ILC3 were not able to generate NK cells or vice versa. These NK and 
ILC3 were obtained through in vitro differentiation of cord blood CD34+ progenitors, 
and assessed after 21 days of culture (9). We reasoned, that these differences in 
plasticity might be due to differences in differentiation state of ILC3. We therefore 
determined whether this plasticity could be found in the stage 3 precursors that arose 
after 14 days of culture. We found the CD94-CD117+ stage 3 NK cell precursor 
population to be heterogeneous, this population could be subdivided on the basis of 
CD117 and IL1R1 expression. Within the stage 3 population, ILC3 can be 
distinguished based on the expression of high levels of CD117, NKp44 and IL1R1. 
These cells expressed RORγt and were devoid of Tbet and Eomes expression. This 
phenotype is compatible with previously published reports on human ILC (4, 6, 7, 9, 
10). The true stage 3 population could be defined as CD94-CD117dim. Within this 
population both IL1R1- and IL1R1+ populations could be detected. These cells have a 
distinct expression profile. IL1R1- stage3 precursors express high levels of Tbet, low 
levels of Eomes and do not upregulate of RORC. On the other hand IL1R1+ stage 3 
cells express low levels of Tbet, are negative for Eomes expression and upregulate 
expression of RORC. While similar CD34+ cord blood progenitor differentiation 
cultures were previously described, we describe for the first time the kinetics of IL1R1 
expression during the development of ILC (6, 11). 
The data we obtained is suggestive for the presence of NK and ILC3 primed 
precursors. This is reflected in the lineage output of these precursors, although 
lineage plasticity can clearly be detected. In culture, the IL1R1- stage 3 population 
generated IL1R1+ stage 3 cells and subsequently formed ILC3, albeit with low 
efficiency and delayed kinetics. These IL1R1- stage 3 cells mainly generated NK cells. 
On the other hand IL1R1+ stage 3 cells mainly gave rise to ILC3 cells, but retained 
NK developmental potential.  
An essential role of RORγt was described for ILC3 development (16, 17), while Tbet 
is essential for the maintenance of NK cells (18). A recent report showed that Tbet is 
highly expressed in NKp46+ ILC22 and has an essential role in their development 
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(19). However, in the human system, such a role for Tbet was not detected, as Tbet 
expression was found to be limited to group1 ILC (NK and ILC1) (5, 6, 20).  
Our expression data of these transcription factors in IL1R1- and IL1R1+ stage 3 
populations, in combination with the lineage potential of these cells, thus suggests a 
gradual differentiation towards ILC3 cells of IL1R1+ stage 3, while IL1R1- stage 3 
precursors show an NK skewed lineage potential. 
We found that IL1R1+ stage 3 cells still hold NK potential, however NK cell 
development was hampered and ILC3 development was stimulated upon strong AHR 
signaling by FICZ, a known AHR agonist (11). AHR stimulation had no apparent 
effect on the lineage output of IL1R1- stage 3 precursors. In the report of Ahn et al., 
NK and ILC3 from day 21 cocultures did not show lineage plasticity in the absence of 
AHR agonist (9). Using the same differentiation protocol, we show that the early 
stage 3 precursors still hold lineage plasticity. During murine NK cell development, no 
stage of RORγt positivity could be detected (7). In addition human IL-22 producing 
NK cells isolated from SLT, currently called ILC3, were unable to generate NK cells 
(12). The seemingly contradictive reports on developmental plasticity of RORγt+ ILC3 
might thus reflect differences in lineage commitment of ILC found in SLT. The fact 
that no RORC marked NK cells could be found in lineage tracing experiments, might 
merely reflect that in homeostasis sufficient AHR agonists are present in locations 
where ILC3 reside (8, 12, 13). This could prevent ILC3 lineage plasticity and block 
differentiation towards conventional NK cells. ILC3 plasticity might thus just be an in 
vitro artefact, induced by insufficient AHR agonist present in culture. It would be 
interesting to revisit the RORC lineage tracing model, to see under which conditions 
in vivo ILC3 reversion would occur. 
 
7.3 How can knowledge of innate lymphoid cell development and function be 
translated to the clinic? 
 
As described earlier, ILC have an important role in clearing gastrointestinal infections, 
in addition they have a role in preventing GVHD (14) and aid in restoring gut epithelia 
during inflammatory bowel disease (15) . On the other hand, they have a disease-
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promoting role in cancer (16), psoriasis (17) and asthma (18). It is thus clear that 
specific ILC subtypes could be used or targeted in vivo in the treatment of certain 
diseases.  To this end the development of different types of ILC could be skewed or 
their activation status could be altered. This could be achieved by administration of 
cytokines, chemical compounds, cytokine binding monoclonal antibodies, or addition 
of monoclonal antibodies that could block signaling through specific receptors.  
Among the family of ILC, ILC3 were described to produce IL-22 (19) and IL-17 (20).  
In the case of IL-17, a pro-inflammatory cytokine also produced by TH17 T cells and 
ILC3, evidence for a causal effect was found for inflammatory bowel disease (21, 22). 
Here, IL-17 induces and sustains an inflammatory response (23). A role for a TH17 
response has also been described in mediating GVHD (24). In both of these 
diseases there seems to be a relation between the TH17 response and the TH1 
response, the latter is often related to the disease etiology.  
In the case of colon cancer, IL-17 has been described to be involved in promoting 
tumor development from colonic epithelial cells, and induces therapy resistance (25). 
Neutralizing IL-17A reduces the tumor load in mouse models and might thus provide 
a means for therapy. 
In the case of psoriaris, the role of IL-17 has is not cleas. IL-17 can be detected in 
activated keratinocytes, however only IL-22 appears implicated in the disease (26).  
A role for IL-17 in asthma has been suggested (reviewed by Chesné et al (27)), this 
role is probably restricted to a subtype of the disease, as anti IL-17 therapy showed 
no beneficial effect in a clinical study on subjects with severe to moderate asthma 
(28).  
Further research is thus needed to link IL-17 to these diseases and to see whether 
IL-17 producing ILC are implied. Understanding the developmental pathways of 
these types of ILC could also provide a means to skew development or plasticity of 
IL-17 producing ILC3 towards IL-22 producing ILC3. 
IL-22 signaling has been reported to play a role in several diseases and might 
provide a novel target for several therapies (reviewed by Sabat et al. (29)). Among 
these are GVHD (14), IBD (15, 30, 31), psoriasis (17) and asthma (18).  
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Interestingly, IL-22 seems to have a differential effect depending on the disease. In 
the case of psoriasis and tumors, the IL-22 signaling pathway seems to have a 
disease promoting role, while in the case of asthma and GVHD, IL-22 signaling 
seems to provide a protecting role. (32).  
Involvement of IL-22 has been described in the development of gastrointestinal 
cancer (16). Here, a decrease in the expression of IL-22 binding protein, which 
strictly maintains IL-22 levels in homeostasis, leads to deregulation of STAT3 
signalling. In colorectal cancer, deregulated STAT3 signalling was detected (33). 
Consequently, a specific IL-22 binding antibody, an IL-22 blocking monoclonal 
antibody or IL-22 binding protein could be administered for the treatment of these 
malignancies. A similar strategy could be used to treat psoriasis. Alternatively, the IL-
23R could be blocked in the intestine, leading to a reduced activation of IL-22 
producing innate lymphoid cells. 
After allogeneic stem cell transplantation, it was shown that IL-22 producing ILC3 
were eliminated through GVH T cell responses, which induced GVHD related 
intestinal toxicity (14). As IL-22 was shown to have a protective role for intestinal 
stem cells, It is thus clear that IL-22 signaling is also involved in this severe pathology. 
Development and function of ILC3 depends on AHR stimulation (34), thus AHR 
agonist stimulation of the limited number of ILC3 might provide a means to increase 
the number of IL-22 producing cells. This could circumvent the prolonged 
administration of IL-22 to these patients. One of these AHR agonists is FICZ, a 
tryptophan derivative (11).  
In the intestine, IL-22 causes the intestinal crypts to bud, restoring the intestinal lining. 
In the case of Crohn’s disease, IL-22 has been described to reconstitute goblet cells, 
increase production of antibacterial proteins and repair the epithelial barrier (30, 31). 
For these diseases, protease resistant IL-22 could be provided. Alternatively, as in 
the case of GVHD, administration of AHR agonists might provide a suitable means 
for the therapy of intestinal bowel disease (35, 36).  
Conventional NK cells have an important function in the immune response against 
cancers. Interestingly, several cancers have been described to increase tryptophan 
metabolisation using tryptophan dioxygenase. This leads to increased production of 
kynurenine (Kyn). In this system signaling through AHR by Kyn has been shown to 
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influence the T cell antitumor responses (37). It was shown that stimulation of the 
AHR influences the balance of NK over ILC3 differentiation. This balance might 
promote cancer development in both ways: by limiting the differentiation of NK cells, 
which could provide antitumor effects, and by increasing the number of ILC3, which 
have been shown to have a cancer promoting effect through the production of IL-17 
and IL-22. The developing tumor might thus not only act locally on the surrounding T 
cells and NK cells, but might influence the development of stage 3 NK cells in the 
secondary lymphoid tissue, through systemic release of AHR agonists. Compounds 
that influence these pathways may prove key in limiting tumor growth and stimulating 
anti-tumor responses. 
 
Adoptive transfer of in vitro generated NK cells might provide a suitable therapy for 
several malignancies. Tumor cells evade the immune-surveillance provided by NK 
cells through several mechanisms: they up-regulate MHCI expression or they down-
regulate the ligands for activating receptors. This causes endogenous cells to be 
incapable of killing the developing or established tumor. To this end, adoptive 
transfer of allogeneic NK cells or NK cell lines might prove a highly functional 
alternative, and this method has been successfully applied in patients (38, 39). 
However, the MHC mismatch might cause elimination of the transfused NK cells. In 
addition, expansion of NK cells in vitro might induce exhaustion (40), and 
freeze/thawing of NK cells hampers their function (41). Also the use of NK cell lines, 
which are often derived from malignantly transformed cells themselves, is 
questionable. As an alternative source of cells for allogeneic transfer, NK cells have 
been efficiently generated from several HSC sources, such as umbilical cord blood 
(UCB) (42) and bone marrow (BM) (43). These in vitro generated NK cells could then 
be directly used for transfusion. 
 
A novel approach in NK cell immunotherapy is the retargeting of NK cells through 
transgenic expression of chimeric antigen receptors (CARs). These CARs consist of 
single-chain variable fragments (scFv) in combination with T-cell signaling domains, 
which enables their triggering upon recognition of antigens by this CAR (44). This 
increases tumor-NK cell interactions. This has been shown to improve cytotoxicity of 
NK cell lines against different antigens (45-50). This method could be applied to 
peripheral blood derived NK cells, NK cell lines or in vitro generated NK cells. Thus 
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combination of in vitro differentiation of NK cells with introduction of CARs into CD34+ 
might provide an interesting source of NK cells for adoptive transfer. 
 
As an alternative source, NK cells have been successfully generated from human 
embryonic stem cells and pluripotent stem cells. As protocols have been described to 
efficiently generate functional NK cells from PSC (51, 52). Sufficient numbers of NK 
cells might be obtained using the xeno-free protocol described by Knorr et al. (52). 
Upon addition of artificial antigen presenting cells to these cultures, the authors were 
able to show 100-1000fold expansion of the NK cells initially obtained (52). 
 
Thus, in conclusion, while several options are possible to treat diseases in which ILC 
are involved, most are these have not been taken beyond proof of principle in vitro or 
in animal models.   
!
! !
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